<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>058 Pharmacology Ini-Cet 2023 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQs / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">34</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x37c9bd=_0x27a8;(function(_0x3b5e8c,_0x568bcc){const _0x2a53cf=_0x27a8,_0x56c1d8=_0x3b5e8c();while(!![]){try{const _0x37ff45=-parseInt(_0x2a53cf(0x161))/0x1*(-parseInt(_0x2a53cf(0x169))/0x2)+-parseInt(_0x2a53cf(0x238))/0x3+parseInt(_0x2a53cf(0x107))/0x4+parseInt(_0x2a53cf(0x379))/0x5*(parseInt(_0x2a53cf(0x329))/0x6)+-parseInt(_0x2a53cf(0x332))/0x7*(-parseInt(_0x2a53cf(0x23b))/0x8)+-parseInt(_0x2a53cf(0x266))/0x9*(-parseInt(_0x2a53cf(0x38b))/0xa)+-parseInt(_0x2a53cf(0x13c))/0xb;if(_0x37ff45===_0x568bcc)break;else _0x56c1d8['push'](_0x56c1d8['shift']());}catch(_0x28ef86){_0x56c1d8['push'](_0x56c1d8['shift']());}}}(_0x2a52,0xc3045));const _0x55b4a8=(function(){let _0x4d6020=!![];return function(_0x110bd0,_0x594738){const _0x400570=_0x4d6020?function(){const _0x2eb8a5=_0x27a8;if(_0x594738){const _0x151779=_0x594738[_0x2eb8a5(0x108)](_0x110bd0,arguments);return _0x594738=null,_0x151779;}}:function(){};return _0x4d6020=![],_0x400570;};}()),_0x2e6aaa=_0x55b4a8(this,function(){const _0x5b2661=_0x27a8,_0x537279={'LmMbH':'(((.+)+)+)+$'};return _0x2e6aaa[_0x5b2661(0x2b2)]()[_0x5b2661(0x308)](_0x537279[_0x5b2661(0x17c)])[_0x5b2661(0x2b2)]()['constructor'](_0x2e6aaa)['search'](_0x537279[_0x5b2661(0x17c)]);});_0x2e6aaa();const _0x516120=(function(){const _0x7b1e3f=_0x27a8,_0x5dcb4c={'IqDjy':_0x7b1e3f(0x141),'rbYtG':_0x7b1e3f(0x1e6),'gNHuj':_0x7b1e3f(0x190),'ysUut':_0x7b1e3f(0x16c),'wQHcb':'submitSection','xJdsn':_0x7b1e3f(0x228),'eYvkK':function(_0x5d9957,_0x363480){return _0x5d9957===_0x363480;},'gXMcI':_0x7b1e3f(0x1d4),'geRgq':_0x7b1e3f(0x1b1),'GxBhd':function(_0x17e186){return _0x17e186();},'DoFEj':_0x7b1e3f(0x13d),'Hlzuo':_0x7b1e3f(0x304),'oiMAG':_0x7b1e3f(0x274),'nFxpD':function(_0x332b2d,_0x5e9d31){return _0x332b2d!==_0x5e9d31;},'tUmWg':_0x7b1e3f(0x1b5)};let _0x2a77f6=!![];return function(_0x41504d,_0x37281d){const _0x3a03b0=_0x2a77f6?function(){const _0x588786=_0x27a8,_0x38c45d={'HfJcU':_0x588786(0x2ef),'jKgwg':_0x5dcb4c[_0x588786(0x137)],'MDtKt':_0x5dcb4c[_0x588786(0x28f)],'QdaCZ':_0x588786(0x194),'Xinsy':_0x5dcb4c[_0x588786(0x24c)],'VVKBx':_0x5dcb4c[_0x588786(0x291)],'AnzaB':'block','OzGoA':_0x588786(0x334),'QPHFB':_0x5dcb4c['wQHcb'],'JvTyr':_0x5dcb4c[_0x588786(0x13a)],'YbMOP':function(_0xe89e29,_0x4181ae){const _0x27eafc=_0x588786;return _0x5dcb4c[_0x27eafc(0x2fa)](_0xe89e29,_0x4181ae);},'kvecz':_0x5dcb4c['gXMcI'],'LrmXu':function(_0x1be991,_0xc2781a){return _0x1be991===_0xc2781a;},'EtKEB':_0x5dcb4c[_0x588786(0x1a2)],'qdzPR':function(_0x2a17e4){const _0x33f093=_0x588786;return _0x5dcb4c[_0x33f093(0x205)](_0x2a17e4);},'jifyt':function(_0x2892c4){return _0x2892c4();},'swSPA':_0x5dcb4c[_0x588786(0x30f)]};if(_0x5dcb4c[_0x588786(0x35e)]===_0x5dcb4c['oiMAG']){_0x133070=_0x48c424['now']();const _0xd134ec=_0x1f93e5[_0x588786(0x1e7)](_0x38c45d[_0x588786(0x14f)]),_0xb9e3cd=_0x11a79b['getElementById'](_0x38c45d[_0x588786(0x2e6)]),_0x3cb85f=_0x31f995['getElementById'](_0x38c45d[_0x588786(0x15a)]),_0x45496d=_0xed8439===_0x38c45d[_0x588786(0x1e9)]||_0x481535===_0x38c45d['Xinsy'];_0x14fb5e['getElementById'](_0x588786(0x290))[_0x588786(0x2b1)][_0x588786(0x1a0)]=_0x45496d?_0x38c45d['VVKBx']:_0x38c45d['AnzaB'],_0x15f0f7[_0x588786(0x1e7)](_0x38c45d[_0x588786(0x1f6)])[_0x588786(0x2b1)][_0x588786(0x1a0)]=_0x45496d?_0x38c45d[_0x588786(0x324)]:_0x38c45d['AnzaB'],_0x301452[_0x588786(0x1e7)]('testModeLegend')[_0x588786(0x2b1)][_0x588786(0x1a0)]=_0x45496d?_0x588786(0x352):_0x38c45d[_0x588786(0x324)],_0x335fe2[_0x588786(0x1e7)](_0x38c45d[_0x588786(0x1c4)])[_0x588786(0x2b1)][_0x588786(0x1a0)]=_0x45496d?_0x588786(0x352):_0x38c45d['VVKBx'],_0xd134ec['style'][_0x588786(0x1a0)]=_0x45496d?_0x38c45d[_0x588786(0x324)]:_0x588786(0x228),_0xb9e3cd[_0x588786(0x2b1)][_0x588786(0x1a0)]=_0x45496d?_0x38c45d[_0x588786(0x13e)]:_0x588786(0x16c),_0x3cb85f[_0x588786(0x2b1)][_0x588786(0x1a0)]=_0x45496d?_0x38c45d[_0x588786(0x13e)]:_0x38c45d['VVKBx'],(_0x38c45d['YbMOP'](_0x7aab6a,_0x38c45d[_0x588786(0x363)])||_0x38c45d[_0x588786(0x21d)](_0x5bf2c2,_0x38c45d[_0x588786(0x29c)]))&&_0x2d559c[_0x588786(0x1e7)](_0x588786(0x2ed))[_0x588786(0x12b)][_0x588786(0x30e)](_0x38c45d['EtKEB']),_0x38c45d['qdzPR'](_0x24bfb3),_0x38c45d['qdzPR'](_0x1b874a),_0x38c45d[_0x588786(0x270)](_0x32f845),_0x28d259();}else{if(_0x37281d){if(_0x5dcb4c['nFxpD'](_0x5dcb4c[_0x588786(0x2a2)],_0x588786(0x1b5)))_0x1e42b6=_0x38c45d[_0x588786(0x29e)],_0x2992da=_0x588786(0x398);else{const _0x4d07f4=_0x37281d[_0x588786(0x108)](_0x41504d,arguments);return _0x37281d=null,_0x4d07f4;}}}}:function(){};return _0x2a77f6=![],_0x3a03b0;};}()),_0x19cc29=_0x516120(this,function(){const _0x3f0db5=_0x27a8,_0x2ced7a={'nHmnN':_0x3f0db5(0x18a),'bbhll':function(_0x2413ae,_0x24d2f6){return _0x2413ae<_0x24d2f6;},'hVNzQ':_0x3f0db5(0x349),'aiBfY':function(_0x3e6249,_0x174b8a){return _0x3e6249+_0x174b8a;},'TXyqp':function(_0x2f9494,_0x23b7d4){return _0x2f9494===_0x23b7d4;},'VxDQn':'Incorrect','wJdjR':function(_0x12223d){return _0x12223d();},'ccjid':function(_0x3f19a4,_0x193444){return _0x3f19a4!==_0x193444;},'JNkYA':_0x3f0db5(0x22c),'Uvhqs':function(_0x4e1855,_0x28bd87){return _0x4e1855+_0x28bd87;},'owYgk':_0x3f0db5(0x27f),'iPTcP':function(_0x269311){return _0x269311();},'rrNPX':function(_0x3351ed,_0x37e5c6){return _0x3351ed!==_0x37e5c6;},'SiUyP':_0x3f0db5(0x199),'MOIWo':_0x3f0db5(0x21f),'fEdJv':_0x3f0db5(0x387),'KvlKH':_0x3f0db5(0x37e),'FWCpl':_0x3f0db5(0x2d4),'yxOGG':'trace','ybDnx':_0x3f0db5(0x185)};let _0x47d9b0;try{if(_0x2ced7a[_0x3f0db5(0x193)](_0x2ced7a[_0x3f0db5(0x264)],_0x3f0db5(0x22c))){const _0x764c90=_0x1febee[_0x3f0db5(0x1e7)](_0x2ced7a[_0x3f0db5(0x2ab)]);_0x764c90[_0x3f0db5(0x216)]='';for(let _0x26d9ad=0x0;_0x2ced7a['bbhll'](_0x26d9ad,_0x2c03b9[_0x3f0db5(0x186)]);_0x26d9ad++){const _0x720bf7=_0x4a4eef['createElement'](_0x2ced7a[_0x3f0db5(0x145)]);_0x720bf7['textContent']=_0x2ced7a['aiBfY'](_0x26d9ad,0x1),_0x720bf7[_0x3f0db5(0x1f3)]=_0x3f0db5(0x22d),_0x720bf7[_0x3f0db5(0x1f1)]=()=>_0x4249ed(_0x26d9ad),_0x720bf7['id']=_0x3f0db5(0x384)+_0x26d9ad,_0x764c90[_0x3f0db5(0x366)](_0x720bf7);}_0x529f16();}else{const _0xc7e75a=Function(_0x2ced7a['aiBfY'](_0x2ced7a['Uvhqs'](_0x3f0db5(0x1b0),_0x2ced7a[_0x3f0db5(0x25e)]),');'));_0x47d9b0=_0x2ced7a[_0x3f0db5(0x338)](_0xc7e75a);}}catch(_0x293dd4){if(_0x2ced7a[_0x3f0db5(0x2f4)](_0x2ced7a[_0x3f0db5(0x31e)],_0x2ced7a[_0x3f0db5(0x31e)])){const _0x3cb0cb=_0x110a2e[_0x3f0db5(0x337)][_0x1fbc66[_0x3f0db5(0x1ce)]];_0x2ced7a[_0x3f0db5(0x279)](_0x3cb0cb['id'],_0x24a2df)?(_0x569601=_0x3f0db5(0x16f),_0x2f07bc='Correct'):(_0x4363ea=_0x3f0db5(0x13d),_0x3a6fe2=_0x2ced7a[_0x3f0db5(0x124)]);}else _0x47d9b0=window;}const _0x13ba00=_0x47d9b0['console']=_0x47d9b0[_0x3f0db5(0x1ef)]||{},_0x8d568d=[_0x3f0db5(0x11e),_0x2ced7a[_0x3f0db5(0x166)],_0x2ced7a[_0x3f0db5(0x28a)],_0x3f0db5(0x131),_0x2ced7a[_0x3f0db5(0x2fb)],_0x2ced7a['FWCpl'],_0x2ced7a[_0x3f0db5(0x313)]];for(let _0x31eff8=0x0;_0x2ced7a[_0x3f0db5(0x2db)](_0x31eff8,_0x8d568d[_0x3f0db5(0x186)]);_0x31eff8++){if(_0x3f0db5(0x126)!==_0x2ced7a['ybDnx']){const _0x5c8141=_0x516120[_0x3f0db5(0x1d3)]['prototype'][_0x3f0db5(0x12e)](_0x516120),_0x563e66=_0x8d568d[_0x31eff8],_0x31c9f6=_0x13ba00[_0x563e66]||_0x5c8141;_0x5c8141[_0x3f0db5(0x316)]=_0x516120[_0x3f0db5(0x12e)](_0x516120),_0x5c8141['toString']=_0x31c9f6[_0x3f0db5(0x2b2)][_0x3f0db5(0x12e)](_0x31c9f6),_0x13ba00[_0x563e66]=_0x5c8141;}else _0x2ced7a[_0x3f0db5(0x16a)](_0x33083e);}});_0x19cc29();let questionsData=[{'text':_0x37c9bd(0x295),'choices':[{'id':0x1,'text':_0x37c9bd(0x25a)},{'id':0x2,'text':_0x37c9bd(0x2b0)},{'id':0x3,'text':_0x37c9bd(0x15e)},{'id':0x4,'text':_0x37c9bd(0x257)}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x20e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0xfc),'choices':[{'id':0x1,'text':_0x37c9bd(0x29b)},{'id':0x2,'text':_0x37c9bd(0x1aa)},{'id':0x3,'text':_0x37c9bd(0x1cd)},{'id':0x4,'text':_0x37c9bd(0x14b)}],'correct_choice_id':0x2,'solution':'<p><strong>Lapatinib</strong>\x20is\x20used\x20for\x20<strong>trastuzumab-resistant\x20HER-2\x20neu-positive\x20breast\x20carcinoma</strong>.</p>\x0a<p>Lapatinib\x20is\x20an\x20orally\x20bioavailable,\x20small-molecule<strong>\x20inhibitor\x20of\x20the\x20EGFR\x20and\x20HER2\x20tyrosine\x20kinases</strong>.\x20Lapatinib\x20is\x20metabolized\x20by\x20<strong>CYP3A4</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Lapatinib</strong>\x20in\x20combination<strong>\x20with\x20capecitabine</strong>\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20patients\x20with<strong>\x20metastatic\x20HER2-positive\x20trastuzumab-refractory\x20breast\x20cancer.</strong>\x20<strong>Lapatinib</strong>\x20is\x20also\x20used\x20in\x20combination<strong>\x20with\x20</strong>the\x20aromatase\x20inhibitor\x20<strong>letrozole</strong>\x20to\x20treat<strong>\x20postmenopausal\x20women\x20with\x20hormone\x20receptor-positive,\x20metastatic\x20breast\x20cancer\x20that\x20overexpresses\x20HER2.</strong></p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Frequent<strong>\x20adverse\x20effects</strong>\x20include\x20acneiform\x20rash,\x20diarrhea,\x20cramping,\x20and\x20exacerbation\x20of\x20gastroesophageal\x20reflux.<strong>\x20Cardiac\x20toxicity</strong>\x20appears\x20less\x20pronounced\x20than\x20with\x20trastuzumab,\x20although\x20lapatinib\x20should\x20be\x20used\x20with\x20caution\x20in\x20combination\x20with\x20cardiotoxic\x20drugs.\x20A\x20dose-dependent\x20<strong>prolongation</strong>\x20of\x20the\x20<strong>QT\x20interval</strong>\x20has\x20been\x20reported;\x20thus,\x20careful\x20monitoring\x20of\x20patients\x20with\x20heart\x20disease\x20is\x20recommended.\x20<strong>Hepatotoxicity</strong>\x20that\x20may\x20be\x20severe\x20has\x20been\x20observed.</p>\x0a<p><strong>Trastuzumab</strong>&nbsp;is\x20a\x20monoclonal\x20antibody\x20that<strong>\x20inhibits\x20the\x20HER2\x20receptor</strong>.\x20It\x20is\x20used\x20in\x20the\x20<strong>treatment\x20of\x20HER2-positive\x20breast\x20cancer.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Option\x20A:&nbsp;</strong><strong>Vismodegib</strong>&nbsp;is\x20a&nbsp;<strong>hedgehog\x20pathway\x20inhibitor</strong>&nbsp;used\x20to\x20treat&nbsp;<strong>metastatic\x20and\x20locally\x20advanced\x20BCCs</strong>.</p>\x0a<p><strong>Option\x20C</strong>:&nbsp;<strong>Vemurafenib</strong>&nbsp;is\x20a&nbsp;<strong>BRAF\x20inhibitors</strong>&nbsp;used\x20in\x20metastatic\x20melanoma\x20and\x20thyroid\x20cancers\x20with\x20BRAF\x20V600E\x20mutation.</p>\x0a<p><strong>Option\x20D</strong>:&nbsp;<strong>Erlotinib</strong>&nbsp;is\x20a\x20protein\x20kinase\x20antagonists\x20which\x20is\x20the\x20first\x20line\x20treatment\x20of&nbsp;<strong>non-small\x20cell\x20lung\x20carcinoma</strong>&nbsp;with\x20EGFR\x20deletion\x20of\x20exon\x2019\x20or\x20L858R\x20mutation</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Nomogram\x20used\x20for\x20vancomycin\x20dosing\x20is?','choices':[{'id':0x1,'text':_0x37c9bd(0x151)},{'id':0x2,'text':'Halsted'},{'id':0x3,'text':'Rummack-mathew'},{'id':0x4,'text':'Matzke'}],'correct_choice_id':0x4,'solution':_0x37c9bd(0x2ad),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x2e2),'choices':[{'id':0x1,'text':_0x37c9bd(0x1c0)},{'id':0x2,'text':'It\x20can\x20cause\x20fine\x20tremors\x20in\x20the\x20therapeutic\x20range'},{'id':0x3,'text':'Approved\x20for\x20the\x20treatment\x20of\x20absent\x20seizures'},{'id':0x4,'text':_0x37c9bd(0x383)}],'correct_choice_id':0x2,'solution':'<p>The\x20true\x20statement\x20about\x20<strong>lithium</strong>\x20is\x20it\x20can<strong>\x20cause\x20fine\x20tremors\x20in\x20the\x20therapeutic\x20range.</strong></p>\x0a<p>Lithium\x20has\x20a\x20very\x20narrow\x20therapeutic\x20index\x20of&nbsp;<strong>0.8-1.2\x20mEq/L.</strong>&nbsp;The\x20severity\x20of\x20lithium\x20toxicity\x20is\x20often\x20divided\x20into\x20the\x20following\x20three\x20grades:&nbsp;</p>\x0a<table\x20style=\x22height:\x20351px;\x22\x20width=\x22495\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Grade</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22>\x0a<p><strong>Sr.\x20lithium\x20concentration&nbsp;</strong>(in\x20mEq/L)</p>\x0a</td>\x0a<td\x20style=\x22width:\x20196.562px;\x22><strong>Symptoms</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Mild\x20symptoms</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22><strong>1.5-2.5&nbsp;</strong></td>\x0a<td\x20style=\x22width:\x20196.562px;\x22>Nausea,\x20vomiting,&nbsp;<strong>tremor</strong>,\x20and\x20fatigue</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Moderate\x20intoxication</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22><strong>2.5-3.5&nbsp;</strong></td>\x0a<td\x20style=\x22width:\x20196.562px;\x22><strong>Confusion</strong>,\x20agitation,\x20delirium,\x20tachycardia,\x20and\x20hypertonia</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Severe\x20intoxication</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22><strong>&gt;3.5&nbsp;</strong></td>\x0a<td\x20style=\x22width:\x20196.562px;\x22>Coma,&nbsp;<strong>seizures</strong>,\x20hyperthermia,\x20and\x20hypotension</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>A\x20fine\x20tremor\x20is\x20common\x20in\x20patients\x20taking\x20lithium\x20at\x20therapeutic\x20doses.&nbsp;Therapeutic\x20lithium\x20tremor\x20is\x20generally\x20symmetric,\x20limited\x20to\x20the\x20arms,\x20and\x20nonprogressive.\x20The\x20tremor\x20from&nbsp;<strong>lithium\x20toxicity</strong>&nbsp;is&nbsp;<strong>coarser</strong>&nbsp;and&nbsp;<strong>more\x20disabling</strong>,\x20may\x20also\x20affect\x20the\x20legs,\x20and\x20occurs\x20with\x20other\x20symptoms\x20of\x20toxicity.&nbsp;Other\x20adverse\x20effects\x20include&nbsp;mental\x20confusion,&nbsp;<strong>hypothyroidism</strong>,&nbsp;<strong>nephrogenic</strong>&nbsp;<strong>diabetes\x20insipidus,</strong>&nbsp;and&nbsp;edema.\x20Lithium\x20use\x20in\x20early\x20pregnancy\x20causes&nbsp;<strong>Ebstein\x20anomaly</strong>&nbsp;in\x20the\x20fetus<strong>(Option\x20D)</strong>.\x20Fetal\x20lithium\x20exposure\x20is\x20associated\x20with&nbsp;<strong>neonatal\x20goiter,\x20CNS\x20depression,\x20hypotonia\x20(floppy\x20baby\x20syndrome),\x20and\x20cardiac\x20murmur.</strong></p>\x0a<p>As\x20lithium\x20is\x20readily\x20dialyzed,\x20lithium\x20overdose\x20or\x20toxicity\x20is\x20treated\x20with&nbsp;<strong>hemodialysis</strong>.</p>\x0a<p><strong>Lithium</strong>&nbsp;is\x20a&nbsp;<strong>mood\x20stabilizer</strong>&nbsp;with\x20a\x20very\x20narrow\x20therapeutic\x20index.\x20Lithium\x20is\x20administered\x20<strong>orally</strong>.\x20Lithium\x20is\x20almost<strong>\x20completely\x20absorbed</strong>\x20from\x20the\x20GI\x20tract(<strong>Option\x20A</strong>).\x20It\x20is\x20the&nbsp;<strong>first\x20line</strong>&nbsp;of\x20management\x20in&nbsp;<strong>bipolar\x20disorder</strong>.</p>\x0a<p>Lithium\x20is\x20also&nbsp;<strong>used</strong>\x20in\x20the\x20<strong>management</strong>\x20of\x20<strong>mania\x20and\x20has\x20anti-suicidal\x20properties.\x20(Option\x20C)</strong>\x20It\x20has\x20a\x20narrow\x20therapeutic\x20index,\x20and\x20blood\x20levels\x20in\x20excess\x20of\x20this\x20may\x20cause\x20symptoms\x20of\x20toxicity.\x20<strong>Therapeutic\x20drug\x20monitoring</strong>\x20is\x20done\x20by\x20measuring\x20lithium\x20<strong>levels\x2012\x20hours\x20after\x20the\x20last\x20dose</strong>.</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x1d0),'choices':[{'id':0x1,'text':_0x37c9bd(0x31f)},{'id':0x2,'text':_0x37c9bd(0x28e)},{'id':0x3,'text':_0x37c9bd(0x249)},{'id':0x4,'text':_0x37c9bd(0x214)}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x1f7),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'True\x20about\x20therapeutic\x20index\x20of\x20a\x20drug\x20is:','choices':[{'id':0x1,'text':_0x37c9bd(0x106)},{'id':0x2,'text':'Denotes\x20safety\x20and\x20efficacy\x20in\x20the\x20population'},{'id':0x3,'text':_0x37c9bd(0x25b)},{'id':0x4,'text':_0x37c9bd(0x267)}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x2c3),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Osimertinib\x20is\x20used\x20in\x20NSCLC\x20with\x20which\x20of\x20the\x20following\x20mutation?','choices':[{'id':0x1,'text':_0x37c9bd(0x377)},{'id':0x2,'text':_0x37c9bd(0x309)},{'id':0x3,'text':_0x37c9bd(0x375)},{'id':0x4,'text':'M790T\x20mutation'}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x197),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x35b),'choices':[{'id':0x1,'text':'Trazodone'},{'id':0x2,'text':_0x37c9bd(0x167)},{'id':0x3,'text':_0x37c9bd(0x1d5)},{'id':0x4,'text':_0x37c9bd(0x1ab)}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x1e3),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x293),'choices':[{'id':0x1,'text':'MDR\x201'},{'id':0x2,'text':'BRCA'},{'id':0x3,'text':_0x37c9bd(0x25d)},{'id':0x4,'text':_0x37c9bd(0x1e4)}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x2c0),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20diabetic\x20patient\x20was\x20started\x20on\x20a\x20drug\x20that\x20decreased\x20her\x20HbA1C\x20from\x207.6\x20to\x206.7.\x20She\x20started\x20complaining\x20of\x20itching\x20around\x20vulvovaginal\x20area\x20.\x20What\x20was\x20the\x20most\x20likely\x20drug\x20she\x20was\x20started\x20on?','choices':[{'id':0x1,'text':_0x37c9bd(0x116)},{'id':0x2,'text':'Canagliflozin'},{'id':0x3,'text':_0x37c9bd(0x38a)},{'id':0x4,'text':_0x37c9bd(0x187)}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x38d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'An\x20anti-diabetic\x20drug\x20causes\x20a\x20decrease\x20in\x20HbA1C\x20by\x20causing\x20an\x20increase\x20in\x20GIP\x20and\x20GLP-1\x20levels\x20and\x20a\x20decrease\x20in\x20glucagon\x20levels.\x20It\x20is\x20an\x20oral\x20drug\x20causing\x20a\x20reduction\x20in\x20both\x20pre\x20and\x20post-prandial\x20glucose.\x20The\x20drug\x20is:','choices':[{'id':0x1,'text':_0x37c9bd(0x24d)},{'id':0x2,'text':_0x37c9bd(0x288)},{'id':0x3,'text':'Liraglutide'},{'id':0x4,'text':'Metformin'}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x28b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x31c),'choices':[{'id':0x1,'text':_0x37c9bd(0x230)},{'id':0x2,'text':'Pembrolizumab\x20used\x20in\x20NSCLC'},{'id':0x3,'text':'Nivolumab\x20plus\x20chemotherapy\x20used\x20in\x20NSCLC'},{'id':0x4,'text':_0x37c9bd(0x35f)}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x2a0),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x364),'choices':[{'id':0x1,'text':_0x37c9bd(0x1db)},{'id':0x2,'text':_0x37c9bd(0x24f)},{'id':0x3,'text':_0x37c9bd(0x152)},{'id':0x4,'text':'Inhibition\x20of\x20IL2,\x20IL4,\x20IL5'}],'correct_choice_id':0x4,'solution':_0x37c9bd(0x2fe),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20is\x20a\x20rare\x20but\x20very\x20severe\x20side\x20effect\x20of\x20clozapine\x20that\x20requires\x20regular\x20monitoring?','choices':[{'id':0x1,'text':'Suicidal\x20tendency'},{'id':0x2,'text':'Agranulocytosis'},{'id':0x3,'text':_0x37c9bd(0x2d1)},{'id':0x4,'text':_0x37c9bd(0x351)}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x36d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20newly\x20approved\x20anti-diabetic\x20drugs\x20can\x20be\x20given\x20for\x20heart\x20failure\x20with\x20reduced\x20ejection\x20fraction\x20and\x20impaired\x20renal\x20function?','choices':[{'id':0x1,'text':_0x37c9bd(0x26d)},{'id':0x2,'text':_0x37c9bd(0x227)},{'id':0x3,'text':_0x37c9bd(0x38a)},{'id':0x4,'text':_0x37c9bd(0x144)}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x2cd),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x2ee),'choices':[{'id':0x1,'text':_0x37c9bd(0xff)},{'id':0x2,'text':_0x37c9bd(0x159)},{'id':0x3,'text':_0x37c9bd(0x286)},{'id':0x4,'text':_0x37c9bd(0x1da)}],'correct_choice_id':0x4,'solution':_0x37c9bd(0x2c4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2025\x20year\x20old\x20male\x20patient\x20presents\x20with\x20several\x20purpuric\x20skin\x20lesions\x20and\x20is\x20diagnosed\x20with\x20idiopathic\x20thrombocytopenic\x20purpura.\x20Which\x20of\x20the\x20following\x20tyrosine\x20kinase\x20inhibitors\x20can\x20be\x20used\x20in\x20his\x20condition?','choices':[{'id':0x1,'text':_0x37c9bd(0x345)},{'id':0x2,'text':_0x37c9bd(0x207)},{'id':0x3,'text':_0x37c9bd(0x273)},{'id':0x4,'text':_0x37c9bd(0x36a)}],'correct_choice_id':0x4,'solution':_0x37c9bd(0x1d8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x39d),'choices':[{'id':0x1,'text':_0x37c9bd(0x184)},{'id':0x2,'text':_0x37c9bd(0x233)},{'id':0x3,'text':_0x37c9bd(0x19a)},{'id':0x4,'text':'Streptomycin'}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x333),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20on\x20amitriptyline\x20was\x20found\x20in\x20an\x20unconscious\x20state.\x20Which\x20of\x20the\x20following\x20does\x20not\x20suggest\x20amitriptyline\x20toxicity?','choices':[{'id':0x1,'text':'Arrhythmias'},{'id':0x2,'text':_0x37c9bd(0x1dd)},{'id':0x3,'text':_0x37c9bd(0x1ed)},{'id':0x4,'text':_0x37c9bd(0x29f)}],'correct_choice_id':0x3,'solution':'<p><strong>Hypothermia</strong>\x20is\x20<strong>not</strong>\x20<strong>associated</strong>\x20with\x20<strong>amitriptyline</strong>\x20use\x20or\x20<strong>tricyclic\x20antidepressant\x20toxicity</strong>.<br\x20/><br\x20/></p>\x0a<p><strong>Tricyclic\x20antidepressants\x20(TCAs)</strong>\x20such\x20as\x20<strong>amitriptyline</strong>\x20are\x20used\x20in\x20the\x20treatment\x20of\u00a0<strong>psychotic\x20depression</strong>,\x20<strong>insomnia</strong>,\x20and\x20several\x20<strong>pain</strong>\x20<strong>conditions</strong>.\x20Their\x20<strong>mechanism\x20of\x20action</strong>\x20is\x20<strong>inhibition\x20of\x20norepinephrine\x20and\x20serotonin\x20reuptake</strong>.\x20They\x20have\x20a\u00a0<strong>quinidine-like\x20sodium\x20channel\x20blockade\x20effect</strong>\u00a0on\u00a0<strong>cardiac</strong>\u00a0conduction.\x20Hence,\x20they\x20cause<strong>\u00a0QT\x20prolongation</strong>.\u00a0Other\x20<strong>cardiotoxic\x20effects</strong>\x20include\x20<strong>atrioventricular\x20(AV)\x20block</strong>\x20and<strong>\u00a0hypotension</strong>.\u00a0<strong>Rightward-axis\x20deviation</strong>\u00a0is\x20also\x20an\x20associated\x20finding.</p>\x0a<p>TCA\x20toxicity\x20can\x20result\x20in\u00a0<strong>ventricular\x20tachyarrhythmias\x20(Option\x20A)</strong>,\x20<strong>status\x20epilepticus</strong>,\x20<strong>hyperthermia</strong>,\x20and\x20<strong>coma</strong>.\x20It\u00a0can\x20also\x20result\x20in\u00a0<strong>anticholinergic\x20syndrome</strong>\u00a0due\x20to\x20muscarinic\x20receptor\x20antagonism.\x20Symptoms\x20include\x20<strong>dilated\x20pupils\x20(Option\x20D)</strong>,\x20high\x20temperature,\x20<strong>confusion\x20(option\x20B)</strong>,\x20dry\x20mouth,\u00a0<strong>urinary\x20retention,\x20tachycardia</strong>,\x20and\x20myoclonic\x20movements.\x20It\x20is\x20managed\x20with\u00a0<strong>intravenous\x20sodium\x20bicarbonate\x20bolus\x20(50-100\x20mEq)</strong>.\x20This\x20helps\x20in\x20the\x20<strong>reversal\x20of\x20sodium\x20channel\x20blockade</strong>.\u00a0<strong>Gastric\x20lavage</strong>\u00a0and\x20administration\x20of\x20<strong>activated\x20charcoal</strong>\x20can\x20be\x20carried\x20out\x20in\x20cases\x20of\x20<strong>recent\x20ingestion.</strong></p>\x0a<p><strong>Other\x20side\x20effects</strong>\x20of\x20TCAs\x20include\u00a0<strong>postural\x20hypotension\x20</strong>from\u00a0<strong>anti-alpha\x201\x20adrenergic</strong>\u00a0action\x20and\x20<strong>sedation\u00a0</strong>from\u00a0<strong>anti-histaminic</strong>\u00a0action.\x20ECG\x20changes\x20such\x20as\u00a0<strong>T\x20wave\x20inversion\u00a0or\x20suppression</strong>\x20are\x20also\x20common.\u00a0</p>\x0a<p>In\x20some\x20cases,\x20it\x20can\x20result\x20in\x20polymorphic\x20ventricular\x20tachycardias\x20with\x20QT\x20prolongation\x20known\x20as<strong>\u00a0torsades\x20de\x20pointes</strong>.\x20Recurrent\x20episodes\x20can\x20be\x20treated\x20with\u00a0<strong>intravenous\x20magnesium\x20sulfate</strong>.\u00a0<br\x20/><br\x20/><br\x20/></p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20is\x20beneficial\x20in\x20reducing\x20the\x20painful\x20crisis\x20of\x20sickle\x20cell\x20anemia?','choices':[{'id':0x1,'text':_0x37c9bd(0x142)},{'id':0x2,'text':_0x37c9bd(0x237)},{'id':0x3,'text':'Methionine'},{'id':0x4,'text':'Eltrombopag'}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x265),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x2bf),'choices':[{'id':0x1,'text':_0x37c9bd(0x328)},{'id':0x2,'text':_0x37c9bd(0x2f1)},{'id':0x3,'text':_0x37c9bd(0x263)},{'id':0x4,'text':_0x37c9bd(0x31b)}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x125),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'An\x20elderly\x20patient\x20with\x20dementia\x20is\x20not\x20compliant\x20with\x20oral\x20medications.\x20Which\x20of\x20the\x20following\x20will\x20be\x20beneficial\x20in\x20this\x20case?','choices':[{'id':0x1,'text':_0x37c9bd(0x2ac)},{'id':0x2,'text':'Rivastigmine'},{'id':0x3,'text':_0x37c9bd(0x10a)},{'id':0x4,'text':_0x37c9bd(0x39f)}],'correct_choice_id':0x2,'solution':'<p><strong>Rivastigmine\x20transdermal\x20patch</strong>\x20can\x20be\x20prescribed\x20to\x20patients\x20with\x20<strong>dementia</strong>\x20who\x20are\x20<strong>non\x20compliant\x20on\x20oral</strong>\x20medications.</p>\x0a<p>Rivastigmine\x20is\x20a<strong>\x20cholinesterase\x20inhibitor\x20</strong>that\x20is\x20available\x20as\x20a\x20<strong>transdermal\x20patch</strong>\x20for\x20use\x20in\x20<strong>alzheimer\x27s\x20disease</strong>\x20and\x20<strong>dementia</strong>.\x20It\x20can\x20be\x20applied\x20for\x20<strong>over\x2024\x20hours</strong>.\x20<strong>Transdermal\x20delivery</strong>\x20<strong>reduces\x20the\x20fluctuation\x20</strong>and\x20<strong>avoids\x20direct\x20gastric\x20irritation</strong>\x20effects\x20associated\x20with\x20<strong>oral\x20formulations</strong>.<br\x20/><br\x20/><strong>Alzheimer\x27s\x20disease</strong>\x20is\x20the<strong>\x20most\x20common\x20cause\x20</strong>of\x20<strong>dementia</strong>\x20in\x20the\x20<strong>elderly</strong>.\x20The\x20characteristic\x20feature\x20of\x20Alzheimer\x27s\x20is\x20the\x20<strong>degeneration\x20of\x20cholinergic\x20neurons</strong>\x20leading\x20to\x20<strong>reduced\x20levels\x20of\x20acetylcholine</strong>.\x20<br\x20/><br\x20/>Treatment\x20includes\x20<strong>cholinesterase</strong>\x20<strong>inhibitors</strong>\x20like\x20<strong>Donepezil</strong>,\x20<strong>Rivastigmine</strong>\x20and\x20<strong>Galantamine</strong>\x20and\x20<strong>NMDA\x20receptor\x20antagonist</strong>\x20like\x20<strong>memantine</strong>.\x20The\x20<strong>cholinesterase\x20inhibitors</strong>\x20cause\x20significant\x20side\x20effects\x20such\x20as<strong>\x20nausea,\x20vomiting,\x20diarrhea\x20</strong>and<strong>\x20peripheral\x20cholinergic\x20effects</strong>,\x20which\x20can\x20be\x20avoided\x20by\x20using\x20a\x20transdermal\x20formulation.<br\x20/><br\x20/><strong>Anticholinesterase\x20drugs<br\x20/><br\x20/></strong></p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100.046%;\x20height:\x20156.789px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Reversible\x20inhibitors</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Carbamates</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Non-Carbamates</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Physostigmine,\x20Neostigmine,\x20Pyridostigmine,\x20Rivastigmine</td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Edrophonium,\x20Tacrine,\x20Donepezil,\x20Galantamine</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Irreversible\x20inhibitors</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Carbamates</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Organophosphates</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Carbaryl,\x20Propoxur</td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Dyflos,\x20Echthiophate,\x20Malathion,\x20Diazinon,\x20Tabun,\x20Sarin,\x20Soman</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><br\x20/>Other\x20options\x20:<br\x20/><br\x20/>Options\x20A,\x20C\x20and\x20D:\x20Donepezil,\x20galantamine\x20and\x20memantine\x20are\x20currently\x20available\x20in\x20the\x20oral\x20form\x20and\x20transdermal\x20formulations\x20are\x20under\x20development\x20and\x20yet\x20to\x20be\x20available\x20in\x20the\x20market.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x192),'choices':[{'id':0x1,'text':'A'},{'id':0x2,'text':'B'},{'id':0x3,'text':'C'},{'id':0x4,'text':'D'}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x39a),'explanation_video':'','question_images':[_0x37c9bd(0x20f)],'explanation_images':[]},{'text':_0x37c9bd(0x163),'choices':[{'id':0x1,'text':'Verapamil'},{'id':0x2,'text':_0x37c9bd(0x36c)},{'id':0x3,'text':_0x37c9bd(0x365)},{'id':0x4,'text':'Amlodipine'}],'correct_choice_id':0x1,'solution':_0x37c9bd(0x2d3),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x271),'choices':[{'id':0x1,'text':_0x37c9bd(0x128)},{'id':0x2,'text':_0x37c9bd(0x378)},{'id':0x3,'text':'Zanamivir'},{'id':0x4,'text':_0x37c9bd(0x241)}],'correct_choice_id':0x1,'solution':'<p><strong>Oral\x20Fidaxomicin\x20</strong>is\x20the\x20antibiotic\x20indicated\x20for\x20this\x20patient\x27s\x20condition\x20which\x20is\x20suggestive\x20of\u00a0<em><strong>Clostridium\x20difficile</strong>\u00a0</em>infection,\x20characterized\x20by\x20<strong>profuse\x20watery\x20diarrhea\x20</strong>and\u00a0<strong>leukocytosis</strong>\u00a0following\x20long\x20term\x20antibiotic\x20use\x20such\x20as\x20<strong>ampicillin</strong>.<br\x20/><br\x20/><em>C\x20difficle\x20infection\u00a0</em>is\x20most\x20commonly\x20associated\x20with\u00a0<strong>prolonged\x20antimicrobial\x20use</strong>\u00a0which\x20<strong>interferes</strong>\x20<strong>with</strong>\x20the\x20<strong>commensal\x20colonic\x20microflora</strong>.\x20The\x20most\x20commonly\x20implicated\x20antibiotics\x20are\u00a0<strong>cephalosporins,\u00a0ampicillin,\u00a0clindamycin,\u00a0</strong>and<strong>\u00a0fluoroquinolones</strong>.\x20Spores\x20of\x20toxigenic<em>\u00a0C.\x20difficile</em>\u00a0when\x20ingested,\x20survive\x20gastric\x20acidity\x20and\x20colonize\x20the\x20lower\x20intestinal\x20tract.\x20Here\x20they\x20produce\x20two\x20toxins:<strong>\x20toxin\x20A\x20(an\x20enterotoxin)</strong>\x20and<strong>\x20toxin\x20B\x20(a\x20cytotoxin)</strong>.\x20These\x20toxins\x20initiate\x20processes\x20that\x20<strong>disrupt\x20the\x20epithelial-cell\x20barrier\x20function</strong>,\x20<strong>diarrhea</strong>,\x20and\x20<strong>pseudomembrane</strong>\x20<strong>formation</strong>.<em>\u00a0</em>The\x20patient\x20presents\x20with\x20<strong>non\x20bloody\x20diarrhea</strong>,\x20<strong>fever</strong>,\x20<strong>abdominal\x20pain,</strong>\x20and\x20<strong>leukocytosis</strong>.<br\x20/><br\x20/>Clinical\x20features\u00a0can\x20range\x20from\x20asymptomatic\x20carriage\x20to\x20fulminant\x20colitis.\u00a0</p>\x0a<ul>\x0a<li><strong>Nonsevere\x20disease</strong>\u00a0-\u00a0Watery\x20diarrhea\x20(≥3\x20loose\x20stools\x20in\x2024\x20hours)\x20is\x20the\x20cardinal\x20symptom.\u00a0Other\x20manifestations\x20include\x20lower\x20abdominal\x20pain\x20and\x20cramping,\x20low-grade\x20fever,\x20nausea,\x20anorexia,\u00a0mucus,\x20or\x20occult\x20blood\x20in\x20the\x20stool.\u00a0Physical\x20examination\x20may\x20demonstrate\x20lower\x20abdominal\x20tenderness.\u00a0Unexplained\x20leukocytosis\x20in\x20hospitalized\x20patients\x20(even\x20in\x20the\x20absence\x20of\x20diarrhea)\x20may\x20reflect\x20underlying\x20CDI</li>\x0a<li><strong>Severe\x20colitis\x20-\u00a0</strong>Clinical\x20manifestations\x20of\x20severe\x20colitis\x20include\x20diarrhea,\x20lower\x20quadrant\x20or\x20diffuse\x20abdominal\x20pain,\x20abdominal\x20distention,\x20fever,\x20hypovolemia,\x20lactic\x20acidosis,\x20hypoalbuminemia,\x20elevated\x20creatinine,\x20and\x20marked\x20leukocytosis.</li>\x0a<li><strong>Fulminant\x20colitis</strong>\u00a0-\x20Characterized\x20by\x20hypotension\x20or\x20shock,\x20ileus,\x20or\u00a0<strong>megacolon.</strong></li>\x0a<li><strong>Recurrent\x20disease\x20-\u00a0</strong>resolution\x20of\x20CDI\x20followed\x20by\x20recurrence\x20of\x20symptoms\x20within\x20two\x20to\x20eight\x20weeks\x20after\x20treatment\x20has\x20been\x20stopped<strong>\u00a0</strong></li>\x0a</ul>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201108\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Nucleic\x20acid\x20amplification</strong>\u00a0tests\x20including\x20polymerase\x20chain\x20reaction\x20(<strong>PCR</strong>)\x20assays,\x20for\u00a0<em>C.\x20difficile</em>\u00a0<strong>toxin\x20A\x20or\x20B\x20gene</strong>\x20<strong>in\x20stool</strong>,\x20are\x20widely\x20used\x20diagnostically.\x20<strong>Glutamate\x20dehydrogenase</strong>\x20is\x20an\x20enzyme\x20immunoassay\x20to\x20detect\u00a0<em>C.\x20difficile</em>\u00a0in\x20stool.\x20Confirmation\x20of\x20the\x20presence\x20of\x20toxin\x20in\x20the\x20stool\x20in\x20addition\x20to\x20PCR\x20or\x20glutamate\x20dehydrogenase\x20positivity\x20is\x20recommended.\u00a0</p>\x0a<p><strong>Oral\x20vancomycin</strong>,\u00a0<strong>fidaxomicin,\u00a0</strong>and<strong>\u00a0metronidazole\u00a0</strong>are\x20used\x20in\x20the\x20management\x20of\x20this\x20condition.\u00a0<strong>Fidaxomicin</strong>\x20acts\x20by\x20<strong>inhibiting\x20protein\x20synthesis</strong>\x20through\x20the\x20<strong>blockade\x20of\x20RNA\x20polymerase</strong>.\u00a0<br\x20/><br\x20/><strong>Management\x20of\x20nonsevere\x20to\x20severe\x20initial\x20disease:</strong></p>\x0a<table\x20style=\x22height:\x20135px;\x20width:\x20676px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20293.438px;\x22>\x0a<p><strong>Nonsevere\x20disease</strong></p>\x0aSupportive\x20clinical\x20data:\x20White\x20blood\x20cell\x20count\x20≤15,000\x20cells/mL\x20and\x20serum\x20creatinine\x20&lt;1.5\x20mg/dL</td>\x0a<td\x20style=\x22width:\x20353.969px;\x22>\x0a<ul>\x0a<li>Vancomycin\x20125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20days,\u00a0<strong>OR</strong></li>\x0a<li><strong>Fidaxomicin</strong>\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days</li>\x0a<li>If\x20above\x20agents\x20are\x20unavailable:\x20Metronidazole\u00a0500\x20mg\x20orally\x203\x20times\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20293.438px;\x22>\x0a<p><strong>Severe\x20disease</strong></p>\x0aSupportive\x20clinical\x20data:\x20White\x20blood\x20cell\x20count\x20&gt;15,000\x20cells/mL\x20and/or\x20serum\x20creatinine\x20≥1.5\x20mg/dL</td>\x0a<td\x20style=\x22width:\x20353.969px;\x22>\u00a0\x0a<ul>\x0a<li>Vancomycin\u00a0125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20days,\u00a0<strong>OR</strong></li>\x0a<li><strong>Fidaxomicin</strong>\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/>Management\x20of\x20recurrent\x20disease:<br\x20/></strong></p>\x0a<table\x20style=\x22height:\x20136px;\x20width:\x20674px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20300.734px;\x22>First\x20recurrence</td>\x0a<td\x20style=\x22width:\x20344.672px;\x22>\x0a<ul>\x0a<li>If\x20vancomycin\x20was\x20used\x20for\x20the\x20initial\x20episode:\x20Vancomycin\x20pulsed-tapered\x20regimen:\x0a<ul>\x0a<li>125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20to\x2014\x20days,\x20then</li>\x0a<li>125\x20mg\x20orally\x20twice\x20daily\x20for\x207\x20days,\x20then</li>\x0a<li>125\x20mg\x20orally\x20once\x20daily\x20for\x207\x20days,\x20then</li>\x0a<li>125\x20mg\x20orally\x20every\x202\x20or\x203\x20days\x20for\x202\x20to\x208\x20weeks,\u00a0<strong>OR</strong></li>\x0a</ul>\x0a<ul>\x0a<li>Fidaxomicin\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</li>\x0a<li>If\x20fidaxomicin\x20or\x20metronidazole\x20was\x20used\x20for\x20the\x20initial\x20episode:\x20Vancomycin\x20125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20300.734px;\x22>Second\x20or\x20subsequent\x20recurrence</td>\x0a<td\x20style=\x22width:\x20344.672px;\x22>\u00a0\x0a<ul>\x0a<li>Vancomycin\x20pulsed-tapered\x20regimen\x20(outlined\x20above),\u00a0<strong>OR</strong></li>\x0a<li><strong>Fidaxomicin</strong>\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days,\u00a0<strong>OR</strong></li>\x0a<li>Vancomycin\x20followed\x20by\x20rifaximin:\x0a<ul>\x0a<li>Vancomycin\x20125\x20mg\x20orally\x204\x20times\x20per\x20day\x20for\x2010\x20days,\x20then</li>\x0a<li>Rifaximin\x20400\x20mg\x203\x20times\x20daily\x20for\x2020\x20days,\u00a0<strong>OR</strong></li>\x0a</ul>\x0a</li>\x0a<li>FMT</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/>Management\x20of\x20fulminant\x20disease\x20-\u00a0</strong></p>\x0a<table\x20style=\x22height:\x20154px;\x20width:\x20673px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20265.938px;\x22>Initial\x20episode</td>\x0a<td\x20style=\x22width:\x20378.469px;\x22>\x0a<ul>\x0a<li>Enteric\x20vancomycin\x20plus\x20parenteral\x20metronidazole:\x0a<ul>\x0a<li>Vancomycin\u00a0500\x20mg\x20orally\x20or\x20via\x20nasogastric\x20tube\x204\x20times\x20daily,\u00a0<strong>AND</strong></li>\x0a<li>Metronidazole\x20500\x20mg\x20intravenously\x20every\x208\x20hours</li>\x0a</ul>\x0a</li>\x0a<li>If\x20ileus\x20is\x20present,\u00a0additional\x20considerations\x20include:\x0a<ul>\x0a<li>FMT\x20(administered\x20rectally)</li>\x0a<li>Rectal\x20vancomycin\x20(administered\x20as\x20a\x20retention\x20enema\x20500\x20mg\x20in\x20100\x20mL\x20normal\x20saline\x20per\x20rectum;\x20retained\x20for\x20as\x20long\x20as\x20possible\x20and\x20readministered\x20every\x206\x20hours)</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20265.938px;\x22>Recurrent\x20episode</td>\x0a<td\x20style=\x22width:\x20378.469px;\x22>\u00a0\x0a<ul>\x0a<li>Antibiotics\x20as\x20for\x20initial\x20fulminant\x20episode\x20above</li>\x0a<li>Some\x20favor\x20FMT\x20in\x20the\x20context\x20of\x20a\x20first\x20or\x20second\x20recurrence\x20that\x20presents\x20as\x20a\x20fulminant\x20episode</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B\x20:\x20<strong>Clindamycin\u00a0</strong>is\x20implicated\x20as\x20a\x20<strong>risk\x20factor</strong>\x20for\x20development\x20of\x20clostridium\x20difficile\x20colitis\x20and\x20is\x20not\x20used\x20to\x20treat\x20it.</p>\x0a<p>Option\x20C\x20:\x20<strong>Zanamavir\u00a0</strong>is\x20a\x20neuraminidase\x20inhibitor\x20used\x20against\x20influenza\x20A\x20and\x20B\x20virus.</p>\x0a<p>Option\x20D\x20:\x20<strong>Cilastatin\u00a0</strong>is\x20a\u00a0<strong>reversible\x20dehydropeptidase\x20inhibitor\u00a0</strong>and\x20used\x20adjunctively\x20with\u00a0<strong>imipenem\u00a0</strong>to\x20prolong\x20its\x20action\x20as\x20it\x20rapidly\x20hydrolysed\x20by\u00a0<strong>renal\x20dehydropeptidase.\u00a0</strong>It\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20clostridium\x20difficile\x20colitis.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x139),'choices':[{'id':0x1,'text':_0x37c9bd(0x2a9)},{'id':0x2,'text':_0x37c9bd(0x20c)},{'id':0x3,'text':'Carbamazepine'},{'id':0x4,'text':_0x37c9bd(0x203)}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x2b4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20pathogens\x20is\x20correctly\x20matched\x20with\x20its\x20intrinsic\x20drug\x20resistance?','choices':[{'id':0x1,'text':_0x37c9bd(0x2ec)},{'id':0x2,'text':_0x37c9bd(0x1c6)},{'id':0x3,'text':'Candida\x20Glabrata\x20-\x20Amphotericin\x20B'},{'id':0x4,'text':'Sporothrix\x20-\x20Itraconazole'}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x2d8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20child\x20was\x20receiving\x20a\x20blood\x20transfusion.\x20At\x20what\x20serum\x20iron\x20level\x20will\x20desferrioxamine\x20be\x20administered\x20to\x20him?','choices':[{'id':0x1,'text':_0x37c9bd(0x11d)},{'id':0x2,'text':_0x37c9bd(0x269)},{'id':0x3,'text':_0x37c9bd(0x223)},{'id':0x4,'text':_0x37c9bd(0x1cc)}],'correct_choice_id':0x4,'solution':_0x37c9bd(0x189),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x150),'choices':[{'id':0x1,'text':_0x37c9bd(0x262)},{'id':0x2,'text':_0x37c9bd(0x385)},{'id':0x3,'text':'Meperidine'},{'id':0x4,'text':_0x37c9bd(0x21a)}],'correct_choice_id':0x1,'solution':'<p><strong>Methadone</strong>\x20is\x20the\x20<strong>causative\x20drug</strong>\x20for\x20this\x20patient\x27s\x20presentation\x20of\x20<strong>syncope</strong>\x20and<strong>\x20prolonged\x20QT\x20interval\x20</strong>after\x20<strong>coadministration</strong>\x20other\x20QT\x20prolonging\x20drugs\x20such\x20as\x20<strong>fluoxetine</strong>.<br\x20/><br\x20/>Unlike\x20other\x20opioids,\x20<strong>QT\x20prolongation</strong>\x20is\x20primarily\x20a<strong>\x20side\x20effect\x20of\x20methadone</strong>,\x20which\x20is\x20<strong>additive</strong>\x20<strong>with\x20other\x20agents</strong>\x20known\x20to\x20cause\x20<strong>QT\x20prolongation</strong>\x20such\x20as\x20<strong>fluoxetine</strong>.\x20<strong>Serious\x20cardiac\x20arrhythmias\x20</strong>including\x20<strong>torsades\x20de\x20pointes</strong>\x20have\x20been\x20noted\x20with\x20methadone\x20use.<strong>\x20Normal\x20QTc\x20</strong>is\x20about\x20<strong>440\x20ms</strong>.\x20Values\x20of\x20<strong>more\x20than\x20440\x20ms\x20in\x20males</strong>\x20and\x20<strong>460\x20ms\x20in\x20females</strong>\x20are\x20considered\x20to\x20be\x20<strong>prolonged</strong>.\x20QT\x20prolongation\x20can\x20present\x20as\x20<strong>syncope</strong>\x20or\x20<strong>cardiac\x20arrest</strong>.<br\x20/><br\x20/><strong>Methadone</strong>\x20is\x20a\x20<strong>synthetic\x20opioid</strong>\x20that\x20is\x20<strong>chemically\x20different</strong>\x20but\x20has<strong>\x20similar\x20pharmacological</strong>\x20<strong>action</strong>\x20to\x20that\x20of\x20<strong>morphine</strong>\x20(Option\x20B).\x20It\x20is\x20a\x20<strong>long-acting\x20mu-opioid\x20receptor\x20agonist</strong>.\x20Although\x20an\x20effective\x20analgesic,\x20the\x20<strong>primary\x20use</strong>\x20of\x20methadone\x20hydrochloride\x20is\x20<strong>detoxification\x20and\x20maintenance</strong>\x20<strong>therapy</strong>\x20treatment\x20for<strong>\x20opioid\x20use\x20disorder</strong>.\x20Methadone\x20is\x20also\x20used\x20for\x20the\x20<strong>management\x20of\x20chronic\x20pain</strong>.<br\x20/><br\x20/><strong>Side\x20effects\x20</strong>of\x20methadone\x20are\x20<strong>similar\x20to\x20that\x20of\x20morphine\x20</strong>such\x20as\x20<strong>lethargy,\x20constipation,\x20respiratory\x20depression,\x20and\x20hypotension</strong>.\x20Like\x20other\x20opioids,\x20methadone\x20will\x20produce\x20<strong>tolerance\x20and\x20dependence</strong>.\x20Development\x20of\x20physical\x20dependence\x20during\x20the\x20long-term\x20administration\x20of\x20methadone\x20can\x20be\x20demonstrated\x20following\x20abrupt\x20drug\x20withdrawal\x20or\x20administration\x20of\x20an\x20opioid\x20antagonist.\u00a0<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B\x20:\x20Morphine\x20is\x20not\x20associated\x20with\x20QT\x20prolongation.</p>\x0a<p>Option\x20C\x20:\x20<strong>Meperidine</strong>,\x20also\x20known\x20as\x20<strong>pethidine</strong>,\x20though\x20chemically\x20unrelated\x20to\x20morphine\x20interacts\x20with\x20µ\x20opioid\x20receptors\x20and\x20its\x20actions\x20are\x20blocked\x20by\x20naloxone.\x20Apart\x20from\x20usual\x20opioid\x20side\x20effects,\x20pethidine\x20produces\x20some\x20<strong>atropinic\x20effects</strong>\x20like\x20dry\x20mouth,\x20blurred\x20vision,\x20tachycardia.\x20Pethidine\x20injected\x20in\x20patients\x20receiving\x20a\x20selective\x20serotonin\x20reuptake\x20inhibitor\x20(SSRI)\x20may\x20produce<strong>\x20serotonin\x20syndrome</strong>.\x20It\x20is\x20occasionally\x20used\x20to\x20<strong>control\x20shivering\x20during\x20recovery\x20from\x20anaesthesia</strong>.</p>\x0a<p>Option\x20D\x20:\x20<strong>Propoxyphene</strong>\x20is\x20a<strong>\x20methadone\x20analogue\x20</strong>that\x20was\x20used\x20to\x20treat\x20mild-tomoderate\x20pain.\x20Due\x20to\x20reports\x20of\x20<strong>cardiotoxicity</strong>,\x20it\x20was\x20<strong>withdrawn</strong>\x20<strong>in\x20UK,\x20Europe,\x20and\x20USA</strong>\x20and\x20it\x20was<strong>\x20banned\x20in\x20India\x20in\x202013</strong>.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x1c5),'choices':[{'id':0x1,'text':_0x37c9bd(0x395)},{'id':0x2,'text':_0x37c9bd(0x1be)},{'id':0x3,'text':_0x37c9bd(0x121)},{'id':0x4,'text':_0x37c9bd(0x360)}],'correct_choice_id':0x2,'solution':_0x37c9bd(0x31d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x37c9bd(0x136),'choices':[{'id':0x1,'text':_0x37c9bd(0x2cf)},{'id':0x2,'text':_0x37c9bd(0x34b)},{'id':0x3,'text':'Darunavir'},{'id':0x4,'text':'Ritonavir'}],'correct_choice_id':0x2,'solution':'<p>This\x20patient\x20was\x20most\x20likely\x20taking\x20<strong>tipranavir</strong>,\x20as\x20it\x20is\x20known\x20to\x20be\x20associated\x20with\x20an\x20<strong>increased\x20risk\x20of\x20intracranial\x20hemorrhage\x20and\x20hepatotoxicity\x20</strong>which\x20is\x20the\x20likely\x20cause\x20of\x20<strong>altered\x20mental\x20status</strong>\x20in\x20this\x20patient\x20with\x20<strong>hemophilia</strong>\x20following\x20complaints\x20of\x20<strong>nausea,\x20vomiting\x20and\x20headache</strong>.<br\x20/><br\x20/><strong>Tipranavir\u00a0</strong>is\x20a\x20<strong>protease\x20inhibitor\x20(PI)\x20</strong>used\x20in\x20patients\x20who\x20are\x20resistant\x20to\x20other\u00a0PIs.\x20It\x20is\x20often\x20combined\x20with\x20<strong>ritonavir,\u00a0</strong>to\x20achieve\x20better\x20therapeutic\x20outcomes.\x20It\x20should\x20be\x20avoided\x20in\x20patients\x20with\u00a0<strong>head\x20trauma\x20</strong>or\u00a0<strong>bleeding\x20diathesis</strong>,\x20such\x20as\x20<strong>hemophilia</strong>\x20as\x20it\x20is\x20associated\x20with\x20an\x20<strong>increased\x20risk\x20of\x20intracranial</strong>\x20<strong>hemorrhage</strong>.\x20Other\x20common\x20adverse\x20effects\x20of\x20tipranavir\x20include\x20nausea,\x20vomiting,\x20diarrhea,\x20abdominal\x20pain,\x20urticarial\x20or\x20maculopapular\x20rash,\x20and\x20liver\x20toxicity.</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2049.1969%;\x20height:\x20134.39px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Antiretroviral\x20drug</strong></td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Mechanism\x20of\x20action</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Nucleotide/\x20nucleoside\x20reverse\x20transcriptase\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Inhibits\x20reverse\x20transcriptase</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Non-nucleoside\x20reverse\x20transcriptase\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Inhibits\x20reverse\x20transcriptase\x20by\x20binding\x20to\x20an\x20allosteric\x20site\x20of\x20the\x20enzyme</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Protease\x20inhibitors</strong></td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Inhibits\x20the\x20viral\x20protease\x20enzyme\x20necessary\x20to\x20produce\x20mature\x20virions\x20upon\x20budding\x20from\x20the\x20host\x20membrane.</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Entry\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>\x0a<p>Interferes\x20with\x20binding,\x20fusion,\x20and\x20entry\x20of\x20HIV\x20-1\x20into\x20the\x20cell\x20by\x20blocking\x20a\x20target.</p>\x0a<p>Maraviroc\x20works\x20by\x20targetting\x20CCR5,\x20a\x20coreceptor\x20located\x20on\x20human\x20helper\x20T-cells</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Integrase\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Inhibits\x20the\x20viral\x20enzyme\x20integrase,\x20which\x20is\x20responsible\x20for\x20the\x20integration\x20of\x20viral\x20DNA\x20into\x20the\x20DNA\x20of\x20the\x20infected\x20cell.</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Other\x20Options\x20:</strong>\u00a0</p>\x0a<p>Option\x20A,\x20C\x20and\x20D\x20:\x20Lopinavir,\x20Darunavir\x20and\x20Ritonavir\x20are\x20protease\x20inhibitors\x20that\x20can\x20cause\x20nausea\x20and\x20vomiting,\x20although\x20they\x20are\x20not\x20contraindicated\x20in\x20patients\x20with\x20bleeding\x20diathesis\x20and\x20not\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20intracranial\x20hemorrhage.</p>\x0a<p><strong><br\x20/></strong>The\x20illustration\x20below\x20shows\x20the\x20mechanism\x20of\x20action\x20of\x20various\x20antiretroviral\x20drugs.</p>','explanation_video':'','question_images':[],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/a35d3bc243d84eabab61ffc2580066dcx769x673.JPEG']},{'text':_0x37c9bd(0x13b),'choices':[{'id':0x1,'text':_0x37c9bd(0x1fb)},{'id':0x2,'text':_0x37c9bd(0x33b)},{'id':0x3,'text':_0x37c9bd(0x2be)},{'id':0x4,'text':_0x37c9bd(0x311)}],'correct_choice_id':0x1,'solution':'<p>Management\x20of\x20hyperkalemia\x20involves\x20an\x20immediate\x20reversal\x20of\x20cardiac\x20effects\x20by\x20administration\x20of\x20<strong>10mL\x20of\x2010%\x20calcium\x20gluconate\x20intravenously</strong>.\x20This\x20leads\x20to\x20the\x20reversal\x20of\x20the\x20depolarization\x20blockade\x20due\x20to\x20hyperkalemia.\x20Redistributing\x20the\x20excess\x20potassium\x20by\x20administering\x20<strong>10U\x20of\x20intravenous\x20insulin\x20</strong>followed\x20by\x20<strong>50mL\x20of\x2050%\x20dextrose</strong>\x20can\x20also\x20be\x20given,\x20as\x20insulin\x20facilitates\x20the\x20intracellular\x20shift\x20of\x20potassium.\x20<strong>Beta-2-agonists</strong>\x20can\x20also\x20be\x20used\x20in\x20the\x20management\x20of\x20hyperkalemia.\x20But\x20patients\x20with\x20end-stage\x20renal\x20disease\x20are\x20resistant\x20to\x20beta-2-agonists\x20and\x20hence\x20must\x20be\x20used\x20with\x20caution.\u00a0Removal\x20of\x20potassium\x20can\x20be\x20done\x20using\x20<strong>cation\x20exchange\x20resins</strong>\x20like\x20<strong>patiromer\x20</strong>and<strong>\x20sodium\x20polystyrene\x20sulfonate</strong>,<strong>\x20diuretics</strong>,<strong>\u00a0</strong>and\x20<strong>dialysis.</strong></p>','explanation_video':'','question_images':[],'explanation_images':[_0x37c9bd(0x221)]},{'text':'Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20used\x20in\x20diabetic\x20neuropathy,\x20post\x20herpetic\x20neuralgia\x20and\x20spinal\x20cord\x20injury?','choices':[{'id':0x1,'text':_0x37c9bd(0x22f)},{'id':0x2,'text':_0x37c9bd(0x181)},{'id':0x3,'text':_0x37c9bd(0x201)},{'id':0x4,'text':'Pregabalin'}],'correct_choice_id':0x4,'solution':_0x37c9bd(0x32e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20antibiotics\x20acts\x20by\x20inhibiting\x20the\x2050s\x20ribosome?','choices':[{'id':0x1,'text':_0x37c9bd(0x113)},{'id':0x2,'text':_0x37c9bd(0x1c3)},{'id':0x3,'text':'Linezolid'},{'id':0x4,'text':_0x37c9bd(0x30b)}],'correct_choice_id':0x3,'solution':_0x37c9bd(0x354),'explanation_video':'','question_images':[],'explanation_images':[_0x37c9bd(0x1e1)]}],quizName=_0x37c9bd(0x160),hierarchy=['Marrow','PYQs','Pharmacology'];if(window[_0x37c9bd(0x260)][_0x37c9bd(0x2d7)][_0x37c9bd(0x1a9)]('custom_quiz.html')){const customData=JSON[_0x37c9bd(0x1d9)](localStorage[_0x37c9bd(0x202)](_0x37c9bd(0x122)));if(customData){const BFQaeJ=_0x37c9bd(0x261)[_0x37c9bd(0x26f)]('|');let vuPJGM=0x0;while(!![]){switch(BFQaeJ[vuPJGM++]){case'0':document[_0x37c9bd(0x1e7)](_0x37c9bd(0x34c))[_0x37c9bd(0x171)]=questionsData['length'];continue;case'1':quizName=customData[_0x37c9bd(0x34e)];continue;case'2':document['title']=quizName+_0x37c9bd(0x251);continue;case'3':document[_0x37c9bd(0x1e7)](_0x37c9bd(0x20a))[_0x37c9bd(0x171)]=hierarchy[_0x37c9bd(0x210)]('\x20>\x20');continue;case'4':hierarchy=customData[_0x37c9bd(0x12f)];continue;case'5':questionsData=customData[_0x37c9bd(0x37f)];continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x37c9bd(0x29d),timer=null,timeRemaining=0x0,questionStartTime=Date['now'](),quizStartTime=Date[_0x37c9bd(0x1c1)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x37c9bd(0x186)])[_0x37c9bd(0x39c)](null)[_0x37c9bd(0x188)](()=>({'status':_0x37c9bd(0x168),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData['length']};const urlParams=new URLSearchParams(window[_0x37c9bd(0x260)][_0x37c9bd(0x308)]);currentQuestionIndex=Math['min'](parseInt(urlParams['get'](_0x37c9bd(0x343)))||0x0,questionsData[_0x37c9bd(0x186)]-0x1);function goBack(){const _0x4b7b83=_0x37c9bd,_0x45b7af={'JZhCo':function(_0x4d640e,_0x3ac110){return _0x4d640e(_0x3ac110);}};(isQuizCompleted||_0x45b7af[_0x4b7b83(0x1bb)](confirm,'Are\x20you\x20sure\x20you\x20want\x20to\x20leave\x20the\x20quiz?\x20Your\x20progress\x20will\x20be\x20lost.'))&&window[_0x4b7b83(0x250)][_0x4b7b83(0x10f)]();}function selectMode(_0x4f8fdf){const _0x2c0058=_0x37c9bd,_0x5222a0={'AOmlk':_0x2c0058(0x16c),'TIfne':function(_0x25fd52){return _0x25fd52();}};currentMode=_0x4f8fdf,document[_0x2c0058(0x1e7)]('modeModal')[_0x2c0058(0x2b1)][_0x2c0058(0x1a0)]=_0x5222a0[_0x2c0058(0x12d)],_0x5222a0[_0x2c0058(0x19c)](initializeQuiz);}function initializeQuiz(){const _0x68ad37=_0x37c9bd,_0x437ec3={'PpyHG':'bookmarkBtn','bgxKw':_0x68ad37(0x1e6),'RVGgM':function(_0x2db3e1,_0x42010f){return _0x2db3e1===_0x42010f;},'MmUcA':'timed_exam','bvQJM':'statsBar','kEXUA':_0x68ad37(0x16c),'FIicc':_0x68ad37(0x352),'ptXIh':_0x68ad37(0x16b),'LCjal':_0x68ad37(0x228),'tKPVj':function(_0x1508d1,_0x2f9d37){return _0x1508d1===_0x2f9d37;},'yQUVG':_0x68ad37(0x1d4),'ubuLq':_0x68ad37(0x2ed),'PWYgN':function(_0xd1f6a){return _0xd1f6a();},'Pghef':function(_0x2904d3){return _0x2904d3();},'DyouI':function(_0x1c52f1){return _0x1c52f1();}};quizStartTime=Date[_0x68ad37(0x1c1)]();const _0x4d3ca6=document['getElementById'](_0x437ec3['PpyHG']),_0x4feae9=document[_0x68ad37(0x1e7)]('markReviewBtn'),_0x3f1c64=document['getElementById'](_0x437ec3[_0x68ad37(0x2ff)]),_0x58d01a=_0x437ec3['RVGgM'](currentMode,'test')||currentMode===_0x437ec3[_0x68ad37(0x1b3)];document[_0x68ad37(0x1e7)](_0x437ec3['bvQJM'])[_0x68ad37(0x2b1)][_0x68ad37(0x1a0)]=_0x58d01a?_0x437ec3[_0x68ad37(0x1ad)]:_0x68ad37(0x352),document[_0x68ad37(0x1e7)](_0x68ad37(0x334))[_0x68ad37(0x2b1)][_0x68ad37(0x1a0)]=_0x58d01a?_0x68ad37(0x16c):_0x437ec3[_0x68ad37(0x1ba)],document['getElementById'](_0x437ec3[_0x68ad37(0x331)])[_0x68ad37(0x2b1)]['display']=_0x58d01a?_0x68ad37(0x352):_0x437ec3[_0x68ad37(0x1ad)],document['getElementById'](_0x68ad37(0x226))[_0x68ad37(0x2b1)]['display']=_0x58d01a?_0x437ec3['FIicc']:_0x68ad37(0x16c),_0x4d3ca6['style'][_0x68ad37(0x1a0)]=_0x58d01a?_0x437ec3[_0x68ad37(0x1ad)]:_0x437ec3['LCjal'],_0x4feae9[_0x68ad37(0x2b1)][_0x68ad37(0x1a0)]=_0x58d01a?_0x437ec3[_0x68ad37(0x340)]:_0x437ec3[_0x68ad37(0x1ad)],_0x3f1c64[_0x68ad37(0x2b1)][_0x68ad37(0x1a0)]=_0x58d01a?_0x437ec3[_0x68ad37(0x340)]:_0x437ec3[_0x68ad37(0x1ad)],(_0x437ec3[_0x68ad37(0x1eb)](currentMode,_0x437ec3[_0x68ad37(0x138)])||currentMode===_0x437ec3['MmUcA'])&&document[_0x68ad37(0x1e7)](_0x437ec3['ubuLq'])[_0x68ad37(0x12b)][_0x68ad37(0x30e)](_0x68ad37(0x1b1)),_0x437ec3[_0x68ad37(0x220)](loadBookmarkedQuestions),_0x437ec3['Pghef'](generateQuestionNav),_0x437ec3[_0x68ad37(0x11a)](updateStats),_0x437ec3[_0x68ad37(0x235)](displayQuestion);}function generateQuestionNav(){const _0x4ab751=_0x37c9bd,_0x1f98b1={'rCKKd':'questionNav','Ratzv':function(_0x25e37b,_0x267bc0){return _0x25e37b<_0x267bc0;},'Toepj':'button','rNBIu':function(_0x29dc1e,_0x37ed68){return _0x29dc1e+_0x37ed68;}},_0x4fc6b7=document[_0x4ab751(0x1e7)](_0x1f98b1[_0x4ab751(0x14c)]);_0x4fc6b7[_0x4ab751(0x216)]='';for(let _0x27c620=0x0;_0x1f98b1[_0x4ab751(0x1e0)](_0x27c620,questionsData[_0x4ab751(0x186)]);_0x27c620++){const _0x563dad=document['createElement'](_0x1f98b1['Toepj']);_0x563dad['textContent']=_0x1f98b1['rNBIu'](_0x27c620,0x1),_0x563dad[_0x4ab751(0x1f3)]=_0x4ab751(0x22d),_0x563dad[_0x4ab751(0x1f1)]=()=>jumpToQuestion(_0x27c620),_0x563dad['id']=_0x4ab751(0x384)+_0x27c620,_0x4fc6b7[_0x4ab751(0x366)](_0x563dad);}updateQuestionNav();}function updateQuestionNav(){const _0xbcfe2e=_0x37c9bd,_0x200a6f={'yGgHE':_0xbcfe2e(0x198),'ztIJV':function(_0x10d452,_0x376dab){return _0x10d452===_0x376dab;},'yuwoz':_0xbcfe2e(0x2a4),'vTauy':'nav-btn-current','vgXEI':_0xbcfe2e(0xfd),'EeJdj':_0xbcfe2e(0x368),'hhGMM':function(_0x4ea43f,_0x35f161){return _0x4ea43f===_0x35f161;},'aEUMt':'idndg','VPdEw':_0xbcfe2e(0x2ea),'eSraC':'nav-btn-marked-review','Zbtok':function(_0x5bea6f,_0x5edab1){return _0x5bea6f===_0x5edab1;},'YsIFE':_0xbcfe2e(0x29d),'MpEzw':function(_0xa5ac17,_0x556e7f){return _0xa5ac17===_0x556e7f;},'xYxOh':_0xbcfe2e(0x1a8),'XUWzy':'correct','yubyy':_0xbcfe2e(0x182),'LpGvK':_0xbcfe2e(0x319),'mKxGt':'nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','zEwAf':function(_0x727c6c,_0x49de40){return _0x727c6c!==_0x49de40;},'HoBrj':_0xbcfe2e(0x1f8)};for(let _0x10338a=0x0;_0x10338a<questionsData[_0xbcfe2e(0x186)];_0x10338a++){const _0x54c917=document[_0xbcfe2e(0x1e7)](_0xbcfe2e(0x384)+_0x10338a),_0x775597=questionStates[_0x10338a];let _0x56e216='';if(_0x200a6f[_0xbcfe2e(0x33d)](_0x10338a,currentQuestionIndex))_0x56e216=_0x200a6f[_0xbcfe2e(0x155)];else{if(_0x775597['bookmarked'])_0x200a6f[_0xbcfe2e(0x33d)]('KDMxZ',_0x200a6f[_0xbcfe2e(0x320)])?_0x56e216=_0x200a6f[_0xbcfe2e(0x173)]:_0x236893['classList'][_0xbcfe2e(0x24b)](_0x200a6f[_0xbcfe2e(0x1b6)],_0x200a6f[_0xbcfe2e(0x33d)](_0x35969f,_0x133b62));else{if(_0x775597[_0xbcfe2e(0x2f6)])_0x200a6f['hhGMM'](_0x200a6f[_0xbcfe2e(0x17a)],_0x200a6f['VPdEw'])?_0x5e0c02['src']=_0x2d606a:_0x56e216=_0x200a6f[_0xbcfe2e(0x35a)];else{if(_0x200a6f['Zbtok'](currentMode,_0x200a6f[_0xbcfe2e(0x19d)])||_0x200a6f[_0xbcfe2e(0x2ca)](currentMode,'timed_study')){if(_0x200a6f[_0xbcfe2e(0x361)](_0x200a6f['xYxOh'],'FNMEJ')){const _0x450c50=_0x45770d[_0xbcfe2e(0x1e7)](_0xbcfe2e(0x141)),_0x52aeb6=_0x4cd2ee[_0xbcfe2e(0x1e7)](_0xbcfe2e(0x1fc)),_0x2d0400=_0x3bf92c[_0xf2ab8a][_0xbcfe2e(0x2f6)];_0x450c50['className']=_0x2d0400?_0x200a6f[_0xbcfe2e(0x19f)]:_0xbcfe2e(0x254),_0x52aeb6[_0xbcfe2e(0x171)]=_0x2d0400?_0xbcfe2e(0x242):_0xbcfe2e(0x2e4);}else{if(_0x200a6f['hhGMM'](_0x775597[_0xbcfe2e(0x2ba)],_0x200a6f[_0xbcfe2e(0x1df)]))_0x56e216=_0x200a6f['yubyy'];else{if(_0x200a6f[_0xbcfe2e(0x361)](_0x775597['status'],_0xbcfe2e(0x13d)))_0x56e216=_0x200a6f[_0xbcfe2e(0x246)];else _0x56e216=_0x200a6f[_0xbcfe2e(0x153)];}}}else{if(_0x200a6f['zEwAf'](_0x775597['selectedAnswer'],null))_0x56e216=_0x200a6f[_0xbcfe2e(0x129)];else _0x56e216=_0x200a6f[_0xbcfe2e(0x153)];}}}}_0x54c917[_0xbcfe2e(0x1f3)]=_0xbcfe2e(0x27b)+_0x56e216;}}function jumpToQuestion(_0x4c3bf6){const _0x3cdd38=_0x37c9bd,_0x2d1f1a={'ZFlAq':function(_0x1682e3,_0x2217f6){return _0x1682e3>=_0x2217f6;},'kdbxL':function(_0x3b8b92,_0x10717c){return _0x3b8b92-_0x10717c;},'jfTVY':function(_0x3bfd34){return _0x3bfd34();}};_0x2d1f1a['ZFlAq'](_0x4c3bf6,0x0)&&_0x4c3bf6<questionsData[_0x3cdd38(0x186)]&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x3cdd38(0x32a)]+=_0x2d1f1a['kdbxL'](Date[_0x3cdd38(0x1c1)](),questionStartTime)),currentQuestionIndex=_0x4c3bf6,_0x2d1f1a['jfTVY'](displayQuestion));}function updateStats(){const _0x628e67=_0x37c9bd,_0xd0e6b2={'kCjmI':_0x628e67(0x29d),'qRUWg':_0x628e67(0x1d4),'mHzlD':_0x628e67(0x2bc),'ZXWVZ':_0x628e67(0x30d),'olXfc':function(_0x1986b5,_0x1f0091){return _0x1986b5*_0x1f0091;},'snzWL':_0x628e67(0x272),'lGtha':function(_0x4b8dad,_0x26c702){return _0x4b8dad/_0x26c702;},'OgxCQ':function(_0x124ce5,_0x2f2207){return _0x124ce5%_0x2f2207;},'JBTTd':function(_0x20cce3,_0x264e3e){return _0x20cce3+_0x264e3e;},'mygyk':function(_0x1983d1,_0x4b6a70){return _0x1983d1+_0x4b6a70;}};if(currentMode===_0xd0e6b2[_0x628e67(0x170)]||currentMode===_0xd0e6b2[_0x628e67(0x1cb)]){document[_0x628e67(0x1e7)](_0xd0e6b2[_0x628e67(0x39b)])[_0x628e67(0x171)]=stats[_0x628e67(0x37b)],document[_0x628e67(0x1e7)](_0xd0e6b2['ZXWVZ'])['textContent']=stats['incorrectAnswers'],document[_0x628e67(0x1e7)](_0x628e67(0x369))[_0x628e67(0x171)]=stats['totalAttempted'];const _0x5e16e7=stats['totalAttempted']>0x0?Math['round'](_0xd0e6b2[_0x628e67(0x15c)](stats[_0x628e67(0x37b)]/stats[_0x628e67(0x369)],0x64)):0x0;document[_0x628e67(0x1e7)](_0xd0e6b2[_0x628e67(0x36b)])[_0x628e67(0x171)]=_0x5e16e7+'%',stats[_0x628e67(0x2fc)]=questionStates[_0x628e67(0x276)]((_0x2937bf,_0x19aecb)=>_0x2937bf+_0x19aecb['timeSpent'],0x0);const _0x11966a=Math[_0x628e67(0x29a)](stats[_0x628e67(0x2fc)]/0x3e8),_0x187eab=Math[_0x628e67(0x29a)](_0xd0e6b2[_0x628e67(0x1ea)](_0x11966a,0x3c)),_0x107121=_0xd0e6b2[_0x628e67(0x21e)](_0x11966a,0x3c);document['getElementById'](_0x628e67(0x32a))[_0x628e67(0x171)]=_0xd0e6b2['JBTTd'](_0xd0e6b2[_0x628e67(0x1af)](_0x187eab,':'),_0x107121[_0x628e67(0x2b2)]()[_0x628e67(0x23d)](0x2,'0'));}}function setupVideo(_0x1b0ddd,_0x2de36f){const _0x5edd8=_0x37c9bd,_0x4da85a={'LdeMj':_0x5edd8(0x15b)};if(Hls['isSupported']()){const _0x458332=new Hls();_0x458332[_0x5edd8(0x356)](_0x2de36f),_0x458332[_0x5edd8(0x14a)](_0x1b0ddd);}else _0x1b0ddd[_0x5edd8(0x367)](_0x4da85a['LdeMj'])&&(_0x1b0ddd[_0x5edd8(0x176)]=_0x2de36f);}function displayQuestion(){const _0x572425=_0x37c9bd,_0x3fc2fe={'zLwGA':function(_0x597441){return _0x597441();},'fmefT':function(_0xe89dd5,_0x5dc06f){return _0xe89dd5===_0x5dc06f;},'HvPSA':'RhKGB','stfUo':function(_0xe6a7bb,_0x45f614){return _0xe6a7bb+_0x45f614;},'wCjLy':_0x572425(0x154),'lMkAn':'selected','NzbYb':function(_0x49b3c0,_0x2c1ac6){return _0x49b3c0+_0x2c1ac6;},'CtTkr':_0x572425(0x21b),'cnJHc':_0x572425(0x13d),'LEXks':_0x572425(0x339),'XzaRM':_0x572425(0x178),'WuHiQ':function(_0x1b4ad3,_0x2ab7c6){return _0x1b4ad3(_0x2ab7c6);},'ABonF':'questionText','IMTJL':_0x572425(0x112),'DsmPy':function(_0x10a20c,_0x5f055d){return _0x10a20c*_0x5f055d;},'rAjmo':function(_0x515e41,_0x202cbd){return _0x515e41/_0x202cbd;},'sOiVD':function(_0x145c4f,_0x5ebc3c){return _0x145c4f+_0x5ebc3c;},'hGcFB':_0x572425(0x156),'YJjqP':_0x572425(0x25c),'NyFbS':function(_0x5449f5,_0x4c9c7e){return _0x5449f5===_0x4c9c7e;},'JldAI':_0x572425(0x2dc),'mBHAF':_0x572425(0x1b1),'gUfeT':_0x572425(0x277),'ktaKM':_0x572425(0x164),'jWSZE':'optionsContainer','zupXl':_0x572425(0x317),'OvKxC':function(_0x3423f2){return _0x3423f2();},'XjyUN':_0x572425(0x1d4),'Kafio':function(_0x20af4d,_0x47ee78){return _0x20af4d===_0x47ee78;}};if(!questionsData||questionsData[_0x572425(0x186)]===0x0){document[_0x572425(0x1e7)](_0x3fc2fe[_0x572425(0x1d7)])[_0x572425(0x216)]=_0x3fc2fe[_0x572425(0x298)];return;};const _0x4398e0=questionsData[currentQuestionIndex];questionStartTime=Date[_0x572425(0x1c1)](),selectedOption=questionStates[currentQuestionIndex][_0x572425(0x1ce)];const _0x38a11d=_0x3fc2fe[_0x572425(0x370)](_0x3fc2fe[_0x572425(0x314)](_0x3fc2fe['sOiVD'](currentQuestionIndex,0x1),questionsData[_0x572425(0x186)]),0x64);document['getElementById'](_0x3fc2fe[_0x572425(0x386)])['style'][_0x572425(0x1f2)]=_0x38a11d+'%',document[_0x572425(0x1e7)](_0x572425(0x2c7))[_0x572425(0x171)]=_0x3fc2fe[_0x572425(0x358)](currentQuestionIndex,0x1),updateQuestionNav(),document[_0x572425(0x1e7)](_0x3fc2fe[_0x572425(0x27e)])[_0x572425(0x348)]=_0x3fc2fe[_0x572425(0x2aa)](currentQuestionIndex,0x0),document[_0x572425(0x1e7)](_0x3fc2fe[_0x572425(0x1e5)])[_0x572425(0x12b)][_0x572425(0x175)](_0x3fc2fe[_0x572425(0x2a8)]),document['getElementById'](_0x3fc2fe[_0x572425(0x1d7)])['innerHTML']=_0x4398e0[_0x572425(0x275)]||_0x3fc2fe['gUfeT'];let _0x3451d6='';if(_0x4398e0[_0x572425(0x3a0)])_0x3451d6+=_0x572425(0x292)+_0x4398e0['question_audio']+_0x572425(0x1f0);if(_0x4398e0[_0x572425(0x2c8)])_0x3451d6+=_0x572425(0x12a)+_0x4398e0[_0x572425(0x2c8)]+'\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>';_0x4398e0[_0x572425(0x2f9)]&&_0x4398e0[_0x572425(0x2f9)][_0x572425(0x27d)](_0x591e3b=>{const _0x4d3890=_0x572425;if(_0x591e3b)_0x3451d6+=_0x4d3890(0x18f)+_0x591e3b+_0x4d3890(0x2f7);});document[_0x572425(0x1e7)](_0x3fc2fe[_0x572425(0x20b)])[_0x572425(0x216)]=_0x3451d6;const _0x36f1d8=document[_0x572425(0x1e7)](_0x3fc2fe[_0x572425(0x2f8)]);_0x36f1d8['innerHTML']='',_0x36f1d8['classList'][_0x572425(0x30e)](_0x3fc2fe[_0x572425(0x1a5)]),_0x4398e0[_0x572425(0x337)]&&Array[_0x572425(0x256)](_0x4398e0[_0x572425(0x337)])&&(_0x4398e0['choices']['forEach']((_0x1dc8ee,_0xc95ee4)=>{const _0x13ff28=_0x572425,_0x47e195={'VYvlP':function(_0x307b15){return _0x3fc2fe['zLwGA'](_0x307b15);}};if(_0x3fc2fe[_0x13ff28(0x2a6)](_0x3fc2fe[_0x13ff28(0x2b8)],_0x3fc2fe[_0x13ff28(0x2b8)])){const _0x544468=String['fromCharCode'](_0x3fc2fe[_0x13ff28(0x213)](0x41,_0xc95ee4)),_0x18b180=selectedOption===_0xc95ee4,_0x3ee20f=document['createElement'](_0x3fc2fe[_0x13ff28(0x23f)]);_0x3ee20f[_0x13ff28(0x216)]=_0x13ff28(0x1bf)+(_0x18b180?_0x3fc2fe[_0x13ff28(0x18e)]:'')+'\x22\x20data-option-index=\x22'+_0xc95ee4+_0x13ff28(0x2df)+_0x544468+_0x13ff28(0x30a)+(_0x1dc8ee[_0x13ff28(0x275)]||_0x3fc2fe[_0x13ff28(0x140)](_0x3fc2fe[_0x13ff28(0x27a)],_0xc95ee4+0x1))+_0x13ff28(0x17b),_0x36f1d8['appendChild'](_0x3ee20f);}else _0x4b52b3[_0x349cfa][_0x13ff28(0x2f6)]=!_0x552611[_0x2c2fdb][_0x13ff28(0x2f6)],_0x47e195[_0x13ff28(0x394)](_0x6cca30),_0x571a31();}),_0x36f1d8[_0x572425(0x1b2)](_0x572425(0x2a5),function(_0x4f07e1){const _0x70883=_0x572425,_0xfb7bf1={'pblKC':_0x3fc2fe[_0x70883(0x110)]},_0x334864=_0x4f07e1[_0x70883(0x224)]['closest'](_0x3fc2fe[_0x70883(0x30c)]);if(_0x334864){if(_0x3fc2fe[_0x70883(0x2a6)](_0x3fc2fe[_0x70883(0x26a)],'LkXTo'))_0x529281[_0x70883(0x337)][_0x58c674[_0x70883(0x1ce)]]['id']===_0x2b9294[_0x70883(0x382)]?(_0x47d5b7++,_0x29b3d7[_0x70883(0x2ba)]='correct'):(_0x1b0f32++,_0x5c698b[_0x70883(0x2ba)]=_0xfb7bf1[_0x70883(0x111)]);else{const _0x5d39c4=parseInt(_0x334864[_0x70883(0x132)](_0x70883(0x312)));_0x3fc2fe[_0x70883(0x283)](selectOption,_0x5d39c4);}}})),_0x3fc2fe[_0x572425(0x37c)](updateBookmarkButton),_0x3fc2fe['zLwGA'](updateMarkReviewButton),(currentMode===_0x3fc2fe[_0x572425(0x393)]||_0x3fc2fe[_0x572425(0x32b)](currentMode,_0x572425(0x190)))&&!isQuizCompleted&&startTimer();}function selectOption(_0x3249b6){const _0x557ec1=_0x37c9bd,_0x493285={'cMmrm':_0x557ec1(0x198),'HVeaf':function(_0x42b0cf,_0x7fcec){return _0x42b0cf===_0x7fcec;},'ILAVq':_0x557ec1(0x33e),'pnwwx':_0x557ec1(0x317),'qKYvY':function(_0x4933f5,_0x3e2ed2){return _0x4933f5-_0x3e2ed2;},'Fxjhm':_0x557ec1(0x339),'Ykapm':function(_0x3d002e,_0x22f5ce){return _0x3d002e===_0x22f5ce;},'KCJEj':_0x557ec1(0x29d),'mSdiZ':function(_0x2abc52,_0x1ffa73){return _0x2abc52===_0x1ffa73;},'AkCOp':_0x557ec1(0x1d4),'vZwfS':function(_0x5f0411,_0x1aedc2,_0xd0b3b7){return _0x5f0411(_0x1aedc2,_0xd0b3b7);},'QddNn':function(_0x3debf9,_0x57bfd4){return _0x3debf9===_0x57bfd4;},'ePVrQ':'not_attempted','UVnvL':function(_0x298d3e){return _0x298d3e();}},_0x17c0d8=document[_0x557ec1(0x1e7)](_0x493285[_0x557ec1(0x306)]);if(_0x17c0d8['classList']['contains'](_0x493285['pnwwx']))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x557ec1(0x32a)]+=_0x493285[_0x557ec1(0x143)](Date['now'](),questionStartTime),questionStartTime=Date[_0x557ec1(0x1c1)]()),selectedOption=_0x3249b6,questionStates[currentQuestionIndex][_0x557ec1(0x1ce)]=_0x3249b6,document[_0x557ec1(0x196)](_0x493285[_0x557ec1(0x102)])[_0x557ec1(0x27d)]((_0xd137a6,_0x45dd65)=>{const _0xafb50e=_0x557ec1;_0xd137a6[_0xafb50e(0x12b)][_0xafb50e(0x24b)](_0x493285[_0xafb50e(0x1cf)],_0x493285[_0xafb50e(0x281)](_0x45dd65,_0x3249b6));}),_0x493285[_0x557ec1(0x24a)](currentMode,_0x493285[_0x557ec1(0x2e8)])||_0x493285[_0x557ec1(0x1c8)](currentMode,_0x493285[_0x557ec1(0x17d)])?_0x493285[_0x557ec1(0x36f)](setTimeout,processAnswer,0x12c):(_0x493285[_0x557ec1(0x22a)](questionStates[currentQuestionIndex]['status'],_0x493285[_0x557ec1(0x148)])&&(questionStates[currentQuestionIndex][_0x557ec1(0x2ba)]=_0x557ec1(0x317),stats[_0x557ec1(0x369)]++,stats[_0x557ec1(0x208)]--),_0x493285['UVnvL'](updateQuestionNav));}function processAnswer(){const _0x26fa1e=_0x37c9bd,_0x174f68={'rCXLz':function(_0x2940c3,_0x4bdbed){return _0x2940c3-_0x4bdbed;},'zLUXG':function(_0x3e2200,_0x43ee93){return _0x3e2200===_0x43ee93;},'DATyU':function(_0x3f88af,_0x11d454){return _0x3f88af===_0x11d454;},'JzFly':function(_0x2fc0e6,_0x1d59f3){return _0x2fc0e6===_0x1d59f3;},'AeikU':_0x26fa1e(0x168),'gDfOm':_0x26fa1e(0x21c),'SQWzH':'correct','hggkU':function(_0x115871,_0x38c199){return _0x115871(_0x38c199);},'hObxf':function(_0x1670d3){return _0x1670d3();}},_0x55e4e5=questionsData[currentQuestionIndex],_0xd40ba2=_0x55e4e5[_0x26fa1e(0x382)];if(_0x174f68[_0x26fa1e(0x11b)](selectedOption,null))return;const _0xf79f9a=_0x55e4e5[_0x26fa1e(0x337)][selectedOption],_0x1b24e4=_0x174f68[_0x26fa1e(0x1a4)](_0xf79f9a['id'],_0xd40ba2);if(_0x174f68[_0x26fa1e(0x27c)](questionStates[currentQuestionIndex][_0x26fa1e(0x2ba)],_0x174f68[_0x26fa1e(0x23a)])){if(_0x174f68[_0x26fa1e(0x2b3)]===_0x174f68[_0x26fa1e(0x2b3)]){stats[_0x26fa1e(0x369)]++,stats['notAttempted']--;if(_0x1b24e4)stats[_0x26fa1e(0x37b)]++;else stats[_0x26fa1e(0x38e)]++;}else _0x56fbd3[_0x4d4611][_0x26fa1e(0x32a)]+=_0x174f68[_0x26fa1e(0x325)](_0x2259c9[_0x26fa1e(0x1c1)](),_0x242f06),_0x6fd9e4=_0x35ffeb[_0x26fa1e(0x1c1)]();}questionStates[currentQuestionIndex][_0x26fa1e(0x2ba)]=_0x1b24e4?_0x174f68[_0x26fa1e(0x2fd)]:_0x26fa1e(0x13d),updateStats(),_0x174f68[_0x26fa1e(0x35c)](showInlineFeedback,_0x1b24e4),_0x174f68[_0x26fa1e(0x16d)](updateQuestionNav);}function showInlineFeedback(_0xc32fa9){const _0x1fa8a7=_0x37c9bd,_0x42c33a={'fBELi':_0x1fa8a7(0x198),'dSzAB':function(_0x27f8ce,_0x4bdcd8){return _0x27f8ce===_0x4bdcd8;},'DXGqG':_0x1fa8a7(0x13d),'ROtpT':'study','YJLfT':function(_0x2536c0,_0x5b25ee){return _0x2536c0!==_0x5b25ee;},'oUgeU':_0x1fa8a7(0x1d4),'PgDKO':'answered','WilAP':function(_0x7b537d,_0x58f1b1,_0x2794ce){return _0x7b537d(_0x58f1b1,_0x2794ce);}};if(currentMode!==_0x42c33a['ROtpT']&&_0x42c33a[_0x1fa8a7(0x1f5)](currentMode,_0x42c33a[_0x1fa8a7(0x372)]))return;const _0x17b021=document[_0x1fa8a7(0x1e7)]('optionsContainer'),_0x3cc85b=_0x17b021[_0x1fa8a7(0x196)](_0x1fa8a7(0x339)),_0x5a4cf3=questionsData[currentQuestionIndex],_0x1d0e07=_0x5a4cf3['correct_choice_id'];let _0x1beb05=_0x5a4cf3['choices'][_0x1fa8a7(0x32f)](_0x3f759e=>_0x3f759e['id']===_0x1d0e07);_0x17b021['classList']['add'](_0x42c33a[_0x1fa8a7(0x218)]),_0x3cc85b[_0x1fa8a7(0x27d)]((_0x5f26d4,_0x21f418)=>{const _0x6d246f=_0x1fa8a7;_0x5f26d4[_0x6d246f(0x12b)][_0x6d246f(0x30e)](_0x42c33a[_0x6d246f(0x390)]);if(_0x42c33a['dSzAB'](_0x21f418,_0x1beb05))_0x5f26d4[_0x6d246f(0x12b)][_0x6d246f(0x175)](_0x6d246f(0x16f));else{if(_0x42c33a[_0x6d246f(0x2d0)](_0x21f418,selectedOption)&&!_0xc32fa9)_0x5f26d4['classList'][_0x6d246f(0x175)](_0x42c33a[_0x6d246f(0x2b6)]);}}),_0x42c33a[_0x1fa8a7(0x231)](setTimeout,showSolution,0x5dc);}function showSolution(){const _0x29ff69=_0x37c9bd,_0x15809b={'kcnnt':_0x29ff69(0x16f),'Huuwa':function(_0xdcac80,_0x32f0be){return _0xdcac80!==_0x32f0be;},'hfoMF':'ncBrI','nLBwq':'UzQNN','KnGTd':_0x29ff69(0x198),'NgTrG':function(_0x19da2c,_0x17ff50){return _0x19da2c===_0x17ff50;},'qpqwd':'incorrect','ItCeq':function(_0x2900df,_0x59af75){return _0x2900df!==_0x59af75;},'qVoRA':_0x29ff69(0x29d),'kFOZk':_0x29ff69(0x1d4),'wJuIn':'No\x20solution\x20provided','IkkWy':_0x29ff69(0x376),'SdVJD':'explanationVideoPlayer','CWPel':function(_0xb586d4,_0x531a09){return _0xb586d4===_0x531a09;},'mXzlA':_0x29ff69(0x10c),'KQdvO':_0x29ff69(0x109),'IpqRr':function(_0x5cdf70,_0x456f6e,_0x1ed144){return _0x5cdf70(_0x456f6e,_0x1ed144);},'DsUua':_0x29ff69(0x177),'rtNYj':_0x29ff69(0x2c9),'CofXg':_0x29ff69(0x2dc),'uPOMd':'hidden'};if(_0x15809b['ItCeq'](currentMode,_0x15809b['qVoRA'])&&_0x15809b['Huuwa'](currentMode,_0x15809b[_0x29ff69(0x23c)]))return;const _0x3ed22f=questionsData[currentQuestionIndex];document[_0x29ff69(0x1e7)]('solutionText')[_0x29ff69(0x216)]=_0x3ed22f[_0x29ff69(0x232)]||_0x15809b[_0x29ff69(0x2d5)];const _0x110969=document['getElementById'](_0x15809b[_0x29ff69(0x147)]),_0x39ecc0=document[_0x29ff69(0x1e7)](_0x15809b[_0x29ff69(0x1c7)]),_0x2b4fd0=_0x3ed22f[_0x29ff69(0x11c)];if(_0x2b4fd0){if(_0x15809b[_0x29ff69(0x10e)](_0x15809b[_0x29ff69(0x303)],_0x15809b[_0x29ff69(0x303)])){_0x110969[_0x29ff69(0x12b)]['remove'](_0x29ff69(0x1b1));if(_0x2b4fd0['includes'](_0x15809b[_0x29ff69(0x211)]))_0x15809b['IpqRr'](setupVideo,_0x39ecc0,_0x2b4fd0);else _0x39ecc0[_0x29ff69(0x176)]=_0x2b4fd0;}else _0x24de70++,_0x4aba8a[_0x29ff69(0x2ba)]=_0x15809b[_0x29ff69(0x2b5)];}else _0x110969['classList']['add']('hidden');const _0x265913=document['getElementById'](_0x15809b['DsUua']);_0x265913['innerHTML']='';_0x3ed22f[_0x29ff69(0x326)]&&(_0x265913[_0x29ff69(0x216)]+=_0x29ff69(0x1e8)+_0x3ed22f[_0x29ff69(0x326)]+_0x29ff69(0x1f0));_0x3ed22f['explanation_audio_hin']&&(_0x265913[_0x29ff69(0x216)]+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22'+_0x3ed22f['explanation_audio_hin']+_0x29ff69(0x1f0));const _0x24c56a=document['getElementById'](_0x29ff69(0x252));_0x24c56a[_0x29ff69(0x216)]='';if(_0x3ed22f[_0x29ff69(0x11f)]){if(_0x15809b[_0x29ff69(0x2c6)]('gtcMc',_0x15809b[_0x29ff69(0x18d)]))_0x3ed22f[_0x29ff69(0x11f)][_0x29ff69(0x27d)](_0x503096=>{const _0x5b531e=_0x29ff69;if(_0x15809b[_0x5b531e(0x1bd)](_0x15809b[_0x5b531e(0x353)],_0x15809b['nLBwq'])){if(_0x503096)_0x24c56a[_0x5b531e(0x216)]+=_0x5b531e(0x114)+_0x503096+_0x5b531e(0x222);}else _0x5d451d[_0x3f77fa[_0x5b531e(0x134)]]['bookmarked']=!![];});else{_0xc654cf['classList'][_0x29ff69(0x30e)](_0x15809b[_0x29ff69(0x1c9)]);if(_0x15809b[_0x29ff69(0x2c5)](_0x313cf8,_0x35cf4e))_0x446b6b[_0x29ff69(0x12b)][_0x29ff69(0x175)](_0x15809b[_0x29ff69(0x2b5)]);else{if(_0xd0aeb===_0x74a12f&&!_0x4e046d)_0x5bee36[_0x29ff69(0x12b)][_0x29ff69(0x175)](_0x15809b[_0x29ff69(0x19b)]);}}}document[_0x29ff69(0x1e7)](_0x15809b[_0x29ff69(0x2cb)])[_0x29ff69(0x12b)][_0x29ff69(0x30e)](_0x15809b[_0x29ff69(0x397)]);}function submitQuiz(){const _0x3df4ea=_0x37c9bd,_0x6e003b={'BLaUI':_0x3df4ea(0x339),'sMgLQ':function(_0x3dcece,_0xcbb7c6){return _0x3dcece(_0xcbb7c6);},'lIEWE':_0x3df4ea(0x312),'HEIzH':function(_0x394495,_0xdf2d9d){return _0x394495(_0xdf2d9d);},'oBmZX':function(_0xd795b1,_0x531b88){return _0xd795b1-_0x531b88;},'sUfbj':function(_0x11cf01,_0x2ef7ff){return _0x11cf01===_0x2ef7ff;},'TmyQl':'JpRTz','WEigp':function(_0x531d3c,_0x42dec){return _0x531d3c!==_0x42dec;},'YQztH':_0x3df4ea(0x1bc),'xwwzt':_0x3df4ea(0x13d),'Jyysv':function(_0xbd7e46,_0x1ff3ef){return _0xbd7e46-_0x1ff3ef;},'IKZnn':'quizPerformanceData','VRnSr':function(_0x16566f,_0x25e44c){return _0x16566f+_0x25e44c;},'aBbkI':function(_0x4a4165,_0x1e27b8,_0x100b73,_0x3b0f08,_0x1b2f7b){return _0x4a4165(_0x1e27b8,_0x100b73,_0x3b0f08,_0x1b2f7b);}};if(timer)clearInterval(timer);if(!_0x6e003b[_0x3df4ea(0x280)](confirm,_0x3df4ea(0x31a)))return;isQuizCompleted=!![];let _0x20cd70=0x0,_0x1d5e13=0x0;const _0x30ef13=_0x6e003b[_0x3df4ea(0x2ce)](Date[_0x3df4ea(0x1c1)](),quizStartTime);questionsData[_0x3df4ea(0x27d)]((_0x137cc6,_0x25bd88)=>{const _0x1001d7=_0x3df4ea,_0x233056={'BYYNx':function(_0x41f3b4,_0x262af4){return _0x6e003b['oBmZX'](_0x41f3b4,_0x262af4);}};if(_0x6e003b[_0x1001d7(0x2d2)](_0x6e003b[_0x1001d7(0x1fa)],_0x6e003b[_0x1001d7(0x1fa)])){const _0x10f07f=questionStates[_0x25bd88];if(_0x6e003b['WEigp'](_0x10f07f['selectedAnswer'],null)){if(_0x6e003b[_0x1001d7(0x2d2)](_0x137cc6[_0x1001d7(0x337)][_0x10f07f[_0x1001d7(0x1ce)]]['id'],_0x137cc6[_0x1001d7(0x382)])){if(_0x6e003b[_0x1001d7(0x2d2)](_0x1001d7(0x1bc),_0x6e003b[_0x1001d7(0x294)]))_0x20cd70++,_0x10f07f[_0x1001d7(0x2ba)]='correct';else{const _0x1977ff=_0x5afb72[_0x1001d7(0x224)][_0x1001d7(0x253)](_0x6e003b[_0x1001d7(0x2c1)]);if(_0x1977ff){const _0x527f64=_0x6e003b[_0x1001d7(0x120)](_0x630498,_0x1977ff[_0x1001d7(0x132)](_0x6e003b[_0x1001d7(0x323)]));_0x6e003b['HEIzH'](_0x4ce0b4,_0x527f64);}}}else _0x1d5e13++,_0x10f07f[_0x1001d7(0x2ba)]=_0x6e003b[_0x1001d7(0x229)];}}else _0x37c471[_0x3c66ff][_0x1001d7(0x32a)]+=_0x233056[_0x1001d7(0x347)](_0x2743ab[_0x1001d7(0x1c1)](),_0x3dce7e);});const _0x8d9e91=JSON[_0x3df4ea(0x1d9)](localStorage[_0x3df4ea(0x202)](_0x6e003b['IKZnn']))||[];_0x8d9e91[_0x3df4ea(0x2da)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x3df4ea(0x1c1)](),'totalTime':_0x30ef13,'stats':{'correct':_0x20cd70,'incorrect':_0x1d5e13,'notAttempted':_0x6e003b[_0x3df4ea(0x2ce)](questionsData[_0x3df4ea(0x186)],_0x6e003b[_0x3df4ea(0x34f)](_0x20cd70,_0x1d5e13))}}),localStorage[_0x3df4ea(0x179)](_0x3df4ea(0x2f0),JSON['stringify'](_0x8d9e91)),_0x6e003b[_0x3df4ea(0x127)](showPerformanceAnalysis,_0x20cd70,_0x1d5e13,questionsData[_0x3df4ea(0x186)]-_0x6e003b['VRnSr'](_0x20cd70,_0x1d5e13),_0x30ef13);}function showPerformanceAnalysis(_0x11eb54,_0x5a0cef,_0x4c2023,_0x2ca7a1){const _0x569e00=_0x37c9bd,_0x34be01={'eyFfE':function(_0x3dc114,_0x12e890){return _0x3dc114+_0x12e890;},'nJVYl':function(_0x4a34ee,_0x1c897d){return _0x4a34ee*_0x1c897d;},'SnMTQ':function(_0x505524,_0x7fd69d){return _0x505524+_0x7fd69d;},'WhpMS':function(_0x5cff43,_0x327110){return _0x5cff43*_0x327110;},'zSsCU':'scoreCircle','rzYmp':function(_0x22072d,_0x345c9b){return _0x22072d/_0x345c9b;},'DhXJj':_0x569e00(0x296),'KrsCP':'correctResult','cGPWR':_0x569e00(0x32c),'zOeAY':'notAttemptedResult','CMpKP':function(_0x4da676,_0xa9dffa){return _0x4da676/_0xa9dffa;},'qzAsi':function(_0x546d04,_0x5466eb){return _0x546d04%_0x5466eb;},'OmBca':_0x569e00(0x396),'yeeEX':function(_0x220314,_0x390952){return _0x220314/_0x390952;},'xzDXn':function(_0x36a2c1,_0x216fa2){return _0x36a2c1%_0x216fa2;},'KiSlx':_0x569e00(0x2cc),'Mftno':'hidden'},_0x381a48=document[_0x569e00(0x1e7)](_0x569e00(0x209)),_0x34f550=_0x34be01[_0x569e00(0x165)](_0x11eb54,_0x5a0cef)>0x0?Math[_0x569e00(0x118)](_0x34be01[_0x569e00(0x287)](_0x11eb54/_0x34be01[_0x569e00(0x180)](_0x11eb54,_0x5a0cef),0x64)):0x0,_0x4ba851=_0x34be01['WhpMS'](0x2*Math['PI'],0x41),_0x13f8af=document['getElementById'](_0x34be01[_0x569e00(0x20d)]);_0x13f8af[_0x569e00(0x2b1)]['strokeDasharray']=_0x4ba851+'\x20'+_0x4ba851,_0x13f8af[_0x569e00(0x2b1)]['strokeDashoffset']=_0x4ba851-_0x34be01[_0x569e00(0x287)](_0x34be01['rzYmp'](_0x34f550,0x64),_0x4ba851),document[_0x569e00(0x1e7)](_0x34be01[_0x569e00(0x28d)])['textContent']=_0x34f550+'%',document[_0x569e00(0x1e7)](_0x569e00(0x330))[_0x569e00(0x171)]=questionsData[_0x569e00(0x186)],document[_0x569e00(0x1e7)](_0x34be01['KrsCP'])[_0x569e00(0x171)]=_0x11eb54,document[_0x569e00(0x1e7)](_0x34be01[_0x569e00(0x15d)])[_0x569e00(0x171)]=_0x5a0cef,document['getElementById'](_0x34be01[_0x569e00(0x236)])[_0x569e00(0x171)]=_0x4c2023;const _0x44d7bb=Math[_0x569e00(0x29a)](_0x2ca7a1/0xea60),_0x3b4bc7=Math[_0x569e00(0x29a)](_0x34be01[_0x569e00(0x2bb)](_0x34be01['qzAsi'](_0x2ca7a1,0xea60),0x3e8));document['getElementById'](_0x34be01[_0x569e00(0x33a)])['textContent']=_0x44d7bb+':'+_0x3b4bc7[_0x569e00(0x2b2)]()['padStart'](0x2,'0');const _0x31e6e8=_0x34be01[_0x569e00(0x2e7)](_0x2ca7a1,questionsData[_0x569e00(0x186)]),_0x37bf2a=Math[_0x569e00(0x29a)](_0x31e6e8/0xea60),_0x41fdad=Math[_0x569e00(0x29a)](_0x34be01['yeeEX'](_0x34be01['xzDXn'](_0x31e6e8,0xea60),0x3e8));document[_0x569e00(0x1e7)](_0x34be01[_0x569e00(0x215)])[_0x569e00(0x171)]=_0x37bf2a+':'+_0x41fdad[_0x569e00(0x2b2)]()[_0x569e00(0x23d)](0x2,'0'),_0x381a48[_0x569e00(0x12b)][_0x569e00(0x30e)](_0x34be01[_0x569e00(0x25f)]);}function closePerformanceModal(){const _0x14e021=_0x37c9bd,_0x1a07bc={'YUFCa':_0x14e021(0x209),'ZudRR':_0x14e021(0x1b1)};document['getElementById'](_0x1a07bc[_0x14e021(0x191)])[_0x14e021(0x12b)]['add'](_0x1a07bc[_0x14e021(0x1f9)]);}function reviewQuestions(){const _0x235935=_0x37c9bd,_0x17ca2f={'jpMwT':function(_0x4cd75a,_0xbea11c){return _0x4cd75a===_0xbea11c;},'kTWwP':_0x235935(0x1dc),'sBgSK':'border-green-500','UiGvm':_0x235935(0x225),'nxdes':_0x235935(0x357),'eoUIA':'Not\x20Attempted','QJqPu':function(_0x5a90d3,_0x434ecc){return _0x5a90d3!==_0x434ecc;},'ntkUP':'fvZNG','CrzPw':function(_0x5a1c75,_0x2b7cd8){return _0x5a1c75===_0x2b7cd8;},'ICabT':_0x235935(0x16f),'eVSrT':_0x235935(0x105),'llWUb':function(_0x498bcc,_0x4a615e){return _0x498bcc!==_0x4a615e;},'tylqP':'OzCXI','wBLbu':_0x235935(0x13d),'zaaAQ':'div','ZexvH':function(_0x5558f9,_0x36d1f5){return _0x5558f9+_0x36d1f5;},'pOzCO':function(_0x4bd9fb,_0x6f8529){return _0x4bd9fb===_0x6f8529;},'XXQBc':_0x235935(0x162),'wuNYX':_0x235935(0x299),'LfNRe':'No\x20solution\x20available.','eJlyj':_0x235935(0x172),'pEwyD':_0x235935(0x157),'GxEVT':function(_0x2c478a){return _0x2c478a();}};document['getElementById'](_0x17ca2f['eJlyj'])['classList'][_0x235935(0x30e)](_0x235935(0x1b1));const _0x3ed63d=document[_0x235935(0x1e7)](_0x17ca2f[_0x235935(0x1a1)]);_0x3ed63d['innerHTML']='',questionsData['forEach']((_0x13f8a9,_0x173dba)=>{const _0x4276d4=_0x235935,_0x3242c6=questionStates[_0x173dba],_0x479421=_0x13f8a9[_0x4276d4(0x382)];let _0xded831=_0x17ca2f['nxdes'],_0x204b3d=_0x17ca2f[_0x4276d4(0x37d)];if(_0x17ca2f[_0x4276d4(0x355)](_0x3242c6[_0x4276d4(0x1ce)],null)){if(_0x17ca2f[_0x4276d4(0x355)](_0x4276d4(0x1d6),_0x17ca2f[_0x4276d4(0x247)])){const _0x4719dc=_0x251e4c?function(){const _0x57b2f3=_0x4276d4;if(_0x255978){const _0x43efec=_0x565043[_0x57b2f3(0x108)](_0x5399e0,arguments);return _0x24bc8d=null,_0x43efec;}}:function(){};return _0x2b11f3=![],_0x4719dc;}else{const _0x236ebb=_0x13f8a9[_0x4276d4(0x337)][_0x3242c6[_0x4276d4(0x1ce)]];if(_0x17ca2f[_0x4276d4(0x133)](_0x236ebb['id'],_0x479421))_0xded831=_0x17ca2f[_0x4276d4(0x1ca)],_0x204b3d=_0x17ca2f['eVSrT'];else{if(_0x17ca2f['llWUb'](_0x17ca2f['tylqP'],_0x17ca2f[_0x4276d4(0x284)])){const _0x133715=_0x332e0e[_0x4276d4(0x108)](_0x1a8dde,arguments);return _0x3663a3=null,_0x133715;}else _0xded831=_0x17ca2f[_0x4276d4(0x1b4)],_0x204b3d=_0x4276d4(0x398);}}}const _0x2d9fc9=document[_0x4276d4(0x245)](_0x17ca2f[_0x4276d4(0x1a3)]);_0x2d9fc9[_0x4276d4(0x1f3)]=_0x4276d4(0x344)+_0xded831;let _0x2ec96d=(_0x13f8a9[_0x4276d4(0x337)]||[])[_0x4276d4(0x188)]((_0x31d2da,_0x4bd69e)=>{const _0xa37a76=_0x4276d4,_0xad1e19=_0x17ca2f['jpMwT'](_0x3242c6['selectedAnswer'],_0x4bd69e),_0x32aafe=_0x17ca2f['jpMwT'](_0x31d2da['id'],_0x479421);let _0x503439=_0x17ca2f[_0xa37a76(0x1de)];if(_0x32aafe)_0x503439=_0x17ca2f[_0xa37a76(0x391)];else{if(_0xad1e19)_0x503439=_0x17ca2f[_0xa37a76(0x389)];}return _0xa37a76(0x2de)+_0x503439+_0xa37a76(0x18b)+String['fromCharCode'](0x41+_0x4bd69e)+_0xa37a76(0x239)+_0x31d2da[_0xa37a76(0x275)]+_0xa37a76(0x258);})[_0x4276d4(0x210)]('');const _0x185a21=_0x13f8a9[_0x4276d4(0x11c)]?'<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-'+_0x173dba+'\x22\x20data-src=\x22'+_0x13f8a9[_0x4276d4(0x11c)]+_0x4276d4(0x373):'';let _0x4e55af='';if(_0x13f8a9[_0x4276d4(0x326)])_0x4e55af+=_0x4276d4(0x37a)+_0x13f8a9['explanation_audio_eng']+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';if(_0x13f8a9[_0x4276d4(0x335)])_0x4e55af+=_0x4276d4(0x2e1)+_0x13f8a9['explanation_audio_hin']+_0x4276d4(0x1f0);let _0x46893b=(_0x13f8a9[_0x4276d4(0x11f)]||[])[_0x4276d4(0x188)](_0x75ea34=>_0x75ea34?_0x4276d4(0x114)+_0x75ea34+_0x4276d4(0x222):'')[_0x4276d4(0x210)]('');_0x2d9fc9['innerHTML']=_0x4276d4(0x259)+_0x17ca2f['ZexvH'](_0x173dba,0x1)+'</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-'+(_0x17ca2f[_0x4276d4(0x342)](_0xded831,_0x4276d4(0x16f))?'green':_0x17ca2f[_0x4276d4(0x2e9)](_0xded831,_0x17ca2f['wBLbu'])?_0x17ca2f[_0x4276d4(0x240)]:_0x17ca2f[_0x4276d4(0x2f2)])+_0x4276d4(0x244)+_0x204b3d+_0x4276d4(0x38c)+_0x13f8a9[_0x4276d4(0x275)]+_0x4276d4(0x1b7)+_0x2ec96d+_0x4276d4(0x26e)+(_0x13f8a9['solution']||_0x17ca2f['LfNRe'])+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x185a21+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x4e55af+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x46893b+_0x4276d4(0x2e3),_0x3ed63d[_0x4276d4(0x366)](_0x2d9fc9);}),_0x17ca2f[_0x235935(0x26c)](initializeReviewVideos);}function initializeReviewVideos(){const _0x12a103=_0x37c9bd,_0x2c201d={'uKLDI':function(_0x2ea600,_0x5270a2){return _0x2ea600-_0x5270a2;},'AdiUM':_0x12a103(0x10b)};document[_0x12a103(0x196)](_0x2c201d[_0x12a103(0x371)])[_0x12a103(0x27d)](_0x397f80=>{const _0x10bf35=_0x12a103,_0x4ec519=_0x397f80['dataset']['src'];if(_0x4ec519&&_0x4ec519[_0x10bf35(0x217)](_0x10bf35(0x109)))_0x10bf35(0x212)!==_0x10bf35(0x350)?setupVideo(_0x397f80,_0x4ec519):(_0x33445f&&(_0x579ae4[_0x446fb2][_0x10bf35(0x32a)]+=_0x2c201d[_0x10bf35(0x38f)](_0x23159b[_0x10bf35(0x1c1)](),_0xf69641)),_0x310d06=_0x252837,_0x553102());else _0x4ec519&&(_0x397f80['src']=_0x4ec519);});}function _0x2a52(){const _0x1ae3aa=['getItem','Topiramate','JtSUv','GxBhd','aBCpU','Romiplostim','notAttempted','performanceModal','quizHierarchy','ktaKM','Valproate','zSsCU','<p>The\x20drug\x20of\x20choice\x20for\x20the&nbsp;<strong>reversal\x20</strong>of<strong>\x20respiratory\x20depression</strong>\x20is<strong>&nbsp;naloxone</strong>.&nbsp;<strong>Naloxone</strong>\x20is\x20a\x20<strong>competitive\x20antagonist\x20at\x20&mu;-opioid\x20receptors</strong>\x20and\x20rapidly\x20reverses\x20the\x20effects\x20of\x20opioid\x20toxicity\x20when\x20administered.</p>\x0a<p>Opioid\x20overdose\x20<strong>symptoms</strong>:</p>\x0a<ul>\x0a<li>Triad\x20of\x20coma,\x20respiratory\x20depression,\x20and\x20pinpoint\x20pupils\x20(miosis).</li>\x0a<li>Hypotension,\x20bradycardia</li>\x0a<li>Shallow\x20breathing</li>\x0a<li>Hypothermia</li>\x0a</ul>\x0a<p>Naloxone\x20is\x20a\x20pure\x20opioid\x20antagonist\x20which\x20reverses\x20all\x20effects,<strong>&nbsp;except\x20sedation</strong>.&nbsp;Naloxone\x20is\x20also\x20used\x20for\x20reversing\x20neonatal\x20asphyxia\x20due\x20to\x20opioid\x20usage\x20in\x20labor.</p>\x0a<p>Other\x20options</p>\x0a<p>Option\x20B\x20-&nbsp;<strong>Meperidine\x20(pethidine)</strong>&nbsp;is\x20a&nbsp;<strong>mu-opioid\x20receptor</strong>&nbsp;(MOR)<strong>&nbsp;agonist</strong>.\x20It\x20has\x20a&nbsp;<strong>strong\x20analgesic</strong>&nbsp;effect\x20on\x20the&nbsp;<strong>central\x20nervous\x20system</strong>.&nbsp;It\x20is\x20mainly\x20used\x20as\x20an<strong>&nbsp;analgesic&nbsp;</strong>but\x20can\x20also\x20be\x20used\x20in\x20post-anesthetic\x20shivering.&nbsp;It\x20has\x20a\x20greater\x20ability\x20to\x20enter\x20the\x20CNS\x20and\x20produce\x20analgesia\x20at\x20lower\x20systemic\x20concentrations\x20compared\x20to\x20morphine.\x20Therefore,&nbsp;<strong>constipation</strong>,\x20urinary\x20retention,\x20and\x20nausea\x20are&nbsp;<strong>less</strong>&nbsp;frequent\x20compared\x20to\x20morphine.</p>\x0a<p>Meperidine\x20can\x20cross\x20the\x20placenta\x20and\x20cause\x20significant&nbsp;<strong>respiratory\x20depression</strong>&nbsp;in\x20the\x20fetus.&nbsp;In\x20patients\x20or\x20addicts\x20who\x20are\x20tolerant\x20to\x20the\x20depressant\x20effects\x20of\x20meperidine,\x20large\x20doses\x20repeated\x20at\x20short\x20intervals\x20may\x20produce\x20an&nbsp;<strong>excitatory\x20syndrome</strong>&nbsp;that\x20includes\x20hallucinations,\x20tremors,\x20muscle\x20twitches,\x20etc.</p>\x0a<div\x20class=\x22ng-scope\x22>Option\x20C\x20-<strong>Atropine</strong>\x20is\x20an&nbsp;<strong>anticholinergic</strong>&nbsp;drug.\x20It\x20acts\x20through&nbsp;<strong>reversible,\x20competitive\x20inhibition</strong>&nbsp;of\x20the\x20postsynaptic\x20muscarinic\x20acetylcholine\x20receptors.\x20It\x20is\x20indicated\x20in\x20the\x20treatment\x20of\x20organophosphate/muscarinic\x20poisoning,\x20in\x20bradycardia,\x20and\x20to\x20reduce\x20salivary\x20secretions.\x0a<p>The\x20adverse\x20effects\x20of\x20atropine\x20are\x20due\x20to\x20the\x20antimuscarinic\x20effects,\x20including\x20xerostomia,\x20blurring\x20of\x20vision,\x20photophobia,\x20tachycardia,\x20flushing,\x20warm,\x20dry\x20skin,\x20constipation,\x20urinary\x20retention,\x20anhidrosis,\x20delirium,\x20and\x20coma.\x20Intoxication\x20with\x20atropine\x20results\x20in\x20all\x20the\x20above\x20symptoms\x20along\x20with\x20convulsions,\x20and\x20circulatory\x20collapse\x20due\x20to\x20respiratory\x20failure.\x20Death\x20may\x20occur\x20secondary\x20to\x20respiratory\x20paralysis.</p>\x0a</div>\x0a<p>Option\x20D\x20-&nbsp;<strong>Buprenorphine</strong>&nbsp;is\x20a&nbsp;<strong>partial&nbsp;&mu;\x20agonist</strong>&nbsp;and\x20an&nbsp;<strong>antagonist</strong>&nbsp;at&nbsp;<strong>&delta;</strong>&nbsp;and&nbsp;<strong>&kappa;</strong>&nbsp;receptors.\x20It\x20is\x20used\x20as\x20an\x20analgesic\x20and\x20in\x20the\x20management\x20of\x20opioid\x20dependence.</p>\x0a<p>&nbsp;</p>','https://cdn1.dailyrounds.org/uploads/0d14e58f54894d9d9389bff9d61b97e6.JPEG','join','KQdvO','XkYiE','stfUo','A-1,\x20B-2,\x20C-3,\x20D-4','KiSlx','innerHTML','includes','PgDKO','qfFvZ','Propoxyphene','Option\x20','ulrof','LrmXu','OgxCQ','warn','PWYgN','https://dhmbxeygs57ff.cloudfront.net/uploads/1d540d18f4024d5cb2c7fa069efee6a3x1280x1585.JPEG','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','450\x20mcg/dL','target','border-red-500','submitSection','Degludec','flex','xwwzt','QddNn','vviNe','Wstfu','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','reload','Amitriptyline','Pembrolizumab\x20plus\x20chemotherapy\x20used\x20in\x20NSCLC','WilAP','solution','Ethionamide','bookmarkedQuestions','Pghef','zOeAY','Methotrexate\x20+\x20leukovorin','330258HxNWIa','</span><span>','AeikU','8xjTEHW','kFOZk','padStart','IXfHl','wCjLy','XXQBc','Cilastatin','Marked','kKydT','-600\x20text-white\x22>','createElement','LpGvK','ntkUP','aPYOV','A-4,\x20B-2,\x20C-3,\x20D-1','Ykapm','toggle','gNHuj','Pramlinitide','quizFile','Supression\x20of\x20angiogenesis','history','\x20-\x20Brain\x20And\x20Scalpel','solutionImages','closest','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','zTCyk','isArray','Buprenorphine','</span></div>','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','Naloxone','Denotes\x20safety\x20and\x20efficacy\x20in\x20an\x20individual','prevBtn','MRP\x201','owYgk','Mftno','location','5|1|4|2|0|3','Methadone','Aprepitant','JNkYA','<p><strong>Hydroxyurea</strong>\x20is\x20beneficial\x20in\x20reducing\x20the\x20<strong>painful\x20vasoocclusive\x20crisis</strong>\x20of\x20<strong>sickle\x20cell\x20anemia.</strong>\u00a0<br\x20/><br\x20/><strong>Hydroxyurea</strong>\x20is\x20a\x20<strong>myelosuppressive\x20agent</strong>\x20that\x20is\x20effective\x20in\x20<strong>reducing\x20the\x20frequency</strong>\x20of\x20<strong>painful\x20episodes</strong>\x20like\x20<strong>dactylitis</strong>\x20and\x20<strong>acute\x20chest\x20syndrome</strong>,\x20<strong>decreasing\x20the\x20rate\x20of\x20hospitalization</strong>,\x20and\x20<strong>requirement\x20for\x20blood\x20transfusion</strong>.\x20It\x20is\x20<strong>safe</strong>\x20and\x20<strong>well-tolerated</strong>\x20in\x20<strong>children</strong>\x20and\x20<strong>infants</strong>.\x20Hydroxyurea\x20is\x20approved\x20for\x20<strong>long-term\x20maintenance\x20of\x20sickle\x20cell\x20disease</strong>,\x20and\x20is\x20recommended\x20for\x20patients\x20of\x20<strong>all\x20ages</strong>\x20regardless\x20of\x20symptoms.\u00a0</p>\x0a<p>Hydroxyurea\x20<strong>increases\x20fetal\x20hemoglobin</strong>\x20levels\x20by\x20an\x20unknown\x20mechanism\x20and\x20<strong>interferes\x20with\x20the\x20polymerization\x20of\x20abnormal\x20HbS</strong>.\u00a0</p>\x0a<p><strong>Newer\x20drugs</strong>\x20for\x20management\x20of\x20<strong>acute\x20painful\x20crisis</strong>\x20of\x20sickle\x20cell\x20anemia\x20include\x20<strong>L-glutamine</strong>\x20and\x20<strong>crizanlizumab</strong>.\x20For\x20individuals\x20<strong>&gt;5\x20years</strong>\x20of\x20age\x20with\x20sickle\x20cell\x20disease\x20who\x20have\x20<strong>pain\x20despite\x20hydroxyurea</strong>\x20(or\x20who\x20<strong>cannot\x20tolerate\x20hydroxyurea</strong>),\x20<strong>L-glutamine</strong>\x20is\x20recommended,\x20regardless\x20of\x20whether\x20they\x20are\x20receiving\x20hydroxyurea.\x20The\x20mechanism\x20of\x20action\x20of\x20this\x20drug,\x20is\x20that\x20it\x20<strong>reduces\x20oxidative\x20stress</strong>\x20in\x20sickle\x20erythrocytes.\x20<strong>Crizanlizumab</strong>\x20is\x20a\x20<strong>P-selectin-blocking\x20monoclonal\x20antibody</strong>\x20which\x20is\x20given\x20<strong>intravenously</strong>\x20every\x20month\x20to\x20reduce\x20acute\x20painful\x20episodes.</p>\x0a<p><strong>Sickle\x20cell\x20anemia</strong>\x20is\x20an\x20<strong>autosomal\x20recessive</strong>\x20disorder\x20that\x20occurs\x20due\x20to\x20the<strong>\x20point\x20mutation</strong>\x20in\x20the<strong>\x20β-globin\x20gene\x20</strong>which\x20results\x20in\x20the\x20<strong>replacement\x20of\x20glutamate\x20</strong>residue\x20with\x20<strong>valine</strong>.\x20This\x20causes\x20the\x20production\x20of\x20<strong>sickle-shaped\x20red\x20blood\x20cells</strong>\x20due\x20to\x20the\x20<strong>polymerization</strong>\x20of\x20<strong>deoxygenated</strong>\x20<strong>hemoglobin\x20(HbS)</strong>.\x20<strong>Factors</strong>\x20that\x20predispose\x20to\x20<strong>sickling</strong>\x20are\x20<strong>infection</strong>,\x20<strong>dehydration</strong>,\x20and\x20<strong>acidosis</strong>.\x20Sickle\x20cell\x20disease\x20causes\x20<strong>hemolytic\x20anemia</strong>\x20due\x20to\x20<strong>increased\x20erythrocyte\x20destruction</strong>.\x20The\x20anemia\x20is\x20generally\x20well\x20compensated.\x20Complications\x20occur\x20due\x20to\x20abnormal\x20erythrocyte\x20configurations\x20that\x20increase\x20hemoglobin\x20polymerization\x20leading\x20to\x20a\x20<strong>painful\x20vaso-occlusive\x20state</strong>.\u00a0</p>\x0a<p><strong>Clinical\x20features\x20</strong>of\x20sickle\x20cell\x20anemia\x20:\u00a0</p>\x0a<p>-\x20<strong>Moderately\x20severe\x20hemolytic\x20anemia</strong>\x20with\x20<strong>jaundice</strong>.<br\x20/>-\x20<strong>Painful\x20bone\x20crisis</strong>\x20:\x20<strong>hand-foot\x20syndrome\x20</strong>or\x20<strong>dactylitis</strong>\x20of\x20the\x20bones\x20of\x20hands\x20and\x20feet.<br\x20/>-\x20<strong>Acute\x20chest\x20syndrome</strong>\x20typically\x20presents\x20with\x20fever,\x20cough,\x20chest\x20pain,\x20and\x20pulmonary\x20infiltrates.<br\x20/>-\x20<strong>Hyposthenuria</strong>\x20:\x20inability\x20to\x20concentrate\x20urine.<br\x20/>-\x20<strong>Aplastic</strong>\x20<strong>crisis</strong>\x20stems\x20from\x20the\x20infection\x20of\x20red\x20cell\x20progenitors\x20by\x20parvovirus\x20B19,\x20which\x20causes\x20a\x20transient\x20cessation\x20of\x20erythropoiesis\x20and\x20a\x20sudden\x20worsening\x20of\x20the\x20anemia.<br\x20/>-\x20Spleen\x20:\x20In\x20children,\x20<strong>splenic\x20sequestration</strong>\x20<strong>crises</strong>\x20occur\x20which\x20results\x20in\x20<strong>splenomegaly</strong>\x20due\x20to<strong>\x20red\x20pulp\x20congestion</strong>.\x20In\x20adolescence\x20or\x20early\x20adulthood,\x20<strong>autosplenectomy</strong>\x20occurs\x20due\x20to\x20splenic\x20infarction,\x20fibrosis,\x20and\x20progressive\x20shrinkage.<br\x20/>-\x20Increased\x20<strong>susceptibility\x20to\x20infection</strong>\x20with\x20<strong>encapsulated</strong>\x20<strong>organisms</strong>\x20like\x20pneumococcal,\x20meningococcal,\x20and\x20Haemophilus\x20influenza\x20septicemia,\x20but\x20can\x20be\x20reduced\x20by\x20vaccination\x20and\x20prophylactic\x20antibiotics.<br\x20/>-\x20Other\x20clinical\x20features\x20include\x20<strong>priapism</strong>,<strong>\x20leg\x20ulcers,\x20stroke,\x20retinopathy,\x20pigment\x20gallstones</strong>,\x20and\x20<strong>growth\x20retardation</strong>.</p>\x0a<p>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B\x20:\x20<strong>Methotrexate</strong>\x20interferes\x20with\x20folate\x20metabolism\x20by\x20acting\x20as\x20a<strong>\x20competitive\x20inhibitor</strong>\x20of\x20the\x20enzyme\x20<strong>dihydrofolate\x20reductase</strong>.\x20This\x20starves\x20cells\x20for\x20tetrahydrofolate\x20and\x20makes\x20them\x20unable\x20to\x20synthesize\x20purines\x20and\x20thymidine\x20monophosphate.\x20It\x20does\x20not\x20treat\x20painful\x20crisis\x20of\x20sickle\x20cell\x20anemia.</p>\x0a<p>Option\x20C\x20:\x20<strong>Methionine</strong>\x20is\x20an\x20<strong>essential\x20amino\x20acid</strong>\x20involved\x20in\x20the\x20synthesis\x20of\x20folate\x20and\x20vitamin\x20B12.\x20It\x20is\x20not\x20used\x20in\x20the\x20management\x20of\x20sickle\x20cell\x20anemia.<br\x20/><br\x20/>Option\x20D\x20:\x20<strong>Eltrombopag\x20</strong>is\x20a\x20<strong>thrombopoetin\x20analog</strong>\x20used\x20to\x20treat\x20immune\x20thrombocytopenia.\x20It\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20painful\x20sickle\x20cell\x20crisis.</p>','45oBTdHi','Ratio\x20of\x20median\x20lethal\x20dose\x20in\x2050%\x20of\x20population\x20to\x20median\x20effective\x20dose\x20in\x2050%\x20of\x20population','keydown','400\x20mcg/dL','XzaRM','RhjZC','GxEVT','Empaglifozin','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','split','jifyt','A\x2012\x20year\x20old\x20boy\x20presents\x20with\x20complaints\x20of\x20profuse\x20watery\x20stools\x20and\x20an\x20elevated\x20WBC\x20count\x20of\x2016000\x20cells/mm3.\x20He\x20has\x20been\x20on\x20treatment\x20with\x20amoxicillin\x20for\x20the\x20past\x201\x20week.\x20What\x20is\x20the\x20treatment\x20of\x20choice\x20for\x20his\x20condition?','accuracy','Bosutinib','ASUKz','text','reduce','No\x20question\x20text\x20available','bHDbj','TXyqp','CtTkr','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','JzFly','forEach','YJjqP','{}.constructor(\x22return\x20this\x22)(\x20)','HEIzH','HVeaf','QiyAb','WuHiQ','tylqP','dcCzH','6-mercaptopurine','nJVYl','Alogliptin','aJUIz','fEdJv','<p><strong>Alogliptin</strong>\x20is\x20a\u00a0<strong>dipeptidyl\x20peptidase-4\x20(DPP)\x20inhibitor.</strong>\x20<strong>Glucagon-like\x20peptide\x20(GLP)\x20and\x20glucose-dependent\x20insulinotropic\x20polypeptide\x20(GIP)</strong>\x20are\x20both\x20<strong>incretins</strong>\x20that\x20promote\x20the\x20exocytosis\x20of\x20insulin\x20into\x20circulation.\x20Both\x20these\x20<strong>incretins</strong>\x20are<strong>\x20rapidly\x20inactivated</strong>\x20by\x20<strong>dipeptidyl\x20peptidase</strong>.\x20So,\x20<strong>inhibition\x20of\x20dipeptidyl\x20peptidase</strong>\x20<strong>enhances</strong>\x20the\x20action\x20of\x20<strong>incretins</strong>\x20and\x20facilitates\x20insulin\x20release.\u00a0<strong>Dipeptidyl\x20peptidase-4\x20inhibitors\u00a0</strong>enhance\x20the\x20release\x20of\x20insulin\x20postprandially,\x20decrease\x20glucagon,\x20and\x20thereby\x20lower\x20mealtime\x20as\x20well\x20as\x20fasting\x20glucose.\u00a0</p>\x0a<p>Other\x20DPP-4\x20inhibitors\x20include\x20<strong>saxagliptin,\x20linagliptin,\x20alogliptin,</strong>\x20and\x20<strong>vildagliptin.\u00a0</strong>They\x20are\x20weight\x20neutral.</p>\x0a<p>DPP-4\x20inhibitors\x20are\x20associated\x20with<strong>\x20severe</strong><strong>\u00a0joint\x20pain\x20which</strong>\x20reduces\x20on\x20discontinuation\x20of\x20the\x20drug.\x20Linagliptin\x20is\x20cleared\x20primarily\x20by\x20hepatobiliary\x20system,\x20with\x20little\x20renal\x20clearance.\x20Only\x20saxagliptin\x20is\x20metabolized\x20by\x20the\x20liver\x20and\x20must\x20be\x20used\x20in\x20lower\x20doses\x20if\x20used\x20along\x20with\x20a\x20cytochrome\x20p450\x20enzyme\x20inhibitor\x20drug.\x20Other\x20drugs\x20are\x20renally\x20excreted\x20and\x20hence\x20must\x20be\x20used\x20with\x20<strong>caution</strong>\x20in\u00a0<strong>renal\x20insufficiency.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A\x20-\u00a0<strong>Pramlintide</strong>\u00a0is\x20an\u00a0<strong>amylin\x20agonist</strong>.\x20It\x20reduces\x20postprandial\x20glycemia\x20and\x20leads\x20to\u00a0<strong>weight\x20loss</strong>.</p>\x0a<p>Option\x20C\x20-\u00a0<strong>Liraglutide</strong>\u00a0is\x20also\x20a\u00a0<strong>GLP-1\x20receptor\x20agonist</strong>\u00a0and\x20is\x20given\x20only\x20in\x20the\u00a0<strong>subcutaneous\x20injectable</strong>\u00a0form.\x20It\x20was\x20recently\x20approved\x20for\x20the\x20treatment\x20of\u00a0<strong>obesity.</strong></p>\x0a<p>Option\x20D\x20-\u00a0<strong>Metformin</strong>\x20belongs\x20to\x20the\u00a0<strong>biguanides</strong>\u00a0class\x20of\x20oral\x20hypoglycemic\x20agents.\x20It\x20acts\x20by\x20activation\x20of\x20AMP-dependent\x20protein\x20kinase\x20(<strong>AMPK</strong>).\x20This\x20results\x20in\x20reduced\x20hepatic\x20glucose\x20production.\u00a0<strong>Side\x20effects</strong>\u00a0of\u00a0<strong>metformin</strong>\u00a0are\u00a0<strong>l</strong><strong>actic\x20acidosis,\u00a0</strong>gastrointestinal\x20disturbance,\x20and\u00a0<strong>vitamin\x20B12\x20deficiency.</strong></p>\x0a<div\x20class=\x22ng-star-inserted\x22>\u00a0</div>','dvCKE','DhXJj','A-3,\x20B-4,\x20C-1,\x20D-2','rbYtG','statsBar','ysUut','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','Cyclosporine-induced\x20cholestasis\x20is\x20due\x20to\x20which\x20receptor?','YQztH','A\x20patient\x20underwent\x20a\x20hysterectomy\x20and\x20was\x20given\x20morphine\x20in\x20the\x20post-operative\x20period\x20and\x20in\x20the\x20ward\x20for\x20pain.\x20She\x20now\x20presents\x20with\x20respiratory\x20depression\x20and\x20pin\x20point\x20pupils.\x20What\x20is\x20the\x20drug\x20used\x20to\x20treat\x20this\x20condition?','accuracyScore','kPfin','IMTJL','gray','floor','Vismodegib','Xinsy','study','swSPA','Mydriasis','<p>Keynote\x20189\x20trial\x20is\x20a\x20<strong>efficacy\x20and\x20safety\x20study\x20of</strong>\x20<strong>pembrolizumab\x20and\x20chemotherapy\x20in\x20metastatic\x20non-small\x20cell\x20carcinoma\x20of\x20lung.</strong></p>\x0a<p>Keynote\x20189\x20trial\x20is\x20an\x20<strong>efficacy\x20and\x20safety\x20study\x20of\x20pembrolizumab</strong>\x20(MK-3475)\x20<strong>combined\x20with\x20pemetrexed/platinum\x20chemotherapy</strong>\x20versus\x20pemetrexed/platinum\x20chemotherapy\x20alone\x20in\x20participants\x20<strong>with\x20advanced\x20or\x20metastatic\x20nonsquamous\x20non-small\x20cell\x20lung\x20cancer\x20(NSCLC)</strong>\x20who\x20have\x20not\x20previously\x20received\x20systemic\x20therapy\x20for\x20advanced\x20disease.\x20Participants\x20will\x20be\x20randomly\x20assigned\x20to\x20receive\x20pembrolizumab\x20combined\x20with\x20pemetrexed/platinum.</p>\x0a<p\x20class=\x22a-article-h2\x20f-h12\x22><strong><span\x20style=\x22font-size:\x2012pt;\x22>Methods</span></strong></p>\x0a<p\x20class=\x22f-body\x22>In\x20this\x20<strong>double-blind,\x20phase\x203\x20trial</strong>,\x20patients\x20were\x20<strong>randomly\x20assigned</strong>\x20(in\x20a\x202:1\x20ratio).\x20616\x20patients\x20with\x20metastatic\x20nonsquamous\x20NSCLC\x20without\x20sensitizing\x20<em>EGFR</em>&nbsp;or&nbsp;<em>ALK</em>&nbsp;mutations\x20who\x20had\x20received\x20no\x20previous\x20treatment\x20for\x20metastatic\x20disease\x20to\x20receive\x20pemetrexed\x20and\x20a\x20platinum-based\x20drug\x20plus\x20either\x20200\x20mg\x20of\x20pembrolizumab\x20or\x20placebo\x20every\x203\x20weeks\x20for\x204\x20cycles,\x20followed\x20by\x20pembrolizumab\x20or\x20placebo\x20for\x20up\x20to\x20a\x20total\x20of\x2035\x20cycles\x20plus\x20pemetrexed\x20maintenance\x20therapy.\x20Crossover\x20to\x20pembrolizumab\x20monotherapy\x20was\x20permitted\x20among\x20the\x20patients\x20in\x20the\x20placebo-combination\x20group\x20who\x20had\x20verified\x20disease\x20progression.\x20The\x20primary\x20endpoints\x20were\x20overall\x20survival\x20and\x20progression-free\x20survival,\x20as\x20assessed\x20by\x20a\x20blinded,\x20independent\x20central\x20radiologic\x20review.</p>\x0a<p\x20class=\x22a-article-h2\x20f-h12\x22><strong><span\x20style=\x22font-size:\x2012pt;\x22>Conclusions</span></strong></p>\x0a<p\x20class=\x22f-body\x22><span\x20class=\x22O1056PNEJMcme1801005DONENA2rxbnh\x20O1056PNEJMcme1801005DONENB2rxbng\x20O1056PNEJMcme1801005DONENC2rxbnf\x20O1056PNEJMcme1801005DONEND2rxbne\x20\x22>In\x20patients\x20with\x20previously\x20untreated\x20metastatic\x20nonsquamous\x20NSCLC\x20without&nbsp;<em>EGFR</em>&nbsp;or&nbsp;<em>ALK</em>&nbsp;mutations,\x20the\x20addition\x20of\x20<strong>pembrolizumab</strong>\x20to\x20standard\x20chemotherapy\x20of\x20pemetrexed\x20and\x20a\x20platinum-based\x20drug\x20resulted\x20in\x20significantly<strong>\x20longer\x20overall\x20survival\x20and\x20progression-free\x20survival\x20than\x20chemotherapy\x20alone.</strong></span><strong>&nbsp;</strong></p>','cbgTD','tUmWg','NDtmN','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','click','fmefT','TcTLu','mBHAF','Lithium','NyFbS','nHmnN','Donepezil','<p>The\x20nomogram\x20used\x20for\x20<strong>vancomycin\x20dosing</strong>\x20is\x20the&nbsp;<strong>Matzke\x20nomogram.</strong></p>\x0a<p>The\x20Matzke\x20nomogram\x20includes\x20<strong>dosing\x20intervals\x20</strong>ranging\x20from\x200.5\x20to\x2012\x20days\x20on\x20a\x20continuum\x20of\x20CL<sub>cr</sub>(<strong>Creatinine\x20clearance</strong>)\x20values\x20from\x200\x20to\x20120\x20mL/min.\x20It\x20is\x20designed\x20to<strong>\x20guide\x20</strong>the\x20<strong>determination\x20of\x20the\x20initial\x20empiric\x20dose\x20</strong>and\x20<strong>interval\x20of\x20intravenous\x20(IV)\x20vancomycin</strong>\x20in\x20<strong>hospitalized\x20adults</strong>\x20who\x20are<strong>\x20not\x20receiving\x20hemodialysis</strong>.&nbsp;The\x20nomogram\x20does\x20not\x20apply\x20to\x20patients\x20who\x20exhibit\x20highly\x20variable\x20vancomycin\x20pharmacokinetics.\x20These\x20patients\x20include\x20the\x20critically\x20ill,\x20those\x20with\x20burn\x20injuries\x20affecting\x20more\x20than\x2020\x20percent\x20of\x20their\x20body\x20surface,\x20patients\x20with\x20rapidly\x20changing\x20renal\x20function,\x20pregnant\x20women,\x20those\x20with\x20liver\x20failure/ascites,\x20individuals\x20at\x20the\x20extremes\x20of\x20weight,\x20patients\x20who\x20are\x20acutely\x20post-transplant,\x20and\x20those\x20with\x20cystic\x20fibrosis</p>\x0a<p>The\x20<strong>Rumack-Matthew\x20nomogram\x20</strong>uses\x20the\x20serum\x20acetaminophen\x20concentration,&nbsp;in\x20relation\x20to\x20the&nbsp;time\x20after\x20ingestion,\x20to\x20<strong>assess\x20potential\x20hepatotoxicity</strong>&nbsp;after\x20a&nbsp;single,\x20acute\x20ingestion\x20of\x20<strong>acetaminophen</strong>.&nbsp;</p>','key','ZClrL','Pethidine','style','toString','gDfOm','<p><strong>Valproate</strong>\x20is\x20a\x20<strong>mood\x20stabilizer</strong>\x20with\x20the\x20side\x20effect\x20of\x20<strong>hepatotoxicity</strong>\x20and\x20<strong>hyperammonemia</strong>.<br\x20/><br\x20/><strong>Valproate</strong>\x20is\x20an<strong>\x20anti-epileptic\x20medication\x20</strong>and\u00a0also\x20used\x20as\x20a\x20<strong>mood\x20stabilizer\x20</strong>in\x20<strong>manic</strong>\x20<strong>episodes</strong>\x20as\x20well\x20as\x20in\x20<strong>bipolar\x20disorder.</strong>\x20The\x20<strong>repetitive\x20firing</strong>\x20caused\x20by\x20the\x20<strong>depolarization\x20of\x20cortical\x20or\x20spinal\x20cord\x20neurons</strong>\x20is\x20<strong>inhibited</strong>\x20by\x20valproate.\x20It\x20also\x20<strong>prolongs</strong>\x20the\x20<strong>sodium\x20channel\x20inactivation</strong>.\x20Valproate\x20can\x20cause\x20an<strong>\x20idiosyncratic\x20hepatic\x20toxicity</strong>\x20and\x20<strong>interfere\x20</strong>with\x20<strong>conversion\x20of\x20ammonia\x20to\x20urea</strong>\x20leading\x20to\x20<strong>hyperammonemia</strong>.\x20Valproate\x20is\x20<strong>contraindicated</strong>\x20in\x20patients\x20with<strong>\x20genetic\x20defects\x20in\x20urea\x20metabolism</strong>.<br\x20/><br\x20/>Valproate\x20therapy\x20<strong>reduces\x20carnitine\x20levels\x20in\x20tissues</strong>,\x20potentially\x20impacting\x20mitochondrial\x20function\x20and\x20leading\x20to\x20<strong>hyperammonemia</strong>\x20and\x20<strong>microvesicular\x20steatosis</strong>.\x20Genetic\x20factors\x20also\x20play\x20a\x20role,\x20as\x20individuals\x20who\x20are\x20heterozygous\x20for\x20mutations\x20in\x20the\x20gamma\x20polymerase\x20gene,\x20which\x20is\x20primarily\x20present\x20in\x20mitochondria,\x20are\x20more\x20susceptible\x20to\x20valproate-induced\x20liver\x20damage.\x20<strong>Intravenous\x20administration</strong>\x20of\x20<strong>carnitine</strong>\x20can\x20be\x20used\x20to\x20manage\x20this\x20condition.<br\x20/><br\x20/>The\x20side\x20effects\x20of\x20valproate\x20(mnemonic:\x20<strong>VALPROATE</strong>)</p>\x0a<p><strong>V</strong>omiting<br\x20/><strong>A</strong>lopecia<br\x20/><strong>L</strong>iver\x20toxicity<br\x20/><strong>P</strong>ancreatitis<br\x20/><strong>R</strong>ash<br\x20/><strong>O</strong>besity<br\x20/><strong>A</strong>norexia<br\x20/><strong>T</strong>eratogenicity<br\x20/><strong>E</strong>dema</p>\x0a<p>It\x20causes\x20<strong>congenital\x20anomalies</strong>\x20like\x20<strong>neural\x20tube\x20defects</strong>\x20(Spina\x20Bifida),\x20clefts,\x20and\x20<strong>cardiac\x20anomalies</strong>.\x20The<strong>\x20intelligence\x20quotient</strong>\x20score\x20of\x20school-going\x20children\x20who\x20were\x20exposed\x20in\x20utero\x20to\x20valproate\x20is\x20found\x20<strong>reduced</strong>.\x20It\x20also\x20contributes\x20to<strong>\x20poor\x20cognitive\x20development</strong>\x20in\x20children.\x20<strong>Folate\x20supplementation</strong>\x20reduces\x20the\x20chances\x20of\x20neural\x20tube\x20defects.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20A\x20:\x20<strong>Lithium</strong>\x20is\x20a<strong>\x20mood\x20stabilizer</strong>\x20with\x20a\x20very\x20<strong>narrow\x20therapeutic\x20index</strong>\x20and\x20is\x20the\x20<strong>first\x20line</strong>\x20of\x20management\x20in<strong>\x20bipolar\x20disorder</strong>.\x20Its\x20<strong>adverse\x20effects\x20</strong>can\x20be\x20<strong>acute</strong>\x20such\x20as<strong>\x20tremors,\x20ataxia,\x20weakness,\x20polyuria,\x20polydipsia</strong>\x20or\x20<strong>chronic</strong>\x20such\x20as\x20<strong>nephrogenic\x20diabetes\x20insipidus,\x20thyroid\x20dysfunction</strong>,\x20and\x20<strong>hyperparathyroidism</strong>.\x20It\x20is\x20not\x20associated\x20with\x20hepatotoxicity\x20or\x20hyperammonemia.\u00a0<br\x20/><br\x20/>Option\x20C\x20:\x20<strong>Carbamazepine\u00a0</strong>is\x20a\x20<strong>sodium\x20channel\x20blocker</strong>\x20used\x20in\x20the\x20management\x20of\x20<strong>complex\x20partial\x20seizures,\x20GTCS,\x20simple\x20partial\x20seizures</strong>\x20and\x20<strong>trigeminal\x20neuralgia</strong>.\x20It\x20is\x20known\x20to\x20be\x20<strong>hepatotoxic</strong>\x20but\x20is<strong>\x20not\x20associated\x20</strong>with\x20<strong>hyperammonemia</strong>.\x20Other\x20adverse\x20effects\x20include\x20<strong>hypersensitivity</strong>\x20reactions,\x20<strong>eosinophilia</strong>,\x20<strong>agranulocytosis</strong>,\x20<strong>aplastic</strong>\x20<strong>anemia</strong>,\x20<strong>hyponatremia</strong>\x20and\x20<strong>stevens-johnson\x20syndrome</strong>.<br\x20/><br\x20/>Option\x20D\x20:\x20<strong>Topiramate\u00a0</strong>is\x20an<strong>\x20anti\x20epileptic\x20</strong>and\x20<strong>non-opioid\x20pain\x20medication</strong>\x20which\x20is\x20associated\x20with\x20<strong>significant\x20weight\x20loss</strong>\x20of\x20<strong>up\x20to\x207%</strong>\x20as\x20a\x20side\x20effect.</p>','kcnnt','DXGqG','BaFFr','HvPSA','contains','status','CMpKP','correctCount','Prkgl','Tall\x20QRS\x20complexes','What\x20is\x20the\x20most\x20useful\x20drug\x20to\x20treat\x20doxorubicin\x20induced\x20cardiotoxicity?','<p><strong>Cyclosporine</strong>\x20induced\x20cholestasis\x20is\x20due\x20to\x20<strong>MDR1\x20transporter</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20111\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>ABC\x20transporters\x20such\x20as\x20MRP2,\x20<strong>MDR1</strong>,\x20BCRP,\x20BSEP,\x20and\x20MDR3\x20in\x20the<strong>\x20bile\x20canalicular\x20membrane\x20of\x20hepatocytes</strong>\x20mediate\x20the\x20<strong>efflux\x20(excretion)\x20of\x20drugs\x20and\x20their\x20metabolites,\x20bile\x20salts,\x20and\x20phospholipids</strong>\x20against\x20a\x20steep\x20concentration\x20gradient\x20from\x20liver\x20to\x20bile.\x20This\x20<strong>primary\x20active\x20transport</strong>\x20is\x20driven\x20by\x20<strong>ATP\x20hydrolysis</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p>Cyclosporine,\x20an\x20<strong>MDR1\x20substrate&nbsp;</strong>can\x20cause\x20cholestatic\x20liver\x20injury\x20through\x20the\x20following\x20mechanisms:</p>\x0a<ul>\x0a<li><strong>Competitive\x20inhibition\x20of\x20ATP\x20dependent\x20transporters.</strong></li>\x0a<li><strong>Inhibition</strong>\x20of\x20<strong>intrahepatic\x20vesicle\x20transport</strong>\x20and\x20targeting\x20of\x20ATP\x20dependent\x20transporters\x20to\x20the\x20canalicular\x20membrane.</li>\x0a<li><strong>Impairment\x20of\x20bile\x20secretion</strong>\x20partly\x20by\x20<strong>increasing\x20canalicular\x20membrane\x20fluidity</strong>\x20without\x20affecting\x20the\x20expression\x20of\x20canalicular\x20transporters.&nbsp;</li>\x0a</ul>\x0a<p><strong>Cyclosporine</strong>\x20is\x20an\x20immunomodulatory\x20drug\x20that&nbsp;<strong>inhibits\x20calcineurin\x20activity</strong>\x20by<strong>&nbsp;</strong>forming\x20a\x20complex\x20with\x20<strong>cyclophilin</strong>,\x20a\x20cytoplasmic-receptor\x20protein\x20present\x20in\x20target\x20cells,\x20to\x20form\x20a\x20<strong>cyclosporine-cyclophilin\x20complex</strong>.Calcineurin\x20is\x20a\x20calcium/calmodulin-dependent\x20phosphatase\x20required\x20for\x20the\x20induction\x20of\x20T\x20cell\x20lymphokine\x20production\x20and\x20proliferation.</p>\x0a<p>This\x20drug-receptor\x20complex\x20specifically\x20and\x20competitively\x20binds\x20to\x20and\x20<strong>inhibits\x20calcineurin</strong>,\x20a\x20calcium\x20and\x20calmodulin-dependent\x20phosphatase.\x20This,\x20in\x20turn,\x20inhibits\x20the\x20translocation\x20of\x20a\x20family\x20of\x20transcription\x20factors\x20(NF-AT),\x20leading\x20to\x20reduced\x20transcriptional\x20activation\x20of\x20cytokine\x20genes\x20for\x20interleukin\x20(IL)-2,\x20tumor\x20necrosis\x20factor\x20(TNF)-alpha,\x20IL-3,\x20IL-4,\x20CD40L,\x20granulocyte-macrophage\x20colony-stimulating\x20factor,\x20and\x20interferon-gamma.\x20Ultimately,\x20the\x20proliferation\x20of\x20T\x20lymphocytes\x20is\x20reduced,\x20resulting\x20in\x20<strong>immunomodulation.</strong></p>\x0a<p>Its\x20uses\x20are\x20as\x20follows:</p>\x0a<ul>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20solid\x20organ\x20transplantation,\x20to\x20prevent\x20organ\x20rejection\x20in\x20kidney,\x20liver,\x20and\x20heart\x20allogeneic\x20transplants</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20patients\x20with\x20rheumatoid\x20arthritis,\x20when\x20the\x20disease\x20has\x20not\x20adequately\x20responded\x20to\x20methotrexate</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>Cyclosporine\x20reportedly\x20is\x20effective\x20in\x20Behçet&rsquo;s\x20disease,\x20acute\x20ocular\x20syndrome,\x20endogenous\x20uveitis,\x20atopic\x20dermatitis,\x20inflammatory\x20bowel\x20disease,\x20and\x20nephrotic\x20syndrome.</li>\x0a</ul>\x0a<p>Adverse\x20effects\x20of\x20cyclosporine\x20include\x20a\x20<strong>decrease</strong>\x20in\x20glomerular\x20filtration\x20rate\x20(<strong>GFR</strong>)&nbsp;and\x20<strong>metabolic\x20disturbances</strong>\x20like\x20hypomagnesemia,\x20hyperkalemia,\x20dyslipidemia,\x20gynecomastia,\x20hypertrichosis;\x20<strong>neurotoxicity</strong>\x20in\x20the\x20form\x20of\x20convulsions.&nbsp;There\x20is\x20an\x20increased\x20risk\x20of\x20developing\x20skin\x20and\x20lymphoproliferative\x20malignancies\x20in\x20cyclosporine-treated\x20psoriasis\x20patients.</p>','BLaUI','JpyYD','<p>The\x20therapeutic\x20index\x20of\x20a\x20drug\x20denotes\x20the\x20<strong>safety\x20and\x20efficacy</strong>\x20of\x20the\x20drug\x20in\x20the\x20<strong>population</strong>\x20(option\x20B),\x20not\x20the\x20individual\x20(option\x20C).</p>\x0a<p>The\x20therapeutic\x20index\x20is\x20calculated\x20with\x20the\x20following\x20equations:</p>\x0a<p>LD<sub>50</sub>/ED<sub>50</sub>\x20or\x20TD<sub>50</sub>/ED<sub>50</sub></p>\x0a<p>where\x20LD<sub>50</sub>\x20is\x20the\x20median\x20lethal\x20dose,\x20TD<sub>50</sub>\x20is\x20the\x20mean\x20toxic\x20dose,\x20and\x20ED<sub>50</sub>\x20is\x20the\x20median\x20effective\x20dose\u00a0</p>\x0a<p>The\x20<strong>therapeutic\x20index\x20</strong>(TI)\x20describes\x20a\x20relationship\x20between\x20the\x20doses\x20of\x20a\x20drug\x20that\x20causes\x20lethal\x20or\x20toxic\x20effects\x20with\x20the\x20dose\x20that\x20causes\x20therapeutic\x20effects.\x20It\x20is\x20also\x20called\x20the\x20therapeutic\x20ratio.\x20The\x20therapeutic\x20index\x20is\x20used\x20to\x20<strong>assess\x20the\x20safety\x20</strong>of\x20the\x20drug\x20administered.</p>\x0a<p><strong>Median\x20lethal\x20dose</strong>\x20(LD<sub>50</sub>)\x20and<strong>\x20median\x20toxic\x20dose</strong>\x20(TD<sub>50</sub>)</p>\x0a<ul>\x0a<li>LD<sub>50</sub>\x20is\x20the\x20dose\x20of\x20the\x20drug\x20at\x20which\x2050%\x20of\x20the\x20experimental\x20animals\x20die</li>\x0a<li>In\x20human\x20trials,\x20TD<sub>50</sub>\x20can\x20be\x20considered.\x20It\x20is\x20the\x20dose\x20of\x20the\x20drug\x20that\x20causes\x20adverse\x20effects\x20in\x2050%\x20of\x20the\x20population\x20(Option\x20D)</li>\x0a<li>The\x20larger\x20the\x20LD<sub>50</sub>\x20or\x20TD<sub>50</sub>,\x20the\x20safer\x20the\x20drug\u00a0</li>\x0a</ul>\x0a<p><strong>Median\x20effective\x20dose</strong>\x20(ED<sub>50</sub>)\x20is\x20the\x20quantity\x20of\x20a\x20drug\x20that\x20can\x20produce\x20the\x20desired\x20therapeutic\x20effects\x20in\x2050%\x20of\x20the\x20population.</p>\x0a<p><strong>Therapeutic\x20window</strong>\x20refers\x20to\x20a\x20range\x20of\x20concentrations\x20at\x20which\x20the\x20likelihood\x20of\x20efficacy\x20is\x20high\x20and\x20the\x20probability\x20of\x20adverse\x20effects\x20is\x20low.</p>\x0a<p>Note:\x20Option\x20D\x20is\x20incorrect\x20as\x20it\x20does\x20not\x20make\x20the\x20necessary\x20distinction\x20that\x20the\x20therapeutic\x20index\x20is\x20the\x20ratio\x20of\x20the\x20median\x20lethal\x20dose\x20in\x2050%\x20of\x20animals\x20(as\x20the\x20human\x20population\x20cannot\x20be\x20used\x20for\x20lethal\x20studies)\x20to\x20the\x20median\x20effective\x20dose\x20in\x2050%\x20of\x20the\x20population.\x20LD<sub>50</sub>\x20is\x20measured\x20in\x20animals,\x20not\x20in\x20humans.\x20Option\x20B\x20is\x20a\x20better\x20choice.</p>','<p><strong>5-aminosalicylic\x20acid</strong>\x20is\x20is\x20effective\x20in\x20<strong>inducing\x20and\x20maintaining\x20remission</strong>\x20and\x20is\x20considered\x20to\x20be\x20the<strong>\x20first\x20line\x20agents</strong>\x20for\u00a0<strong>mild\x20to\x20moderate</strong>\x20<strong>ulcerative\x20colitis,\u00a0</strong>seen\x20in\x20this\x20patient\x20with<strong>\x202-3\x20bloody\x20stools\x20per\x20day</strong>.<br\x20/><br\x20/><strong>Treatment</strong>\x20of\x20<strong>ulcerative\x20colitis</strong>\x20differs\x20based\x20on\x20the\x20<strong>severity\x20of\x20the\x20disease</strong>\x20and\x20involves\x20medical\x20and\x20surgical\x20management.\x20Patients\x20with\x20<strong>mild\x20to\x20moderate\x20disease</strong>\x20are\x20treated\x20with\x20<strong>topical\x20or\x20systemic\x205-aminosalicylate\x20drugs</strong>\x20such\x20as\x20<strong>Salazopyrine/Sulfasalazine</strong>\x20and\x20<strong>Mesalamine\x20(5\x20ASA)</strong>\x20which\x20are<strong>\x20first-line\x20therapy.</strong>\x20<strong>Glucocorticoids\x20(option\x20A),\x20immunosuppressants</strong>,\x20and\x20<strong>biologics</strong>\x20are\x20effective\x20in\x20patients\x20with\x20<strong>moderate</strong>\x20<strong>to</strong>\x20<strong>severe</strong>\x20disease.\x20<br\x20/><br\x20/><strong>Azathioprine\x20</strong>and\x20<strong>cyclosporin</strong>\x20are\x20used\x20as<strong>\x20steroid-sparing</strong>\x20agents.<strong>\x20Anti-TNF\x20alpha\x20inhibitors\x20(infliximab,\x20adalimumab)\x20</strong>can\x20be\x20used\x20as\x20<strong>anti-inflammatories</strong>.</p>\x0a<p><strong>Surgery</strong>\x20is\x20recommended\x20for\x20patients\x20who\x20<strong>do\x20not\x20improve\x20after\x20medical\x20treatment\x20</strong>or\x20with<strong>\x20toxic\x20megacolon</strong>,\x20and\x20<strong>perforation</strong>.\x20Indications\x20for\x20<strong>elective\x20surgery</strong>\x20include\x20<strong>failure\x20of\x20medical\x20therapy</strong>,\x20<strong>growth\x20retardation</strong>,<strong>\x20extraintestinal\x20disease</strong>,\x20and\x20<strong>malignant\x20change</strong>.<br\x20/><br\x20/><strong>Ulcerative\x20colitis\x20</strong>is\x20an\x20<strong>inflammatory\x20bowel\x20disease</strong>\x20resulting\x20in<strong>\x20superficial\x20erosions</strong>\x20confined\x20to\x20the\x20<strong>mucosa\x20and\x20submucosa</strong>\x20of\x20the\x20colon.\x20It\x20<strong>starts\x20from\x20the\x20rectum</strong>\x20and\x20extends\x20proximally\x20in\x20a\x20<strong>continuous</strong>\x20manner.\x20The\x20clinical\x20features\x20include\x20abdominal\x20pain,\x20diarrhea,\x20<strong>rectal\x20bleeding</strong>,\x20tenesmus,\x20and\x20passage\x20of\x20mucus.\x20Other\x20symptoms\x20include\x20anorexia,\x20nausea,\x20vomiting,\x20fever,\x20and\x20weight\x20loss.<br\x20/><br\x20/>Ulcerative\x20colitis\x20is\x20<strong>graded</strong>\x20based\x20on\x20the\x20<strong>frequency\x20of\x20bowel\x20movements\x20</strong>and\x20<strong>systemic\x20involvement</strong>.\u00a0</p>\x0a<p>-\x20<strong>Mild</strong>\x20disease\x20-\x20<strong>≤4\x20stools\x20per\x20day</strong>\x20with/without\x20<strong>rectal\x20bleeding</strong>;<br\x20/>-\x20<strong>Moderate</strong>\x20disease\x20-\x20<strong>≥4\x20stools\x20per\x20day</strong>\x20with<strong>\x20few\x20systemic\x20signs</strong>\x20of\x20illness;\u00a0<br\x20/>-\x20<strong>Severe</strong>\x20disease\x20-<strong>\x20≥6\x20blood\x20stools\x20per\x20day\x20</strong>with\x20<strong>fever,\x20tachycardia\x20(≥90\x20beats/min)</strong>,\x20<strong>anemia\x20(hemoglobin\x20&lt;10.5\x20g/dL)</strong>,\x20and\x20elevated\x20levels\x20of\x20<strong>inflammatory\x20markers\x20(ESR\x20≥30\x20mm/h)</strong><br\x20/>-\x20<strong>Fulminant</strong>\x20disease\x20-\x20<strong>&gt;10\x20stools\x20per\x20day</strong>\x20with\x20<strong>severe\x20anemia</strong>\x20requiring\x20blood\x20transfusion\x20and\x20<strong>progressive\x20colonic\x20dilation\x20(toxic\x20megacolon)</strong><br\x20/><br\x20/>Investigations\x20show\x20<strong>elevated\x20C-reactive\x20protein</strong>,\x20<strong>platelet\x20count,\x20erythrocyte\x20sedimentation\x20rate,\x20fecal\x20calprotectin,\x20and\x20fecal\x20lactoferrin</strong>.\x20A\x20<strong>colonoscopy</strong>\x20reveals\x20<strong>loss\x20of\x20typical\x20vascular\x20pattern</strong>,\x20<strong>erythema</strong>,\x20<strong>friability</strong>,\x20<strong>regenerative</strong>\x20<strong>mucosal</strong>\x20<strong>nodules</strong>,\x20<strong>pseudopolyps</strong>,\x20and\x20<strong>ulcerations</strong>.\u00a0</p>\x0a<p><strong>Extraintestinal\x20manifestations</strong>\x20associated\x20with\x20IBD\x20include\x20<strong>ocular\x20features\x20</strong>(episcleritis,\x20and\x20uveitis),\x20<strong>dermatological</strong>\x20manifestations\x20(erythema\x20nodosum,\x20pyoderma\x20gangrenosum),\x20<strong>rheumatological</strong>\x20(arthropathies,\x20sacroiliitis,\x20ankylosing\x20spondylitis)\x20and\x20<strong>primary\x20sclerosing\x20cholangitis</strong>.\x20Complications\x20include\x20<strong>toxic\x20megacolon</strong>,\x20hemorrhage,\x20strictures,\x20and\x20perforations.\x20These\x20patients\x20are\x20also\x20at\x20increased\x20risk\x20of\x20<strong>colon\x20cancer</strong>.<br\x20/><br\x20/>Other\x20options\u00a0<br\x20/><br\x20/>Option\x20B\x20&amp;\x20C\x20:\x20Azathioprine\x20and\x206-mercaptopurine\x20are\x20not\x20first\x20line\x20agents\x20for\x20ulcerative\x20colitis.</p>','NgTrG','ItCeq','currentQuestion','question_video','jLgMU','MpEzw','CofXg','avgTimeResult','<p><strong>Empaglifozin</strong>,\x20which\x20is\x20a\x20<strong>sodium-glucose\x20transporter-2\x20(SGLT-2)\x20inhibitor</strong>\x20has\x20been\x20recently\x20approved\x20for\x20use\x20in\x20patients\x20with\x20<strong>Heart\x20Failure\x20with\x20Reduced\x20Ejection\x20Fraction</strong>,\x20and\x20can\x20be\x20initiated\x20in\x20patients\x20with\x20<strong>impaired\x20renal\x20function</strong>\x20with\x20<strong>estimated\x20glomerular\x20filtration\x20rate\x20&gt;\x2020\x20mL/min/1.73</strong>\x20<strong>m2</strong>.</p>\x0a<p>Empagliflozin\x20works\x20by\x20inhibiting\x20the\x20sodium-glucose\x20co-transporter-2\x20<strong>(SGLT-2)</strong>\x20in\x20the\x20<strong>proximal\x20renal\x20tubules</strong>\x20resulting\x20in\x20<strong>reduced\x20reabsorption</strong>\x20and\x20<strong>increased\x20urinary\x20excretion\x20of\x20glucose</strong>.\x20The<strong>\x20glucose-lowering</strong>\x20effect\x20is\x20<strong>independent\x20of\x20insulin</strong>.\x20Empagliflozin\x20acts\x20as\x20a\x20<strong>diuretic</strong>\x20and\x20<strong>natriuretic</strong>\x20by\x20reducing\x20sodium\x20and\x20volume\x20load,\x20causing\x20intravascular\x20contraction.\x20Empagliflozin\x20is\x20also\x20associated\x20with\x20<strong>weight\x20loss</strong>,\x20with\x20<strong>reductions\x20in\x20blood\x20pressure</strong>\x20without\x20increasing\x20heart\x20rate.\x20Empagliflozin\x20has\x20been\x20found\x20to\x20<strong>decrease\x20the\x20risk\x20of\x20mortality</strong>\x20from\x20<strong>cardiovascular\x20causes\x20in\x20diabetic\x20patients</strong>.\u00a0<br\x20/><br\x20/>SGLT-2\x20inhibitors\x20have\x20a\x20<strong>cardioprotective\x20effect</strong>\x20resulting\x20from<strong>\x20improved\x20cardiac\x20cell\x20metabolism</strong>,<strong>\x20improvement\x20of\x20ventricular\x20loading\x20mechanism</strong>,\x20<strong>reduction\x20of\x20cardiac\x20cell\x20necrosis</strong>\x20and\x20<strong>fibrosis</strong>.\x20It\x20also\x20has\x20a\x20<strong>renoprotective</strong>\x20property.</p>\x0a<p><strong>Except\x20for\x20empaglifozin</strong>\x20which\x20<strong>can\x20be\x20used\x20in\x20chronic\x20kidney\x20disease</strong>,\x20use\x20of\x20<strong>other\x20SGLT-2\x20inhibitors\x20might\x20lead\x20to\x20acute\x20kidney\x20injury</strong>\x20and\x20should\x20be\x20avoided\x20in\x20patients\x20with\x20renal\x20failure.\x20<strong>Side\x20effects\x20</strong>of\u00a0<strong>empaglifozin\u00a0</strong>includes\u00a0<strong>dehydration,\x20euglycemic\x20diabetic\x20ketoacidosis,\x20urinary\x20tract\x20infections,\x20genital\x20mycotic\x20infections,\x20hypoglycemia\x20and\x20necrotizing\x20fasciitis.</strong><br\x20/><br\x20/><strong>Side</strong>\x20<strong>effects</strong>\x20of\x20<strong>SGLT-2\x20inhibitors</strong>\x20include\x20<strong>dehydration</strong>,\x20<strong>hyperkalemia</strong>,\x20<strong>worsening\x20of\x20diabetic\x20ketoacidosis</strong>,\x20increased\x20risk\x20of\x20<strong>fractures</strong>,\x20<strong>leg\x20and\x20foot\x20amputation</strong>\x20with\x20<strong>canagliflozin</strong>,\x20and\x20a\x20possible\x20increased\x20risk\x20of\x20<strong>bladder\x20cancer\x20with\x20dapagliflozin</strong>.\x20<strong>Dapagliflozin</strong>\x20has\x20also\x20been\x20recently\x20approved\x20by\x20the\x20FDA\x20for\x20treatment\x20of\x20<strong>Heart\x20failure\x20with\x20Reduced\x20Ejection\x20Fraction</strong>\x20in\x20both\x20<strong>diabetic\x20and\x20non-diabetic</strong>\x20patients,\x20it\x20has\x20been\x20associated\x20with\x20<strong>increased\x20risk</strong>\x20of\x20<strong>bladder\x20cancer</strong>\x20and<strong>\x20breast\x20cancer</strong>.\u00a0<br\x20/><br\x20/><strong>Other\x20options\x20:\u00a0<br\x20/><br\x20/></strong>Option\x20B\x20:\x20<strong>Degludec</strong>\x20is\x20a\x20form\x20of\x20<strong>long\x20acting\x20insulin</strong>,\x20and\x20is\x20not\x20indicated\x20for\x20the\x20treatment\x20of\x20heart\x20failure.<br\x20/><br\x20/>Option\x20C\x20:\x20<strong>Linagliptin</strong>\x20is\x20a\u00a0<strong>dipeptidyl\x20peptidase-4\x20(DPP-4)\x20inhibitor</strong>,\x20which\x20<strong>enhances\x20the\x20action\x20of\x20incretins</strong>\x20that\x20<strong>promote\x20the\x20release\x20of\x20insulin</strong>\x20into\x20circulation.\x20Dipeptidyl\x20peptidase-4\x20inhibitors\x20enhance\x20the\x20release\x20of\x20insulin\x20postprandially,<strong>\x20decrease\x20glucagon</strong>,\x20and\x20thereby<strong>\x20lower\x20mealtime\x20as\x20well\x20as\x20fasting\x20glucose</strong>.\x20Linagliptin\x20is<strong>\x20safe\x20to\x20use\x20in\x20chronic\x20kidney\x20disease</strong>\x20as\x20it\x20is\x20cleared\x20primarily\x20by\x20hepatobiliary\x20system,\x20but\x20is\x20<strong>not\x20approved\x20for\x20heart\x20failure</strong>.\u00a0<br\x20/><br\x20/>Option\x20D\x20:\x20<strong>Rosiglitazone</strong>\x20is\x20a\x20<strong>thiazolidinedione</strong>,\x20which\x20<strong>activates\x20PPAR-γ\x20receptors\x20</strong>in\x20adipose\x20tissue\x20and\x20skeletal\x20muscles.\x20These\x20are\x20<strong>insulin\x20sensitizers</strong>\x20and<strong>\x20increase\x20insulin-mediated\x20glucose\x20uptake</strong>\x20in\x20patients\x20with\x20type\x202\x20diabetes.\x20Rosiglitazone\x20is\x20<strong>currently\x20banned\x20in\x20India</strong>\x20as\x20it\x20has\x20shown\x20an\x20increased\x20risk\x20of\x20developing\x20<strong>myocardial\x20infarction,\x20stroke,\x20congestive\x20heart\x20failure,\x20and\x20death</strong>.\u00a0</p>','Jyysv','Lopinavir','dSzAB','Myocarditis','sUfbj','<p><strong>Verapamil</strong>\x20is\x20a\x20<strong>potent\x20inhibitor\x20of\x20P-glycoprotein\x20drug\x20transporter\x20</strong>which\x20belongs\x20to\x20the\x20family\x20of\x20<strong>ATP-binding\x20cassette\x20(ABC)\x20transporters</strong>.<br\x20/><br\x20/>A\x20group\x20of\x20<strong>primary\x20active\x20transporters</strong>,\x20the\x20<strong>ATP-binding\x20cassette\x20(ABC)\x20family</strong>,\x20hydrolyze\x20ATP\x20to\x20export\x20substrates\x20across\x20membranes.\x20<strong>P-glycoprotein\x20(P-gp)</strong>\x20is\x20an\x20ATP-binding\x20cassette\x20(ABC)\x20transporter,\x20which\x20acts\x20as\x20an<strong>\x20efflux\x20membrane\x20transporter</strong>.\x20It\x20is\x20responsible\x20for<strong>\x20limiting\x20cellular\x20uptake\x20</strong>and\x20the\x20<strong>distribution\x20of\x20xenobiotics\x20and\x20toxic\x20substances</strong>.\x20P-glycoprotein\x20is\x20also\x20called\x20<strong>ABCB1\x20or\x20MDR1</strong>,\x20and\x20it\x20<strong>exports\x20bulky\x20neutral\x20</strong>or\x20<strong>cationic</strong>\x20<strong>compounds</strong>\x20<strong>from\x20cells</strong>.\x20<strong>MDR1</strong>\x20<strong>exports</strong>\x20many\x20drugs\x20as\x20well.\x20It\x20is\x20associated\x20with\x20multidrug\x20resistance\x20(MDR)\x20to\x20<strong>cancer\x20chemotherapeutics</strong>\x20through\x20the\x20<strong>multidrug\x20resistance\x20protein\x201\x20or\x20MDR1</strong>.<br\x20/><br\x20/><strong>Verapamil</strong>\x20can\x20cause<strong>\x20interactions\x20with\x20drugs</strong>\x20whose\x20disposition\x20is\x20dependent\x20upon\x20P-glycoprotein.\x20<strong>Drugs\x20that\x20inhibit\x20P-glycoprotein</strong>\x20are\x20-</p>\x0a<ol>\x0a<li><strong>Clarithromycin</strong></li>\x0a<li><strong>Erythromycin</strong></li>\x0a<li><strong>Amiodarone</strong></li>\x0a<li><strong>Quinidine</strong></li>\x0a<li><strong>Verapamil</strong></li>\x0a<li><strong>Diltiazem</strong></li>\x0a<li><strong>Cyclosporine</strong></li>\x0a<li><strong>Itraconazole</strong></li>\x0a<li><strong>Propafenone</strong></li>\x0a<li><strong>Flecainide</strong>.</li>\x0a</ol>\x0a<p>P-glycoprotein\x20pumps\x20play\x20a\x20major\x20role\x20in\x20the\x20elimination\x20of\x20certain\x20drugs\x20such\x20as\x20<strong>digoxin</strong>.\x20Drugs\x20that\x20inhibit\x20P-glycoprotein\x20can\x20thereby\x20decrease\x20their\x20elimination\x20and\x20lead\x20to\x20<strong>toxicity</strong>.\x20For\x20eg,\x20digoxin\x20is\x20metabolized\x20by\x20P-glycoprotein,\x20and\x20drugs\x20that\x20inhibit\x20it\x20increase\x20the\x20plasma\x20levels\x20of\x20digoxin\x20and\x20may\x20result\x20in\x20toxicity.</p>\x0a<p><strong>Increased\x20P-gp\x20expression</strong>:\x20<strong>Reduces\x20the\x20absorption</strong>\x20of\x20drugs\x20that\x20are\x20substrates\x20for\x20P-gp.<br\x20/><strong>Decreased\x20P-gp\x20expression</strong>:\x20Leads\x20to\x20<strong>supratherapeutic\x20plasma\x20concentrations</strong>\x20and\x20drug\x20toxicity.<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B,\x20C,\x20and\x20D:\x20Although\x20diltiazem,\x20nifedipine,\x20and\x20amlodipine\x20have\x20been\x20reported\x20in\x20the\x20literature\x20to\x20act\x20as\x20p-glycoprotein\x20inhibitors,\x20verapamil\x20is\x20more\x20potent\x20and\x20commonly\x20used\x20for\x20p-glycoprotein\x20inhibition\x20in\x20trials,\x20and\x20would\x20be\x20the\x20best\x20answer.</p>','table','wJuIn','nxbAy','pathname','<p>Among\x20the\x20given\x20options,\x20<strong>Candida\x20krusei\x20</strong>shows\x20an\x20<strong>intrinsic\x20resistance</strong>\x20to\x20<strong>fluconazole</strong>.\x20<br\x20/><br\x20/>The\x20<strong>primary</strong>\x20or\x20<strong>intrinsic\x20resistance</strong>\x20of\x20<strong>C.\x20krusei\x20</strong>to\x20<strong>azoles</strong>\x20(<strong>fluconazole</strong>\x20and\x20<strong>itraconazole</strong>)\x20is\x20mediated\x20through\x20<strong>reduced\x20susceptibility\x20of\x20the\x20target\x20enzyme</strong>\x20<strong>(lanosterol\x2014α-demethylase)\x20to\x20inhibition</strong>\x20by\x20these\x20drugs.\x20However,\x20<strong>improved\x20susceptibility</strong>\x20is\x20seen\x20with\x20<strong>newer\x20generation\x20azoles</strong>\x20such\x20as\x20<strong>voriconazole</strong>.</p>\x0a<p><strong>Life-threatening\x20systemic\x20infections</strong>\x20caused\x20by\x20<strong>Candida</strong>\x20and\x20<strong>Aspergillus</strong>\x20species\x20are\x20usually\x20seen\x20in\x20<strong>severely\x20ill</strong>\x20and\x20<strong>immunocompromised</strong>\x20patients\x20such\x20as\x20<strong>HIV</strong>,\x20<strong>chemotherapy</strong>-<strong>induced</strong>\x20<strong>neutropenia</strong>,\x20and\x20<strong>transplant</strong>\x20<strong>recipients</strong>\x20on\x20<strong>immunosuppressants</strong>.\x20<strong>C.\x20albicans</strong>\x20and\x20<strong>C.\x20dubliniensis</strong>\x20are\x20<strong>most\x20susceptible</strong>\x20to\x20<strong>currently\x20available\x20azoles</strong>,\x20<strong>C.\x20glabrata</strong>\x20is\x20<strong>less\x20susceptible</strong>,\x20whereas\x20<strong>C.\x20krusei</strong>\x20is\x20<strong>intrinsically\x20resistant</strong>\x20to\x20<strong>fluconazole</strong>.\x20Resistance\x20occurs\x20due\x20to\x20<strong>overexpression\x20or\x20point\x20mutation</strong>\x20in\x20the\x20gene\x20encoding\x20the\x20target\x20enzyme<strong>\x20lanosterol\x2014α-demethylase</strong>.\x20<strong>Voriconazole</strong>\x20is\x20the\x20preferred\x20therapy\x20for\x20<strong>multi-drug\x20resistant\x20infection</strong>\x20with<strong>\x20C.\x20krusei</strong>.</p>\x0a<p><strong>C.\x20albicans</strong>\x20and\x20<strong>C.\x20glabrata</strong>\x20(Option\x20C)\x20showing\x20<strong>resistance\x20to\x20Amphotericin\x20B</strong>\x20has\x20been\x20increasingly\x20reported\x20over\x20the\x20past\x20several\x20years.\x20But\x20this\x20is\x20a\x20<strong>secondary\x20resistance</strong>\x20due\x20to\x20<strong>alteration</strong>\x20or\x20a\x20<strong>decrease</strong>\x20in\x20the<strong>\x20amount\x20of\x20ergosterol</strong>\x20in\x20the\x20cell\x20membrane.\x20Amphotericin\x20B\x20is\x20indicated\x20to\x20treat\x20C.\x20glabrata\x20that\x20has\x20developed\x20resistance\x20to\x20azoles.</p>\x0a<p><strong>Aspergillus\x20fumigatus</strong>,\x20the\x20most\x20common\x20species\x20to\x20cause\x20Aspergillus\x20infection\x20worldwide,\x20also\x20shows\x20an\x20<strong>intrinsic\x20resistance\x20to\x20fluconazole</strong>.\x20It\x20is\x20<strong>susceptible\x20to\x20echinocandins</strong>\x20like\x20micafungin,\x20which\x20acts\x20by\x20<strong>inhibiting\x20beta-(1,3)-D-glucan\x20synthase</strong>,\x20an\x20enzyme\x20necessary\x20for\x20the\x20synthesis\x20of\x20the\x20cell\x20wall.</p>\x0a<p>Other\x20options<br\x20/><br\x20/>Option\x20A\x20:\x20<strong>Aspergillus\x20niger</strong>\x20is\x20a\x20common\x20cause\x20of\x20<strong>otomycosis</strong>\x20and\x20is<strong>\x20susceptible\x20to\x20azoles</strong>\x20like\x20<strong>voriconazole</strong>,\x20amphotericin\x20B,\x20and\x20echinocandins.<br\x20/><br\x20/>Option\x20D\x20:\x20The\x20<strong>drug\x20of\x20choice</strong>\x20for\x20treatment\x20of\x20<strong>sporotrichosis</strong>\x20is\x20<strong>itraconazole</strong>.</p>','CgoVV','push','bbhll','solutionContainer','Bookmark','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','modeModal','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','Which\x20of\x20the\x20following\x20is\x20true\x20statement\x20regarding\x20lithium?','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','Mark\x20for\x20Review','AVGin','jKgwg','rzYmp','KCJEj','jpMwT','oeSAa','QwOkY','Aspergillus\x20niger\x20-\x20Voriconazole','timerContainer','A\x20patient\x20diagnosed\x20with\x20ulcerative\x20colitis\x20presents\x20with\x202-3\x20episodes\x20of\x20bloody\x20stools\x20per\x20day.\x20What\x20should\x20be\x20given\x20to\x20manage\x20this\x20patient\x20?','bookmarkBtn','quizPerformanceData','Dexamethasone','wuNYX','gDBeX','rrNPX','kiYQW','markedForReview','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','jWSZE','question_images','eYvkK','KvlKH','totalTime','SQWzH','<p><strong>Thalidomide</strong>\x20does\x20<strong>not\x20cause</strong>\x20teratogenicity\x20by\x20<strong>inhibition\x20of\x20IL2,\x20IL4,\x20and\x20IL5.</strong></p>\x0a<p>The\x20mechanism\x20of\x20thalidomide\x20teratogenicity\x20include\u00a0<strong>oxidative\x20stress,\x20anti-angiogenesis,</strong>\x20and\x20thalidomide-binding\x20protein,\x20<strong>cereblon\x20</strong>which\x20has\x20a\x20role\x20in\x20the\x20development\x20of\x20cerebral\x20tissues\x20and\x20because\x20its\x20expression\x20in\x20the\x20hippocampus\x20among\x20other\x20areas\x20is\x20associated\x20with\x20<strong>memory\x20and\x20learning\x20processes\x20(CRBN).\u00a0</strong>Fetal\x20thalidomide\x20exposure\x20causes\x20phocomelia.\x20This\x20disorder\x20is\x20associated\x20with\x20<strong>underdeveloped\x20limbs</strong>\x20and\x20<strong>absent\x20pelvic\x20bones.</strong>\x20Both\x20<strong>upper</strong>\x20and\x20<strong>lower</strong>\x20limbs\x20are\x20<strong>affected</strong>,\x20and\x20a\x20part\x20of\x20the\x20limbs\x20may\x20be\x20missing.\x20Fused\x20fingers\x20and\x20missing\x20thumbs\x20are\x20also\x20seen.\x20Thalidomide\x20was\x20originally\x20used\x20for\x20the\x20treatment\x20of\x20<strong>pregnancy-associated\x20morning\x20sickness</strong>\x20but\x20was\x20<strong>withdrawn</strong>\x20due\x20to\x20this\x20adverse\x20effect.\u00a0It\x20is\x20now\x20used\x20for\x20the\x20treatment\x20of\x20erythema\x20nodosum\x20leprosum.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201423\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Thalidomide\x20is\x20an\x20immunomodulator.\x20Thalidomide\x20absorption\x20from\x20the\x20GI\x20tract\x20is\x20slow\x20and\x20highly\x20variable.\x20It\x20distributes\x20throughout\x20most\x20tissues\x20and\x20organs,\x20without\x20significant\x20binding\x20to\x20plasma\x20proteins.\x20Thalidomide\x20and\x20its\x20metabolites\x20are\x20excreted\x20in\x20the\x20urine,\x20while\x20the\x20<strong>nonabsorbed</strong>\x20portion\x20of\x20the\x20drug\x20is\x20<strong>excreted\x20unchanged\x20in\x20feces</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p>\u00a0Common\x20adverse\x20effects\x20of\x20thalidomide\x20include\x20sedation\x20and\x20constipation.\x20However,\x20one\x20of\x20the\x20most\x20serious\x20adverse\x20effects\x20is\x20<strong>peripheral\x20sensory\x20neuropathy</strong>,\x20characterized\x20by\x20<strong>asymmetrical,\x20painful,\x20peripheral\x20paresthesia\x20with\x20sensory\x20loss</strong>.\x20Symptoms\x20often\x20present\x20as\x20numbness\x20of\x20the\x20toes\x20and\x20feet,\x20muscle\x20cramps,\x20weakness,\x20signs\x20of\x20pyramidal\x20tract\x20involvement,\x20and\x20carpal\x20tunnel\x20syndrome.</p>','bgxKw','cduCj','BEpBe','jGdxC','mXzlA','LkpUf','bookmarkText','ILAVq','sYWCK','search','L858R\x20mutation','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','Rifampicin','LEXks','incorrectCount','remove','DoFEj','elkQQ','Prolonged\x20PR\x20intervals','data-option-index','yxOGG','rAjmo','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','__proto__','answered','prototype','nav-btn-incorrect','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','Amifostine','What\x20is\x20true\x20about\x20keynote\x20189\x20trial?','<p><strong>Hyponatremia</strong>\x20occurs\x20<strong>more\x20frequently</strong>\x20in\x20the\x20case\x20of\x20<strong>oxcarbazepine</strong>\x20than\x20carbamazepine.</p>\x0a<p>Both\x20carbamazepine\x20and\x20oxcarbazepine\x20are<strong>\x20sodium-channel\x20blockers\x20</strong>that\x20<strong>stabilize\x20neuronal\x20membranes</strong>.\x20Oxcarbazepine\x20is\x20the\x2010-keto\x20analog\x20of\x20carbamazepine\x20and\x20and\x20cannot\x20form\x20an\x20epoxide\x20metabolite.\x20<strong>Carbamazepine</strong>\x20<strong>potentiates</strong>\x20the\x20action\x20of<strong>\x20antidiuretic\x20hormone</strong>\x20(ADH).\x20It\x20can\x20result\x20in\x20<strong>water\x20retention</strong>\x20with\x20decreased\x20osmolarity\x20and\x20<strong>hyponatremia</strong>,\x20especially\x20in\x20elderly\x20patients\x20with\x20cardiac\x20disease.\x20Although\x20<strong>hyponatremia\x20may\x20occur\x20more\x20commonly\x20with\x20oxcarbazepine</strong>\x20than\x20with\x20carbamazepine,\x20most\x20adverse\x20effects\x20of\x20oxcarbazepine\x20are\x20similar\x20to\x20those\x20of\x20carbamazepine.\x20<br\x20/><br\x20/>Carbamazepine\x20and\x20oxcarbazepine\x20can\x20cause\x20<strong>leukopenia,\x20aplastic\x20anemia,\x20hepato-toxicity</strong>\x20in\x20the\x20elderly.\u00a0<br\x20/><br\x20/><strong>Oxcarbazepine</strong>\x20shows\x20<strong>lesser\x20hypersensitivity</strong>\x20reaction.\x20Hence,<strong>\x20rashes\x20(option\x20A)\x20are\x20more\x20commonly\x20seen\x20with\x20carbamazepine\x20</strong>than\x20with\x20oxcarbazepine.<br\x20/><br\x20/>Studies\x20have\x20shown\x20that\x20<strong>carbamazepine</strong>\x20<strong>elevates\x20enzyme\x20gamma-glutamyl\x20transpeptidases\x20(GGT)\x20more\x20frequently</strong>\x20than\x20oxcarbazepine\x20because\x20of\x20<strong>enzyme</strong>\x20<strong>P450\x20induction</strong>.\x20Hepatotoxicity\x20from\x20oxcarbazepine\x20occurs\x20less\x20commonly\x20compared\x20to\x20carbamazepine\x20(Option\x20D).\u00a0<br\x20/><br\x20/><strong>Side\x20effects\x20of\x20carbamazepine</strong>\x20therapy\x20include:\x20<strong>mnemonic:\x20HEADS</strong></p>\x0a<p><strong>H</strong>ypersensitivity\x20reactions<br\x20/><strong>E</strong>osinophilia<br\x20/><strong>A</strong>granulocytosis:\x20report\x20symptoms\x20like\x20sore\x20throat/fever<br\x20/><strong>A</strong>plastic\x20anemia<br\x20/><strong>A</strong>taxia<br\x20/><strong>D</strong>ilutional\x20hyponatremia<br\x20/><strong>D</strong>iplopia,\x20blurred\x20vision<br\x20/><strong>S</strong>plenomegaly<br\x20/><strong>S</strong>tevens-Johnson\x20syndrome</p>\x0a<p><strong>Carbamazepine</strong>\x20is\x20most\x20effective\x20in\x20<strong>complex\x20partial\x20seizures</strong>.\x20It\x20is\x20also\x20used\x20in\x20<strong>GTCS</strong>\x20and\x20<strong>simple\x20partial\x20seizures</strong>,\x20<strong>trigeminal\x20and\x20related\x20neuralgias</strong>,\x20and\x20<strong>manic\x20depressive\x20psychosis.\x20Oxcarbazepine</strong>\x20has\x20been\x20used\x20to\x20treat<strong>\x20intractable\x20trigeminal\x20neuralgia\x20refractory</strong>\x20to\x20other\x20anticonvulsants.\u00a0</p>\x0a<p>Mechanism\x20of\x20action\x20of\x20some\x20common\x20antiepileptics:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2051.1244%;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Mechanism\x20of\x20action</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>Antiepileptics</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Sodium-channel\x20blockers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Phenytoin</p>\x0a<p>Carbamazepine,\x20Oxcarbamazepine</p>\x0a<p>Eslicarbazepine</p>\x0a<p>Lamotrigine</p>\x0a<p>Topiramate</p>\x0a<p>Felbamate</p>\x0a<p>Valproate</p>\x0a<p>Rufinamide</p>\x0a<p>Levetiracetam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Calcium-channel\x20blockers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Valproate</p>\x0a<p>Lamotrigine</p>\x0a<p>Ethosuximide</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>GABA\x20A\x20receptor\x20modulators</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Benzodiazepines</p>\x0a<p>Phenobarbital</p>\x0a<p>Felbamate</p>\x0a<p>Primidone</p>\x0a<p>Topiramate</p>\x0a<p>Carbamazepine,\x20Oxcarbamazepine</p>\x0a<p>Stiripentol</p>\x0a<p>Clobazam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>GABA\x20uptake\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Tiagabine</p>\x0a<p>Vigabatrin</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>NMDA\x20receptor\x20antagonist</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>Felbamate</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>AMPA/Kainate\x20receptor\x20antagonist</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Phenobarbital</p>\x0a<p>Topiramate</p>\x0a<p>Perampanel</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>HCN\x20channel\x20activity\x20enhancers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>Lamotrigine</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Inhibitors\x20of\x20brain\x20carbonic\x20anhydrase</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Acetazolamide</p>\x0a<p>Zonisamide</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Potassium-channel\x20openers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Retigabine</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>\u00a0</p>','SiUyP','A-2,\x20B-3,\x20C-4,\x20D-1','vgXEI','iVwgA','CHVWx','lIEWE','VVKBx','rCXLz','explanation_audio_eng','ndpHE','Dexrazoxane','6pZfYbX','timeSpent','Kafio','incorrectResult','QWZst','<p><strong>Pregabalin</strong>\x20can\x20be\x20used\x20for\x20<strong>diabetic\x20neuropathy,</strong>\x20<strong>post\x20herpetic\x20neuralgia</strong>\x20and\x20<strong>spinal\x20cord\x20injury</strong>.\x20Although\x20<strong>amitriptyline</strong>\x20can\x20also\x20be\x20used\x20for\x20these\x20conditions,\x20<strong>pregabalin</strong>\x20is\x20found\x20to\x20be\x20<strong>recommended</strong>\x20over\x20amitriptyline\x20considering\x20<strong>safety\x20and\x20efficacy\x20</strong>and\x20hence\x20is\x20the\x20best\x20option.</p>\x0a<p><strong>Pregabalin</strong>\x20is\x20an\x20<strong>anti</strong>-<strong>epileptic</strong>\x20drug.\x20Its\x20<strong>analgesic\x20effect</strong>\x20is\x20mediated\x20by\x20<strong>binding</strong>\x20<strong>to\x20α2δ</strong>,\x20a\x20<strong>protein</strong>\x20that\x20is\x20a\x20<strong>subunit</strong>\x20of\x20<strong>voltage-gated\x20calcium\x20channels</strong>\x20and\x20causes\x20a\x20<strong>decrease\x20in\x20glutamate\x20release</strong>\x20at\x20<strong>excitatory\x20synapses</strong>.\x20Decreased\x20neurotransmitter\x20release\x20is\x20associated\x20with\x20<strong>reduced\x20neuronal\x20hyperexcitability</strong>.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>neuropathic\x20pain</strong>\x20<strong>associated\x20with\x20diabetic\x20peripheral\x20neuropathy</strong>,\x20<strong>spinal\x20cord\x20injury</strong>\x20or\x20<strong>postherpetic\x20neuralgia</strong>.\u00a0</p>\x0a<p>Currently,\x20only\x20<strong>duloxetine\x20and\x20pregabalin</strong>\x20are\x20<strong>approved\x20by\x20the\x20U.S.\x20Food\x20and\x20Drug\x20Administration</strong>\x20and\x20the\x20European\x20Medicines\x20Agency\x20to\x20treat\x20<strong>painful\x20diabetic\x20neuropathy</strong>.\u00a0Diabetic\x20Neuropathy\x20is\x20the\x20<strong>most\x20common\x20cause\x20of\x20peripheral\x20neuropathy</strong>\x20in\x20<strong>developed\x20countries</strong>.\x20<strong>Risk\x20factors</strong>\x20include\x20<strong>long-standing,\x20poorly\x20controlled\x20DM</strong>\x20and\x20the\x20<strong>presence</strong>\x20<strong>of</strong>\x20<strong>retinopathy\x20and\x20nephropathy</strong>.</p>\x0a<p><strong>Side\x20effects</strong>\x20of\x20<strong>pregabalin</strong>\x20include\x20<strong>sedation</strong>\x20and\x20<strong>peripheral\x20edema</strong>.</p>\x0a<p>Other\x20options\x20:\u00a0</p>\x0a<p>Option\x20A\x20:\x20<strong>Tricyclic\x20antidepressants\x20(TCAs)</strong>\x20such\x20as\x20<strong>amitriptyline</strong>\x20are\x20used\x20in\x20the\x20<strong>treatment\x20of\x20several\x20pain\x20conditions</strong>\x20such\x20as\x20<strong>diabetic\x20neuropathy,\x20post\x20herpetic\x20neuralgia</strong>\x20and\x20following\x20<strong>spinal\x20cord\x20injury</strong>.\x20Their\x20mechanism\x20of\x20action\x20is\x20<strong>inhibition\x20of\x20norepinephrine\x20and\x20serotonin\x20reuptake.</strong>\x20Although\x20both\x20pregabalin\x20and\x20amitriptyline\x20are\x20among\x20the\x20first\x20line\x20drugs\x20for\x20neuropathic\x20pain,\x20amitriptyline\x20would\x20be\x20the\x20<strong>next\x20best\x20option</strong>\x20in\x20this\x20question,\x20owing\x20to\x20its\x20<strong>side\x20effect\x20profile</strong>\x20and\x20good\x20yet\x20<strong>controversial\x20efficacy\x20in\x20pain\x20control</strong>.\x20It\x20is\x20a\x20<strong>non\x20FDA\x20approved</strong>\x20<strong>drug</strong>\x20for\x20<strong>diabetic\x20neuropathy\x20(off\x20label\x20indication).\x20</strong>Side\x20effects\x20associated\x20with\x20amitriptyline\x20include\x20<strong>anticholinergic\x20side\x20effects</strong>\x20(dry\x20mouth,\x20tachycardia,\x20hyperthermia),\x20<strong>cardiac\x20effects\x20(arrhythmias)</strong>\x20and\x20<strong>sedation</strong>.</p>\x0a<p>Option\x20B\x20:\x20<strong>Phenytoin</strong>\x20is\x20an\x20<strong>antiepileptic</strong>\x20drug\x20that\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20pain.</p>\x0a<p>Option\x20C\x20:\u00a0<strong>Carbamazepine</strong>\x20is\x20an\x20<strong>iminostilbine</strong>\x20<strong>derivative</strong>.\x20It\x20<strong>blocks\x20voltage-activated\x20sodium\x20channels</strong>,\x20slowing\x20their\x20rate\x20of\x20recovery\x20and\x20limiting\x20the\x20repetitive\x20firing\x20of\x20action\x20potentials.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>generalized,\x20focal-to-bilateral\x20and\x20idiopathic\x20tonic-clonic\x20seizures,\x20focal\x20seizures,\x20neuropathic\x20pain</strong>\x20associated\x20with\x20<strong>trigeminal\x20and\x20glossopharyngeal\x20neuralgias</strong>.</p>','findIndex','totalQuestionsResult','ptXIh','9051609RuTWSW','<p>The\x20given\x20clinical\x20features\x20are\x20suggestive\x20of<strong>\x20hypothyroidism\x20with\x20goiter,</strong>\x20which\x20is\x20a\x20known\x20<strong>adverse\x20effect\x20of\x20ethionamide</strong>.</p>\x0a<p><strong>Mutidrug-resistant\x20tuberculosis\x20(MDR-TB)</strong>\x20is\x20treated\x20with\x20<strong>2nd\x20line\x20agents</strong>\x20that\x20include\x20<strong>ethionamide\x20(ETH)</strong>.\x20ETH\x20is\x20not\x20a\x20first-line\x20agent\x20due\x20to\x20its\x20<strong>gastrointestinal\x20side\x20effects</strong>.\x20Ethionamide\x20<strong>inhibits\x20activity\x20of\x20the\x20InhA\x20gene\x20product</strong>,\x20resulting\x20in\x20<strong>inhibition\x20of\x20mycolic\x20acid\x20synthesis</strong>.\x20It\x20is\x20<strong>structurally\x20related\x20to\x20thionamides</strong>\x20(propylthiouracil\x20and\x20methimazole)\x20and\x20therefore<strong>\x20causes\x20hypothyroidism</strong>\x20by\x20<strong>preventing\x20organification\x20of\x20iodine\x20in\x20thyroid\x20hormone\x20synthesis.</strong>\x20<strong>Another\x20antitubercular\x20</strong>drug\x20that\x20can\x20cause<strong>\x20hypothyroidism\x20</strong>is<strong>\x20Para-amino\x20salicylic\x20acid\x20(PAS)</strong>.\u00a0</p>\x0a<p>ETH/PAS-induced\x20hypothyroidism\x20should\x20be<strong>\x20treated\x20with\x20thyroxine\x20replacement\x20</strong>therapy,\x20instead\x20of\x20changing\x20the\x20regimen.\x20Thyroid\x20function\x20usually\x20optimizes\x20within\x202\x20months\x20after\x20completing\x20MDR\x20therapy.<br\x20/><br\x20/><strong>Ethionamide</strong>\x20also\x20causes\x20<strong>hepatotoxicity</strong>\x20and\x20<strong>neurological</strong>\x20<strong>adverse</strong>\x20<strong>effects</strong>\x20and\x20may\x20require\x20<strong>pyridoxine\x20supplementation</strong>.</p>\x0a<p><strong>MDR-TB</strong>\x20is\x20when\x20there\x20is\x20<strong>resistance\x20to\x20atleast\x20isoniazid\x20and\x20rifampicin\x20</strong>which\u00a0are\x20the\x20most\x20potent\x20first-line\x20drugs.\u00a0The\x20treatment\x20of\x20MDR-TB\x20is\x20curated\x20with\x20drugs\x20grouped\x20into\x20different\x20classes\x20by\x20the\x20world\x20health\x20organization\x20(WHO).</p>\x0a<p><strong>Group\x20A:\x20Levofloxacin,\x20bedaquiline,\x20linezolid</strong><br\x20/><strong>Group\x20B:\x20Clofazimine,\x20cycloserine</strong><br\x20/><strong>Group\x20C:\x20Ethambutol,\x20pyrazinamide,\x20delamanid,\x20ethionamide</strong><br\x20/><br\x20/>In\x20patients<strong>\x20treated\x20previously</strong>\x20or\x20with\x20<strong>additional\x20drug\x20resistance</strong>,\x20a\x20<strong>longer\x20MDR-TB\x20regimen</strong>\x20of\x20<strong>18-20\x20months</strong>\x20is\x20recommended.\x20Drugs\x20belonging\x20to\x20<strong>group\x20A\x20are\x20preferred\x20along\x20with\x20one\x20drug\x20from\x20group\x20B</strong>\x20whenever\x20possible.\x20A<strong>\x20shorter\x20regimen\x20of\x206\x20months</strong>\x20including\x20<strong>bedaquiline</strong>\x20with\x20other\x20drugs\x20can\x20be\x20used\x20in\x20<strong>patients\x20not\x20treated\x20before</strong>\x20and\x20<strong>without\x20extensive\x20disease.</strong>\x20In\x20<strong>pregnant</strong>\x20<strong>women</strong>\x20with\x20MRD-TB,\x20drugs\x20such\x20as\x20<strong>bedaquiline</strong>\x20and\x20<strong>delamanid</strong>\x20should\x20be\x20<strong>avoided</strong>.</p>\x0a<p>Other\x20options\x20:<br\x20/><br\x20/>Option\x20A\x20:\x20<strong>Pyrazinamide\x20inhibits\x20fatty\x20acid\x20synthase-I\x20</strong>leading\x20to<strong>\x20inhibition\x20of\x20cell\x20membrane\x20synthesis</strong>.\x20Pyrazinamide\x20causes\x20<strong>hyperuricemia</strong>\x20and\x20<strong>hepatotoxicity</strong>.\u00a0<br\x20/><br\x20/>Option\x20C\x20:\x20Adverse\x20effects\x20of\x20<strong>cycloserine</strong>\x20are\x20mainly\x20<strong>neurological</strong>.\x20Half\x20of\x20the\x20patients\x20on\x20cycloserine\x20(1g/day)\x20experience\x20<strong>neuropsychiatric</strong>\x20<strong>symptoms</strong>.\x20It\x20ranges\x20from\x20<strong>headaches\x20to\x20psychosis,\x20seizures,\x20and\x20suicidal\x20ideas</strong>.</p>\x0a<p>Option\x20D\x20:\x20<strong>Streptomycin</strong>\x20is\x20an\x20<strong>aminoglycoside</strong>\x20which\x20binds\x20to\x20the\x20<strong>30S\x20ribosomal</strong>\x20subunit\x20and\x20<strong>interferes\x20with\x20the\x20initiation\x20of\x20protein\x20synthesis</strong>.\x20\u00a0It\x20is\x20a\x20<strong>second-line\x20agent\x20</strong>for\x20the\x20treatment\x20of\x20active\x20tuberculosis.\x20Streptomycin\x20produces\x20<strong>ototoxicity,\x20vestibulotoxicity,\x20optic\x20nerve\x20dysfunction,\x20including\x20scotomas,\x20and\x20peripheral\x20neuritis.</strong></p>','studyModeLegend','explanation_audio_hin','tbaTx','choices','iPTcP','.option-button','OmBca','Flat\x20T\x20waves','AlNCo','ztIJV','optionsContainer','UWaFo','LCjal','dglIM','pOzCO','startAt','review-question\x20','Eltrombopag','bookmarked','BYYNx','disabled','button','VuPGr','Tipranavir','totalQuestions','aibwU','name','VRnSr','tVxCi','Cerebral\x20bleeding','block','hfoMF','<p><strong>Linezolid</strong>\x20is\x20a\x20<strong>protein\x20synthesis\x20inhibitor</strong>\x20that\x20acts\x20by\x20<strong>inhibiting</strong>\x20the<strong>\x2050s\x20ribosomal</strong>\x20<strong>subunit</strong>.<br\x20/><br\x20/>Linezolid\x20binds\x20to\x20the\x20<strong>P\x20site</strong>\x20of\x20the\x20<strong>50s\x20ribosomal\x20subunit</strong>\x20and\x20<strong>inhibits\x20bacterial\x20protein\x20synthesis.</strong>\x20It\x20is\x20an\x20<strong>oxazolidinone</strong>\x20that\x20is\x20active\x20against\x20<strong>various\x20resistant\x20organisms</strong>\x20including\x20<strong>MRSA</strong>.\x20It\x20has\x20<strong>excellent</strong>\x20<strong>oral\x20bioavailability</strong>.\x20Linezolid\x20is\x20used\x20to\x20treat\x20infections\x20caused\x20by\x20<strong>gram-positive\x20bacteria</strong>,\x20particularly\x20<strong>vancomycin-resistant\x20enterococcus\x20</strong>and\x20<strong>methicillin-resistant\x20Staphylococcus\x20aureus</strong>.\x20Linezolid\x20is\x20also\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>community-acquired\x20pneumonia\x20</strong>due\x20to<strong>\x20S.\x20pneumoniae</strong>\x20and\x20<strong>nosocomial\x20pneumonia</strong>\x20due\x20to\x20<strong>S.\x20aureus.</strong><br\x20/><br\x20/>The\x20<strong>intrinsic\x20resistance</strong>\x20of\x20<strong>gram-negative\x20bacteria\x20</strong>to\x20linezolid\x20is\x20mediated\x20by\x20<strong>endogenous\x20efflux\x20pumps.</strong><br\x20/><br\x20/>Linezolid\x20is\x20associated\x20with\x20the\x20<strong>side\x20effect\x20of\x20myelosuppression\x20</strong>(anemia,\x20leukopenia,\x20pancytopenia,\x20and\x20thrombocytopenia).\x20<strong>Thrombocytopenia\x20is\x20the\x20most\x20common\x20side\x20effect</strong>.\x20Linezolid\x20has<strong>\x20MAOI\x20(monoamine\x20oxidase\x20inhibitors)\x20activity\x20</strong>and\x20therefore\x20can\x20<strong>precipitate\x20serotonin\x20syndrome\x20with\x20concomitant\x20use\x20of\x20SSRI\x20(paroxetine)\x20</strong>or\x20with\x20other\x20<strong>serotonergic\x20medications.\u00a0</strong><strong><br\x20/><br\x20/></strong>Other\x20adverse\x20effects\x20include\x20<strong>peripheral\x20neuropathy,\x20optic\x20neuropathy,\x20lactic\x20acidosis</strong>.<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20A\x20:\x20<strong>Aztreonam</strong>\x20is\x20a\x20<strong>monobactam</strong>,\x20and\x20acts\x20similar\x20to\x20penicillin\x20by<strong>\x20inhibiting\x20peptiglycan\x20crosslinking\x20</strong>and\x20inhibiting\x20bacterial\x20cell\x20wall\x20synthesis.</p>\x0a<p>Option\x20B\x20:\x20<strong>Daptomycin</strong>\x20is\x20a\x20<strong>cyclic\x20lipopeptide</strong>\x20antibiotic.\x20It\x20acts\x20by<strong>\x20depolarising\x20bacterial\x20membranes</strong>\x20resulting\x20in\x20loss\x20of\x20membrane\x20potential\x20and\x20cell\x20death.\u00a0</p>\x0a<p>Option\x20D\x20:\x20<strong>Rifampicin\u00a0</strong>is\x20an\x20anti\x20tubercular\x20antibiotic\x20that\x20acts\x20by\u00a0<strong>inhibiting\x20bacterial\x20DNA-dependent\x20RNA\x20polymerase.</strong></p>','QJqPu','loadSource','not-attempted','sOiVD','fNnpL','eSraC','A\x20patient\x20was\x20started\x20on\x20a\x20drug\x20for\x20mood\x20disorder\x20and\x20he\x20developed\x20priapism.\x20The\x20causative\x20drug\x20is:','hggkU','lpcvG','Hlzuo','Nivolumab\x20is\x20used\x20in\x20NSCLC','Hepatitis','Zbtok','title','kvecz','Which\x20of\x20the\x20following\x20is\x20not\x20a\x20mechanism\x20for\x20thalidomide\x20teratogenicity?','Nifedipine','appendChild','canPlayType','nav-btn-bookmarked','totalAttempted','Fostamatinib','snzWL','Diltiazem','<p\x20class=\x22p1\x22><strong>Agranulocytosis</strong>\x20is\x20a&nbsp;rare\x20but\x20very\x20severe\x20side\x20effect\x20of\x20<strong>clozapine</strong>\x20that\x20<strong>requires\x20regular\x20monitoring.&nbsp;</strong></p>\x0a<p\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>A\x20patient\x20who\x20is\x20on\x20clozapine\x20should\x20undergo\x20<strong>regular\x20hematological\x20monitoring</strong>\x20due\x20to\x20the\x20risk\x20of\x20<strong>agranulocytosis</strong>.\x20Avoid\x20combining\x20clozapine\x20with\x20other\x20agranulocytosis-causing\x20drugs\x20like\x20carbamazepine,\x20phenytoin,\x20propylthiouracil,\x20and\x20sulfonamides.</span></p>\x0a<p\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Adverse\x20effects\x20of\x20clozapine\x20are:</span></p>\x0a<ul>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Sedation\x20and\x20weight\x20gain-\x20H<sub>1</sub>\x20antagonism</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Syncope,\x20tachycardia,\x20hypotension-&nbsp;&alpha;<sub>1</sub>\x20antagonism</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Hypersalivation/sialorrhea-\x20M<sub>4&nbsp;</sub>agonism</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Seizures-\x20dose-dependant</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Agranulocytosis-\x20dose-independent</span></li>\x0a</ul>\x0a<p><span\x20style=\x22font-size:\x2010pt;\x22>Clozapine\x20reduces\x20the\x20seizure\x20threshold\x20thus<strong>\x20increasing</strong>\x20the\x20risk\x20of\x20<strong>seizures.&nbsp;</strong></span><span\x20style=\x22font-size:\x2010pt;\x22>Clozapine,\x20an\x20atypical\x20antipsychotic,\x20is\x20an\x20antagonist\x20of\x205HT<sub>2A</sub>,\x20D<sub>1</sub>,\x20D<sub>3</sub>,\x20D<sub>4,&nbsp;</sub>and&nbsp;&alpha;-receptors.&nbsp;</span><span\x20style=\x22font-size:\x2010pt;\x22>Clozapine\x20is\x20used\x20in\x20<strong>treatment-resistant</strong>\x20<strong>schizophrenia,\x20suicidal\x20patients\x20with\x20schizophrenia,</strong>\x20severe\x20psychotic\x20depression,\x20and\x20Huntington\x27s\x20disease.\x20&nbsp;</span></p>\x0a<p>&nbsp;</p>','xcRSM','vZwfS','DsmPy','AdiUM','oUgeU','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','replace','T890M\x20mutation','solutionVideo','T790M\x20mutation','Clindamycin','7554485amaSAU','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','correctAnswers','OvKxC','eoUIA','exception','questions','ZdfWd','txIOP','correct_choice_id','It\x20is\x20not\x20teratogenic','navBtn_','Morphine','hGcFB','info','VKyOu','UiGvm','Linagliptin','919850mvxbGJ','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','<p>In\x20the\x20above\x20clinical\x20scenario,\x20the\x20most\x20likely\x20cause\x20of\x20itching\x20around\x20the\x20vulvovaginal\x20area\x20is&nbsp;<strong>canagliflozin</strong>.\x20The&nbsp;side\x20effects\x20associated\x20with\x20canagliflozin\x20are\x20<strong>urinary\x20tract\x20infections</strong>,&nbsp;<strong>genital\x20mycotic\x20infections</strong>\x20due\x20to\x20the\x20high\x20glucose\x20content\x20of\x20the\x20urine,&nbsp;<strong>increased\x20risk\x20of\x20fractures</strong>,\x20and\x20<strong>lower\x20extremity\x20amputations</strong>.</p>\x0a<p>Canagliflozin\x20is\x20a\x20<strong>sodium-glucose\x20transporter\x202</strong>\x20(SGLT-2)\x20<strong>inhibitor</strong>.\x20Other\x20SGLT-2\x20inhibitors\x20include\x20dapagliflozin\x20and\x20empagliflozin.\x20They\x20act\x20by&nbsp;inhibiting\x20the&nbsp;SGLT-2\x20transporter\x20which\x20is\x20present\x20on\x20the\x20<strong>proximal</strong>\x20segment\x20of\x20the\x20<strong>renal\x20tubule</strong>.\x20It\x20is\x20responsible\x20for\x20the\x20reabsorption\x20of\x2080-90%\x20of\x20filtered\x20glucose.&nbsp;It&nbsp;inhibits\x20glucose\x20reabsorption\x20resulting\x20in\x20glycosuria\x20and\x20a\x20change\x20in\x20the\x20renal\x20threshold.</p>\x0a<p>SGLT2\x20inhibitors\x20can\x20cause\x20<strong>mild\x20weight\x20loss</strong>\x20and\x20reduction\x20in\x20blood\x20pressure.\x20Drugs\x20like&nbsp;empagliflozin\x20and\x20canagliflozin\x20are\x20found\x20to\x20<strong>reduce</strong>\x20major\x20<strong>cardiovascular\x20events</strong>.</p>\x0a<p>The\x20common\x20side\x20effects\x20include\x20<strong>urinary\x20tract\x20infections</strong>\x20and<strong>\x20genital\x20mycotic\x20infections</strong>\x20due\x20to\x20the\x20high\x20glucose\x20content\x20of\x20the\x20urine.&nbsp;There\x20is\x20a\x20risk\x20of\x20the\x20development\x20of\x20<strong>diabetic\x20ketoacidosis</strong>.\x20It\x20increases\x20the\x20<strong>risk\x20of\x20fractures</strong>\x20and\x20<strong>lower\x20limb\x20amputations</strong>\x20due\x20to\x20the\x20creation\x20of\x20an\x20imbalance\x20with\x20the\x20minerals\x20and\x20circulating\x20parathormone\x20and\x20vitamin\x20D.\x20Since\x20SGLT2\x20inhibitors\x20depend\x20on\x20the\x20rate\x20of\x20glucose\x20filtration\x20to\x20be\x20effective,\x20potency\x20decreases\x20if\x20given\x20in\x20stage\x203\x20kidney\x20disease\x20(GFR\x2060&ndash;30\x20mL/min).</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Acarbose\x20is\x20an\x20a</strong><strong>lpha-glucosidase\x20inhibitor.\x20</strong>It&nbsp;reduces\x20the\x20intestinal\x20absorption\x20of\x20glucose\x20by\x20inhibiting\x20the\x20intestinal\x20brush\x20border\x20enzyme,\x20alpha-glucosidase.\x20These\x20drugs\x20also\x20increase\x20GLP-1\x20levels\x20in\x20circulation.\x20They&nbsp;<strong>reduce\x20post-prandial\x20glucose</strong>&nbsp;levels.</p>\x0a<p>Option\x20C:&nbsp;<strong>Linagliptin</strong>&nbsp;is\x20a&nbsp;<strong>dipeptidyl-peptidase-4&nbsp;</strong>(DPP-4)<strong>&nbsp;inhibitor</strong>.\x20It\x20is\x20used\x20in\x20type\x202\x20diabetes\x20as\x20monotherapy\x20or\x20in\x20combination\x20therapy\x20when\x20metformin\x20is\x20not\x20tolerated\x20or\x20contraindicated.\x20It&nbsp;binds\x20extensively\x20to\x20plasma\x20proteins\x20and\x20is\x20cleared<strong>&nbsp;primarily\x20by\x20the\x20hepatobiliary\x20system.&nbsp;</strong>Hence,\x20no\x20dosage\x20adjustment\x20is\x20needed\x20in\x20renal\x20failure.&nbsp;<strong>Dipeptidyl\x20peptidase-4\x20inhibitors&nbsp;</strong>enhance\x20the\x20release\x20of\x20insulin\x20postprandially,\x20decrease\x20glucagon,\x20and\x20thereby\x20lower\x20mealtime\x20as\x20well\x20as\x20fasting\x20glucose.\x20They\x20are\x20weight\x20neutral.</p>\x0a<p>Option\x20D:&nbsp;<strong>Liraglutide</strong>&nbsp;is\x20also\x20a&nbsp;<strong>GLP-1\x20receptor\x20agonist</strong>&nbsp;and\x20is\x20given\x20only\x20in\x20the&nbsp;<strong>subcutaneous\x20injectable</strong>&nbsp;form.\x20It\x20was\x20recently\x20approved\x20in\x20the\x20treatment\x20of&nbsp;<strong>obesity.</strong></p>\x0a<p>&nbsp;</p>','incorrectAnswers','uKLDI','fBELi','sBgSK','HbYiF','XjyUN','VYvlP','Rashes','totalTimeResult','uPOMd','Incorrect','HMPSw','<p><strong>Sodium\x20valproate</strong>\x20has\x20an\x20<strong>inhibitory\x20action</strong>\x20on\x20the\x20<strong>metabolism</strong>\x20and\x20<strong>degradation</strong>\x20of\x20<strong>GABA</strong>,\x20and\x20also<strong>\x20increases\x20its\x20synthesis</strong>.<br\x20/><br\x20/><strong>Valproate</strong>\x20is\x20an\x20<strong>anti-epileptic\x20</strong>medication\x20and\x20also\x20used\x20as\x20a\x20<strong>mood\x20stabilizer</strong>\x20in\x20<strong>bipolar\x20disorder</strong>.\x20Valproate\x20<strong>acts\x20via\x20multiple\x20mechanisms</strong>.\x20It\x20<strong>blocks</strong>\x20<strong>both</strong>\x20<strong>sodium</strong>\x20and\x20<strong>calcium</strong>\x20<strong>channels</strong>.\x20It\x20<strong>prolongs\x20sodium\x20channel\x20inactivation</strong>\x20and\x20<strong>attenuates\x20calcium-mediated\x20\x27T\x27\x20current</strong>.\x20It\x20<strong>inhibits\x20metabolism\x20and\x20degradation</strong>\x20of\x20the\x20inhibitory\x20neurotransmitter\x20<strong>GABA</strong>\x20and\x20<strong>increases\x20its\x20synthesis</strong>\x20from\x20<strong>glutamic\x20acid</strong>\x20(Option\x20A).\x20It\x20also\x20<strong>inhibits\x20excitatory\x20NMDA\x20glutamate\x20receptors</strong>.\x20The\x20<strong>repetitive\x20firing</strong>\x20caused\x20by\x20the\x20<strong>depolarization\x20of\x20cortical\x20or\x20spinal\x20cord\x20neurons</strong>\x20is\x20<strong>inhibited</strong>\x20by\x20valproate.</p>\x0a<p>Valproate\x20is\x20a<strong>\u00a0broad\x20spectrum\x20antiseizure\x20drug</strong>\x20used\x20in\x20<strong>partial\x20seizures,\x20generalised\x20tonic-clonic\x20seziures\x20(GTCS),\x20absence\x20seizures,\x20myoclonic\x20seziures</strong>\x20and\x20<strong>atonic\x20seziures</strong>.\x20It\x20can\x20be\x20used\x20in\x20absence\x20seizures,\x20but\x20it\x20is\x20preferred\x20when\x20the\x20child\x20also\x20suffers\x20from\x20GTCS.\x20It\x20is\x20the\x20<strong>drug\x20of\x20choice</strong>\x20for\x20<strong>juvenile\x20myoclonic\x20epilepsy</strong>.\u00a0</p>\x0a<p>The<strong>\x20side\x20effects\x20</strong>of\x20valproate\x20(mnemonic:\x20VALPROATE)</p>\x0a<p><strong>V</strong>omiting<br\x20/><strong>A</strong>lopecia<br\x20/><strong>L</strong>iver\x20toxicity<br\x20/><strong>P</strong>ancreatitis<br\x20/><strong>R</strong>ash<br\x20/><strong>O</strong>besity<br\x20/><strong>A</strong>norexia<br\x20/><strong>T</strong>eratogenicity<br\x20/><strong>E</strong>dema</p>\x0a<p>It\x20causes\x20<strong>congenital\x20anomalies</strong>\x20like\x20<strong>neural\x20tube\x20defects\x20(Spina\x20Bifida)</strong>,\x20<strong>clefts</strong>,\x20and\x20<strong>cardiac\x20anomalies</strong>.\x20The\x20<strong>intelligence\x20quotient</strong>\x20score\x20of\x20school-going\x20children\x20who\x20were\x20<strong>exposed\x20in\x20utero\x20to\x20valproate</strong>\x20is\x20found\x20<strong>reduced</strong>.\x20It\x20also\x20contributes\x20to\x20<strong>poor\x20cognitive\x20development</strong>\x20in\x20children.\x20<strong>Folate\x20supplementation</strong>\x20<strong>reduces</strong>\x20the\x20chances\x20of\x20<strong>neural\x20tube\x20defects.</strong></p>\x0a<p>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20C\x20:\x20Drugs\x20such\x20as\x20<strong>vigabatrine\x20and\x20tiagabine</strong>\x20<strong>inhibit\x20GABA\x20reuptake</strong>\x20by\x20inhibiting\x20the\x20GABA\x20reuptake\x20transporter.\x20<strong>Vigabatrine</strong>\x20is\x20the\x20<strong>drug\x20of\x20choice</strong>\x20for\x20<strong>infantile\x20spasms\x20(West\x20syndrome</strong>)\x20seen\x20in\x20<strong>tuberous\x20sclerosis</strong>.</p>\x0a<p>Option\x20D\x20:\x20<strong>Flumazenil</strong>\x20acts\x20as\x20an\x20<strong>antagonist</strong>\x20at\x20the\x20<strong>GABA\x20receptor</strong>\x20and\x20is\x20used\x20as\x20an\x20<strong>antidote\x20for\x20benzodiazepine\x20overdose</strong>.\x20<strong>Benzodiazepines</strong>\x20act\x20by\x20<strong>promoting\x20GABA\x20inhibition</strong>\x20by\x20<strong>binding\x20to\x20the\x20GABA\x20receptor</strong>\x20itself\x20and\x20<strong>inhibiting\x20nerve\x20transmission</strong>.</p>','mHzlD','fill','A\x2040-year-old\x20woman\x20with\x20multidrug-resistant\x20tuberculosis\x20presents\x20with\x20fatigue,\x20constipation,\x20weight\x20gain,\x20and\x20neck\x20swelling.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20implicated\x20in\x20this\x20case?','giBNI','Memantine','question_audio','Drug\x20used\x20for\x20trastuzumab-resistant\x20her\x202\x20positive\x20breast\x20cancer\x20is:','KDMxZ','JhHVW','Budesonide','lOGAT','olOLo','Fxjhm','open','Opauc','Correct','Denotes\x20safety\x20and\x20efficacy\x20after\x20experiments\x20on\x20humans','338192HvWuob','apply','.m3u8','Galantamine','video[data-src]','jefRG','filter','CWPel','back','cnJHc','pblKC','No\x20questions\x20available\x20for\x20this\x20quiz.','Aztreonam','<div\x20class=\x22mt-4\x22><img\x20src=\x22','2|3|5|4|0|1','Acarbose','\x20>\x20','round','PxWug','DyouI','zLUXG','explanation_video','350\x20mcg/dL','log','explanation_images','sMgLQ','Blood\x20dyscrasia','customQuizData','OrNoe','VxDQn','<p><strong>Dexrazoxane</strong>\x20is\x20the\x20drug\x20of\x20choice\x20to\x20treat\x20<strong>doxorubicin</strong>\x20<strong>induced</strong>\x20<strong>cardiomyopathy</strong>.<br\x20/><br\x20/><strong>Doxorubicin</strong>\x20is\x20an\x20<strong>anthracycline</strong>\x20group\x20of\x20anticancer\x20antibiotics\x20that\x20acts\x20by\x20<strong>inhibiting\x20topoisomerase\x20II</strong>,\x20and\x20is\x20known\x20to\x20cause\x20<strong>cardiotoxicity</strong>.\x20<strong>Dexrazoxane</strong>\x20is\x20a\x20<strong>cardioprotective</strong>\x20<strong>iron-chelating\x20agent\x20</strong>that\x20is\x20indicated\x20for\x20use\x20along\x20with\x20<strong>high\x20dose\x20doxorubicin</strong>\x20to\x20<strong>avoid\x20cardiotoxicity</strong>.\u00a0<br\x20/><br\x20/><strong>Dexrazoxane</strong>\x20is\x20currently\x20approved\x20to\x20<strong>prevent\x20or\x20reduce\x20anthracycline-induced\x20cardiotoxicity</strong>\x20in\x20women\x20with<strong>\x20metastatic\x20breast\x20cancer\x20</strong>who\x20have\x20received\x20a\x20<strong>total\x20cumulative\x20dose\x20of\x20doxorubicin\x20of\x20300\x20mg/m2</strong>\x20.</p>\x0a<p>Doxorubicin-induced\x20cardiomyopathy\x20takes\x20two\x20forms:</p>\x0a<p>-\x20<strong>Acute</strong>:\x20<strong>pericarditis-myocarditis\x20syndrome</strong>,\x20arrhythmias,\x20ST\x20and\x20T\x20wave\x20changes\x20in\x20ECG.\x20Occurs\x20within\x20the\x20first\x202–3\x20days,\x20is\x20transient\x20and\x20in\x20most\x20cases\x20asymptomatic.<br\x20/>-\x20<strong>Chronic</strong>:\x20Dose\x20dependendent\x20<strong>dilated\x20cardiomyopathy\x20associated\x20with\x20heart\x20failure</strong>.\u00a0</p>\x0a<p><strong>Doxorubicin,\x20daunorubicin\x20and\x20epirubicin</strong>\x20share\x20<strong>similar\x20cardiotoxicity</strong>\x20profile.\x20<strong>Idarubicin</strong>\x20has<strong>\x20least\x20cardiotoxicity</strong>\x20when\x20compared\x20to\x20other\x20anthracyclines.<br\x20/><br\x20/><strong>Endomyocardial\x20biopsy\x20</strong>showing\x20<strong>vacuolar\x20degeneration</strong>\x20and\x20<strong>myofibrillar</strong>\x20<strong>loss</strong>\x20is\x20seen\x20in\x20cardiotoxicity\x20due\x20to\x20anthracyclines.<br\x20/><br\x20/><strong>Difference</strong>\x20between\x20cardiotoxicity\x20due\x20to\x20<strong>anthracyclins\x20and\x20trastuzumab</strong>:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100.046%;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Anthracyclins</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Trastuzumab</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Irreversible</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Reversible</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Dose-dependent</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Not\x20dose-dependent</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Biopsy\x20shows\x20myocyte\x20destruction</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Biopsy\x20does\x20not\x20show\x20myocyte\x20destruction</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><br\x20/><strong>Anthracyclines</strong>\x20like\x20doxorubicin\x20can\x20result\x20in\x20a\x20<strong>radiation\x20recall\x20reaction</strong>,\x20where\x20<strong>erythema\x20and\x20desquamation\x20of\x20skin</strong>\x20are\x20observed\x20at\x20sites\x20of\x20<strong>previous\x20radiation\x20injury.</strong>\x20The\x20risk\x20of\x20cardiotoxicity\x20also\x20increases\x20with\x20previous\x20irradiation.\x20Therefore,\x20careful\x20monitoring\x20and\x20dosage\x20adjustments\x20are\x20required\x20for\x20doxorubicin.<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B,\x20C\x20and\x20D\x20:\x20Dexamethasone,\x20aprepitant\x20and\x20amifostine\x20are\x20not\x20used\x20in\x20the\x20management\x20of\x20anthracycline\x20induced\x20cardiotoxicity.</p>','XmPTA','aBbkI','Fidaxomycin','HoBrj','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','classList','DfBHw','AOmlk','bind','hierarchy','aJGIu','error','getAttribute','CrzPw','questionIndex','kXgSN','A\x20patient\x20with\x20hemophilia\x20on\x20antiretroviral\x20therapy\x20is\x20brought\x20in\x20altered\x20mental\x20status\x20following\x20complaints\x20of\x20nausea,\x20vomiting\x20and\x20headache.\x20Which\x20of\x20the\x20following\x20medications\x20was\x20he\x20taking?','IqDjy','yQUVG','Which\x20of\x20the\x20following\x20mood\x20stabilisers\x20causes\x20hepatotoxicity\x20and\x20hyperammonemia?','xJdsn','A\x2060-year-old\x20patient\x20with\x20chronic\x20kidney\x20disease\x20suddenly\x20develops\x20chest\x20pain\x20and\x20palpitations.\x20He\x20had\x20previously\x20complained\x20about\x20feeling\x20weak\x20for\x20the\x20past\x20week.\x20Serum\x20potassium\x20was\x20found\x20to\x20be\x206.5mEq/L.\x20Which\x20of\x20the\x20following\x20is\x20likely\x20to\x20be\x20found\x20in\x20this\x20patients\x20ECG?','32817609Qsznoe','incorrect','JvTyr','TdtgC','NzbYb','markReviewBtn','Hydroxyurea','qKYvY','Rosiglitazone','hVNzQ','PPRNh','IkkWy','ePVrQ','XjshN','attachMedia','Erlotinib','rCKKd','qODTu','CcBdu','HfJcU','A\x20patient\x20on\x20fluoxetine\x20was\x20started\x20on\x20a\x20pain\x20control\x20drug\x20for\x20neuropathic\x20pain.\x20He\x20developed\x20an\x20episode\x20of\x20syncope\x20after\x202\x20weeks.\x20ECG\x20reveals\x20QT\x20interval\x20of\x20477\x20ms.\x20Which\x20of\x20the\x20following\x20is\x20the\x20causative\x20drug?','Salazar','Cereblon\x20binding','mKxGt','div','vTauy','progressBar','reviewQuestionsContainer','jOYjD','Azathioprine','MDtKt','application/vnd.apple.mpegurl','olXfc','cGPWR','Atropine','cWspO','058\x20Pharmacology\x20Ini-Cet\x202023','399LPdoTX','red','Which\x20of\x20the\x20following\x20drugs\x20acts\x20via\x20the\x20ATP-binding\x20cassette\x20transporter?','questionMedia','eyFfE','MOIWo','Venlafaxine','not_attempted','2726sgsZrt','wJdjR','testModeLegend','none','hObxf','gacMX','correct','kCjmI','textContent','questionReviewSection','EeJdj','toLowerCase','add','src','solutionAudio','urZRW','setItem','aEUMt','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','LmMbH','AkCOp','BRIiw','GDQrh','SnMTQ','Phenytoin','nav-btn-correct','saywY','Pyrazinamide','NwKvH','length','Liraglutide','map','<p><strong>IV\x20desferrioxamine</strong>\x20(also\x20known\x20as\u00a0<strong>deferoxamine)</strong>\u00a0is\x20indicated\x20when<strong>\x20serum\x20iron\x20levels</strong>\x20are\x20<strong>greater\x20than\x20500\x20mcg/dL</strong>\x20in\x20cases\x20of\x20<strong>iron\x20toxicity.</strong></p>\x0a<p><strong>Desferrioxamine</strong>\x20is\x20selectively\x20used\x20as\x20a\x20<strong>chelating\x20agent\x20</strong>to\x20manage\x20cases\x20of\x20<strong>acute\x20iron\x20poisoning,</strong>\x20<strong>hemochromatosis</strong>,\x20and\x20patients\x20with\x20<strong>iron</strong>\x20<strong>overload</strong>\x20from\x20<strong>repetitive\x20blood\x20transfusions</strong>.\x20Desferrioxamine\x20can\x20be\x20<strong>administered\x20intramuscularly</strong>,\x20<strong>intravenously</strong>,\x20or\x20<strong>subcutaneously</strong>\x20but\x20<strong>not\x20orally</strong>.</p>\x0a<p><strong>Deferiprone</strong>\x20and\x20<strong>deferasirox</strong>\x20are\x20both\x20<strong>oral\x20drugs</strong>\x20and\x20can\x20be\x20given\x20in<strong>\x20transfusion\x20related\x20siderosis</strong>\x20but\x20are\x20less\x20effective\x20than\x20desferrioxamine.\x20Although,\x20they\x20can\x20be\x20preferred\x20because\x20of\x20the\x20ease\x20of\x20administration\x20through\x20oral\x20route\x20and\x20multiple\x20transfusions\x20required\x20for\x20beta\x20thalassemia\x20patients.<br\x20/><br\x20/>Iron\x20exhibits<strong>\x20toxic\x20effects</strong>\x20by\x20<strong>hydration\x20of\x20the\x20ferric\x20(F<sup>3+</sup>)\x20ion</strong>\x20which<strong>\x20generates\x20H<sup>+</sup></strong>.\x20Non\x20transferrin\x20bound\x20iron\x20catalyses\x20<strong>free\x20radical\x20formation\x20</strong>which\x20causes\x20<strong>mitochondrial\x20injury,\x20lipid\x20peroxidation,\x20increased\x20capillary\x20permeability,\x20vasodilation,\x20and\x20organ\x20toxicity</strong>.<br\x20/><br\x20/><strong>Clinical\x20features</strong>\x20of\x20iron\x20toxicity\x20include<strong>\x20initial\x20nausea,\x20vomiting,\x20abdominal\x20pain</strong>\x20and\x20<strong>diarrhea</strong>.\x20In\x20<strong>severe\x20cases\x20</strong>there\x20is<strong>\x20high\x20anion\x20gap\x20metabolic\x20acidosis</strong>,\x20<strong>cardiovascular\x20and\x20CNS\x20depression</strong>,\x20<strong>hepatitis</strong>,\x20<strong>coagulopathy</strong>,\x20and\x20<strong>seizures</strong>.<br\x20/><br\x20/>In\x20the\x20case\x20of<strong>\x20toxic\x20iron\x20ingestion</strong>,\x20<strong>radiopaque\x20iron\x20tablets</strong>\x20may\x20be\x20seen\x20on\x20<strong>abdominal\x20x-ray</strong>.</p>\x0a<p><strong>Management</strong>\x20of\x20iron\x20toxicity\x20includes\x20the\x20following\x20:\u00a0</p>\x0a<ul>\x0a<li><strong>Whole-bowel\x20irrigation</strong>\x20for<strong>\x20large\x20ingestions</strong>,\x20<strong>endoscopy</strong>\x20and\x20<strong>gastrostomy</strong>\x20if\x20clinical\x20toxicity\x20and\x20large\x20number\x20of\x20tablets\x20are\x20still\x20visible\x20on\x20x-ray.</li>\x0a<li><strong>\x20IV\x20hydration</strong>.</li>\x0a<li><strong>\x20Sodium\x20bicarbonate</strong>\x20for\x20<strong>acidemia</strong>.</li>\x0a<li><strong>IV\x20desferrioxamine</strong>\x20for\x20<strong>systemic</strong>\x20<strong>toxicity</strong>,\x20<strong>iron\x20level\x20&gt;90\x20μmol/L</strong>\x20(<strong>500</strong>\x20<strong>μg/dL</strong>).</li>\x0a</ul>','questionNav','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','custom_quiz.html','rtNYj','lMkAn','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','timed_exam','YUFCa','Sodium\x20valproate\x20has\x20an\x20inhibitory\x20action\x20at\x20which\x20of\x20the\x20following\x20sites?','ccjid','test','FlGUC','querySelectorAll','<div\x20class=\x22page\x22\x20title=\x22Page\x201404\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The<strong>\x20T790M\x20mutation</strong>\x20in\x20the\x20<strong>EGFR\x20gene</strong>\x20is\x20known\x20to\x20<strong>cause\x20resistance\x20to\x20first\x20and\x20second-generation\x20EGFR\x20inhibitors</strong>.\x20<strong>Osimertinib</strong>,\x20as\x20a\x20<strong>third-generation\x20EGFR\x20inhibitor</strong>,\x20is\x20effective\x20against\x20this\x20resistance,\x20hence\x20it\x20is\x20often\x20<strong>used\x20for\x20patients\x20with\x20the\x20T790M\x20mutation</strong>\x20<strong>after</strong>\x20<strong>they\x27ve\x20progressed</strong>\x20on\x20first\x20or\x20second-generation\x20EGFR\x20inhibitors.</p>\x0a<p>The\x20question\x20seems\x20to\x20be\x20asking\x20specifically\x20for\x20the\x20mutation\x20that\x20osimertinib\x20is\x20particularly\x20known\x20for\x20being\x20used\x20against,\x20and\x20that\x20would\x20be\x20the\x20T790M\x20mutation.</p>\x0a<p>Osimertinib&nbsp;is\x20a\x20kinase\x20inhibitor\x20that\x20is\x20approved\x20for&nbsp;</p>\x0a<ul>\x0a<li>Patients\x20with\x20<strong>metastatic\x20non\x20small\x20cell\x20lung\x20carcinoma</strong>(NSCLC)&nbsp;that\x20has\x20progressed\x20<strong>after\x20prior\x20EGFR\x20TKI\x20treatment\x20and\x20is\x20positive\x20for\x20the\x20EGFR\x20T790M\x20mutation</strong>.</li>\x0a<li>First-line\x20treatment\x20of\x20patients\x20with\x20<strong>metastatic\x20NSCLC</strong>\x20and\x20<strong>adjuvant\x20therapy</strong>\x20after\x20<strong>resection\x20of\x20NSCLC\x20with\x20EGFR\x20exon\x2019\x20deletions\x20or\x20exon\x2021\x20L858R\x20mutations</strong></li>\x0a</ul>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201404\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>So,\x20osimertinib\x20is\x20used\x20both\x20for\x20the\x20L858R\x20mutation\x20and\x20T790M\x20mutation\x20in\x20different\x20settings.\x20But\x20T790M\x20mutation\x20is\x20often\x20highlighted\x20because\x20of\x20its\x20association\x20with\x20resistance\x20to\x20first\x20and\x20second-generation\x20EGFR\x20inhibitors,\x20and\x20because\x20osimertinib\x20can\x20overcome\x20this\x20resistance.</p>\x0a<p>Osimertinib\x20is\x20<strong>administered\x20orally\x20</strong>and&nbsp;is\x20a\x20<strong>substrate\x20of\x20CYP3A</strong>.\x20The\x20drug\x20is\x20primarily\x20eliminated\x20in\x20the\x20feces\x20and\x20to\x20a\x20lesser\x20extent\x20in\x20the\x20urine.\x20Concurrent\x20administration\x20of\x20inducers\x20of\x20CYP3A4\x20may\x20necessitate\x20an\x20increase\x20in\x20the\x20dose.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201405\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The<strong>&nbsp;adverse\x20effects</strong>\x20after\x20osimertinib\x20treatment\x20are&nbsp;<strong>leukopenia</strong>,&nbsp;<strong>diarrhea</strong>,\x20skin\x20rash,\x20<strong>interstitial\x20lung\x20disease</strong>,\x20<strong>QTc\x20prolongation</strong>,\x20and\x20left\x20ventricular\x20dysfunction.</p>\x0a<p>&nbsp;</p>\x0a<p>&nbsp;</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','selected','lBBeo','Cycloserine','qpqwd','TIfne','YsIFE','pop','yuwoz','display','pEwyD','geRgq','zaaAQ','DATyU','zupXl','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','bMrca','dpjgT','endsWith','Lapatinib','Mirtazapine','GIlYQ','kEXUA','YPVKU','mygyk','return\x20(function()\x20','hidden','addEventListener','MmUcA','wBLbu','BVTHV','yGgHE','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','abMVs','yQXMM','FIicc','JZhCo','MrHJa','Huuwa','Hyponatremia','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','It\x20is\x20not\x20absorbed\x20from\x20the\x20stomach','now','ozgcJ','Daptomycin','QPHFB','All\x20of\x20the\x20following\x20side\x20effects\x20are\x20more\x20commonly\x20seen\x20with\x20carbamazepine\x20than\x20oxcarbazepine\x20except','Candida\x20krusei\x20-\x20Fluconazole','SdVJD','mSdiZ','KnGTd','ICabT','qRUWg','500\x20mcg/dL','Vemurafenib','selectedAnswer','cMmrm','Match\x20the\x20following','vbklQ','FdLyp','constructor','timed_study','Bupropion','fvZNG','ABonF','<p><strong>Fostamatinib</strong>\x20is\x20a<strong>\x20tyrosine\x20kinase\x20inhibitor</strong>\x20used\x20in\x20the\x20treatment\x20of\x20<strong>chronic\x20immune\x20thrombocytopenia</strong>\x20(<strong>idiopathic\x20thrombocytopenic\x20purpura</strong>).<br\x20/><br\x20/><strong>Fostamatinib</strong>\x20has\x20activity\x20against\x20<strong>spleen\x20tyrosine\x20kinase\x20(SYK)</strong>.\x20The\x20<strong>major\x20metabolite</strong>\x20of\x20fostamatinib,\x20<strong>R406</strong>,\x20<strong>inhibits\x20signal\x20transduction</strong>\x20of\x20<strong>Fc-activating\x20receptors</strong>\x20and\x20<strong>B-cell\x20receptors</strong>.\x20The\x20fostamatinib\x20metabolite<strong>\x20R406\x20reduces\x20antibody-mediated\x20destruction\x20of\x20platelets.<br\x20/><br\x20/>Idiopathic\x20thrombocytopenic\x20purpura\x20(ITP)</strong>\x20is\x20an\x20<strong>acquired</strong>\x20disorder\x20characterized\x20by\x20the\x20<strong>immune-mediated\x20destruction\x20of\x20platelets</strong>\x20and\x20possibly\x20<strong>inhibition\x20of\x20platelet\x20release</strong>\x20from\x20the\x20<strong>megakaryocyte</strong>.\x20It\x20is\x20an\x20autoimmune\x20disorder\x20caused\x20by\x20antibodies\x20directed\x20against\x20<strong>platelet\x20membrane\x20glycoproteins\x20IIb-IIIa\x20or\x20Ib-IX</strong>.\x20<strong>Secondary</strong>\x20<strong>causes</strong>\x20of\x20ITP\x20include\x20<strong>systemic\x20lupus\x20erythematosus\x20(SLE)</strong>,\x20<strong>HIV-AIDS</strong>,\x20and\x20<strong>Hepatitis\x20C</strong>.</p>\x0a<p>ITP\x20usually\x20presents\x20with\x20<strong>mucocutaneous\x20bleeding</strong>,\x20<strong>very\x20low\x20platelet\x20count</strong>,\x20and\x20<strong>normal\x20peripheral\x20blood\x20cells</strong>.\x20Patients\x20typically\x20exhibit\x20<strong>ecchymoses</strong>\x20and\x20<strong>petechiae</strong>\x20or\x20they\x20may\x20incidentally\x20discover\x20<strong>thrombocytopenia</strong>\x20during\x20a\x20routine\x20complete\x20blood\x20count.\x20Rarely,\x20<strong>life-threatening\x20bleeding</strong>\x20may\x20occur.\x20The\x20presence\x20of\x20<strong>wet\x20purpura\x20</strong>(<strong>blood\x20blisters\x20in\x20the\x20mouth</strong>)\x20and\x20<strong>retinal\x20hemorrhages</strong>\x20can\x20serve\x20as<strong>\x20warning\x20signs</strong>\x20of\x20potentially<strong>\x20life-threatening\x20bleeding</strong>.<br\x20/><br\x20/>The\x20treatment\x20of\x20ITP\x20is\x20as\x20follows:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100.046%;\x20height:\x20380.781px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x2022.3984px;\x22>Clinical\x20features</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x2022.3984px;\x22>Management</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x20153.594px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x20153.594px;\x22>1.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x20153.594px;\x22>\x0a<p>Minor\x20bleeding\x20manifestations\x20(and/or)</p>\x0a<p>Platelet\x20count\x20&gt;\x205000/\x20μL</p>\x0a</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x20153.594px;\x22>\x0a<p>Prednisone\x20(OR)</p>\x0a<p>Anti-D\x20immunoglobulin\x20therapy\x20-\x20effective\x20only\x20in\x20Rh-positive\x20patients\x20(OR)</p>\x0a<p>Intravenous\x20immunoglobulin\x20(IVIG)</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x20159.992px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x20159.992px;\x22>2.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x20159.992px;\x22>\x0a<p>Severe\x20ITP\x20(any\x20of\x20the\x20following):</p>\x0a<p>-\x20Significant\x20GI\x20/\x20intracranial\x20bleeding<br\x20/>-\x20Platelet\x20count\x20&lt;\x205000/μL<br\x20/>-\x20Signs\x20of\x20impending\x20bleeding\x20(retinal\x20or\x20large\x20oral\x20mucosal\x20bleeds)</p>\x0a</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x20159.992px;\x22>\x0a<p>Platelet\x20transfusion\x20(AND)</p>\x0a<p>High-dose\x20glucocorticoids\x20(AND)</p>\x0a<p>IVIG\x20/\x20Anti-D\x20immunoglobulins\x20+\x20Rituximab</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x2022.3984px;\x22>3.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x2022.3984px;\x22>Relapse\x20after\x20first-line\x20therapy</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x2022.3984px;\x22>Splenectomy</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x2022.3984px;\x22>4.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x2022.3984px;\x22>Unresponsive\x20to\x20all\x20other\x20therapy\x20or\x20relapse\x20after\x20splenectomy</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x2022.3984px;\x22>Thrombopoietin\x20receptor\x20agonists\x20-\x20romiplostim\x20(subcutaneous),\x20eltrombopag\x20(oral)</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/></strong>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20A\x20and\x20B:\x20<strong>Eltrombopag</strong>\x20and\x20<strong>Romiplostim\x20</strong>are\u00a0<strong>thrombopoietin\x20(TPO)\x20receptor\x20agonists\x20</strong>used\x20in\x20the\x20treatment\x20of\x20<strong>immune\x20thrombocytopenia</strong>\x20which\x20have\x20failed\x20to\x20respond\x20to\x20conventional\x20treatments.\x20Both\x20drugs\x20act\x20via\x20the\x20<strong>Mpl\x20receptor</strong>\x20to\x20increase\x20platelet\x20counts\x20and\x20not\x20via\u00a0tyrosine\x20kinase\x20inhibition.</p>\x0a<p>Option\x20C:\x20<strong>Bosutinib</strong>\x20is\x20a<strong>\x20BCR-ABL</strong>\x20<strong>tyrosine\x20kinase\x20inhibitor</strong>\x20indicated\x20in\x20<strong>CML</strong>.\u00a0</p>','parse','5-aminosalicylic\x20acid','Release\x20of\x20reactive\x20oxygen\x20species\x20and\x20free\x20radicles','border-gray-600','Confusion','kTWwP','XUWzy','Ratzv','https://dhmbxeygs57ff.cloudfront.net/uploads/daaf90ecdf2b4851873eddbe9c1c2392x1280x1258.JPEG','RQSjh','<p><strong>Trazodone</strong>\x20causes\x20<strong>priapism</strong>.&nbsp;</p>\x0a<p>Trazodone\x20is\x20an<strong>\x20atypical&nbsp;antidepressant\x20drug</strong>.\x20It\x20is\x20a\x20<strong>serotonin\x20receptor\x20antagonist</strong>.\x20Other\x20drugs\x20which\x20belong\x20to\x20this\x20include\x20<strong>nefazodone,\x20mirtazapine,\x20and\x20mianserin</strong>.\x20Low\x20doses\x20of\x20trazodone\x20(50&ndash;200\x20mg)\x20have\x20been\x20used\x20widely,\x20both\x20alone\x20and\x20concurrently\x20with\x20SSRIs\x20or\x20SNRIs,\x20to\x20treat\x20<strong>insomnia</strong>.\x20Trazodone\x20use\x20is\x20associated\x20with\x20<strong>priapism</strong>\x20in\x20rare\x20instances.\x20Intracavernous\x20injection\x20of\x20<strong>phenylephrine</strong>\x20can\x20be\x20used\x20to\x20<strong>treat\x20priapism.</strong></p>\x0a<p>&nbsp;Other\x20options:</p>\x0a<p>Option\x20B:\x20Venlafaxine\x20is\x20a&nbsp;<strong>second-line</strong>&nbsp;drug\x20used\x20in\x20generalized\x20anxiety\x20disorder.\x20It\x20belongs\x20to\x20the\x20class\x20of&nbsp;serotonin-norepinephrine\x20reuptake\x20inhibitors&nbsp;<strong>(SNRIs).&nbsp;</strong>Venlafaxine\x20can\x20induce\x20sustained\x20diastolic\x20hypertension\x20(diastolic\x20blood\x20pressure\x20&gt;90\x20mmHg\x20at\x20consecutive\x20weekly\x20visits).\x20Venlafaxine\x20also\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20perinatal\x20complications.</p>\x0a<p>Option\x20C:\x20Bupropion\x20is\x20a\x20first-line\x20drug\x20used\x20for&nbsp;<strong>nicotine\x20cessation</strong>&nbsp;and\x20has\x20the\x20added\x20benefit\x20of\x20causing&nbsp;<strong>weight\x20loss</strong>.\x20Weight\x20gain\x20is\x20commonly\x20seen\x20after\x20stopping\x20nicotine\x20use.\x20Hence\x20this\x20drug\x20can\x20be\x20used\x20in\x20this\x20patient\x20as\x20it\x20treats\x20both\x20of\x20these.</p>\x0a<p>Option\x20D:&nbsp;<strong>Mirtazapine&nbsp;</strong>is\x20used\x20in\x20major\x20depressive\x20disorder.\x20It\x20increases\x20appetite\x20and\x20causes\x20significant\x20weight\x20gain.</p>\x0a<p>&nbsp;</p>','OAT1B1','JldAI','testModeReviewLegend','getElementById','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','QdaCZ','lGtha','tKPVj','rtUdy','Hypothermia','Bookmarked','console','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','onclick','width','className','rEuwb','YJLfT','OzGoA','<table\x20style=\x22width:\x20240.562px;\x20height:\x20165px;\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2033px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2033px;\x22>A.\x20Mirabegron</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2033px;\x22>&nbsp;3.\x20Beta\x203</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2028px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2028px;\x22>B.\x20Indacaterol</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2028px;\x22>&nbsp;4.\x20Beta\x202</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2030px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2030px;\x22>C.\x20Betaxolol</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2030px;\x22>&nbsp;1.\x20Beta\x201</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2031.5px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2031.5px;\x22>D.\x20Isoproterenol</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2031.5px;\x22>&nbsp;2.\x20Beta&nbsp;</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Mirabegron</strong>&nbsp;is\x20a&nbsp;<strong>&beta;3-adrenergic\x20receptor\x20agonist</strong>&nbsp;which\x20is\x20used\x20for&nbsp;<strong>bladder\x20incontinence</strong>.\x20Activation\x20of\x20this\x20receptor\x20in\x20the\x20bladder\x20leads\x20to\x20detrusor\x20muscle\x20relaxation\x20and\x20increased\x20bladder\x20capacity.\x20This\x20action\x20prevents\x20voiding\x20and\x20provides\x20relief\x20for\x20those\x20with\x20an\x20overactive\x20bladder\x20and\x20urinary\x20incontinence.&nbsp;</p>\x0a<p><strong>Indacaterol</strong>\x20is\x20a\x20very\x20long\x20acting\x20beta\x202\x20agonists<strong>&nbsp;(V-LABA)&nbsp;</strong>and\x20can\x20be\x20used\x20once\x20daily\x20in\x20COPD\x20maintenance<strong>.</strong></p>\x0a<p><strong>Betaxolol\x20</strong>is\x20a\x20&beta;<sub>1</sub>&nbsp;selective\x20third-generation\x20&beta;-blocker\x20with\x20additional\x20<strong>calcium\x20entry\x20blockade</strong>\x20activity\x20and\x20a\x20slight\x20membrane-stabilizing\x20property.\x20It\x20does\x20not\x20have\x20agonist\x20activity.</p>\x0a<p><strong>Isoproterenol</strong>\x20is\x20a<strong>&nbsp;non-selective\x20beta\x20agonist\x20(&beta;<sub>1</sub>=&beta;<sub>2</sub>)\x20with\x20no&nbsp;&alpha;\x20action</strong>.\x20The\x20direct\x20action\x20on\x20cardiac&nbsp;<strong>&beta;<sub>1</sub></strong>&nbsp;receptors\x20causes\x20an\x20increased\x20risk\x20of&nbsp;<strong>tachycardia</strong>&nbsp;and\x20arrhythmias.\x20The\x20decrease\x20in\x20peripheral\x20vascular\x20resistance\x20is\x20due\x20to&nbsp;<strong>&beta;<sub>2</sub></strong>&nbsp;action\x20causing\x20a<strong>&nbsp;fall\x20in\x20diastolic\x20blood\x20pressure.</strong>&nbsp;Isoproterenol\x20currently\x20may\x20be\x20used\x20as\x20a<strong>&nbsp;cardiac\x20stimulant</strong>&nbsp;in\x20patients\x20with<strong>&nbsp;bradycardia\x20or\x20heart\x20block,&nbsp;</strong>particularly\x20in\x20anticipation\x20of\x20inserting\x20an\x20artificial\x20cardiac\x20pacemaker.</p>','nav-btn-answered','ZudRR','TmyQl','Tall\x20peaked\x20T\x20waves','markReviewText','YBFJX','WnKIq','Uorpk','ZzvUl','Carbamazepine'];_0x2a52=function(){return _0x1ae3aa;};return _0x2a52();}function retakeQuiz(){const _0x537cc1=_0x37c9bd,_0x4394ad={'PjAye':_0x537cc1(0x115),'gDBeX':_0x537cc1(0x20a),'QiyAb':_0x537cc1(0x117),'Opauc':function(_0x2b5b13,_0x3c5150){return _0x2b5b13+_0x3c5150;},'ndpHE':_0x537cc1(0x251),'yQXMM':function(_0x8784ee,_0x43b13d){return _0x8784ee(_0x43b13d);},'tDZLK':'Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','IXfHl':_0x537cc1(0x18c),'qODTu':function(_0xbbc759,_0x1a86f5){return _0xbbc759===_0x1a86f5;},'aBCpU':_0x537cc1(0x1ec),'TcTLu':_0x537cc1(0x122)};if(_0x4394ad[_0x537cc1(0x1b9)](confirm,_0x4394ad['tDZLK'])){if(window['location'][_0x537cc1(0x2d7)][_0x537cc1(0x1a9)](_0x4394ad[_0x537cc1(0x23e)])){if(_0x4394ad[_0x537cc1(0x14d)](_0x4394ad[_0x537cc1(0x206)],_0x4394ad['aBCpU']))localStorage['removeItem'](_0x4394ad[_0x537cc1(0x2a7)]);else{const _0x2757f6=_0x4394ad['PjAye']['split']('|');let _0x38a760=0x0;while(!![]){switch(_0x2757f6[_0x38a760++]){case'0':_0x434447['getElementById'](_0x537cc1(0x34c))['textContent']=_0x346d52['length'];continue;case'1':_0x2f65bc[_0x537cc1(0x1e7)](_0x4394ad[_0x537cc1(0x2f3)])[_0x537cc1(0x171)]=_0x122dba[_0x537cc1(0x210)](_0x4394ad[_0x537cc1(0x282)]);continue;case'2':_0x2b752d=_0x4883dd[_0x537cc1(0x37f)];continue;case'3':_0x699ab4=_0x5dac40[_0x537cc1(0x34e)];continue;case'4':_0x2cd53a[_0x537cc1(0x362)]=_0x4394ad[_0x537cc1(0x104)](_0x430d47,_0x4394ad[_0x537cc1(0x327)]);continue;case'5':_0x3c4b3a=_0x2fdbeb[_0x537cc1(0x12f)];continue;}break;}}}location['reload']();}}function loadBookmarkedQuestions(){const _0x27ba3e=_0x37c9bd,_0x5156a6={'jGdxC':function(_0x5e9ab8){return _0x5e9ab8();},'JYHEK':function(_0xa24f1e,_0x225bf6){return _0xa24f1e===_0x225bf6;},'VuPGr':_0x27ba3e(0x392),'jOYjD':_0x27ba3e(0x1c2),'TdtgC':function(_0x543523,_0x2ebe4f){return _0x543523!==_0x2ebe4f;},'bMrca':_0x27ba3e(0x1b8),'kPfin':'bookmarkedQuestions'},_0x5a9248=JSON[_0x27ba3e(0x1d9)](localStorage['getItem'](_0x5156a6[_0x27ba3e(0x297)]))||[];_0x5a9248[_0x27ba3e(0x27d)](_0xf0d0d9=>{const _0x425c2d=_0x27ba3e,_0x1a32d7={'ZnTuE':function(_0x4ae741){const _0x1b3acf=_0x27a8;return _0x5156a6[_0x1b3acf(0x302)](_0x4ae741);}};if(_0xf0d0d9['quizFile'][_0x425c2d(0x217)](quizName[_0x425c2d(0x174)]()[_0x425c2d(0x374)](/ /g,'-'))){if(_0x5156a6['JYHEK'](_0x5156a6[_0x425c2d(0x34a)],_0x5156a6[_0x425c2d(0x158)])){const _0x2abc01={'cduCj':function(_0x39cead,_0x3cafd4){return _0x39cead<_0x3cafd4;}},_0x5096e4=_0x2eee57[_0x425c2d(0x1d9)](_0x772943['getItem'](_0x425c2d(0x234)))||[];_0x5096e4[_0x425c2d(0x27d)](_0x2cd697=>{const _0x15acde=_0x425c2d;_0x2cd697[_0x15acde(0x24e)][_0x15acde(0x217)](_0x18fca5[_0x15acde(0x174)]()[_0x15acde(0x374)](/ /g,'-'))&&(_0x2abc01[_0x15acde(0x300)](_0x2cd697[_0x15acde(0x134)],_0x31c432[_0x15acde(0x186)])&&(_0x4ed5e2[_0x2cd697[_0x15acde(0x134)]][_0x15acde(0x346)]=!![]));});}else _0xf0d0d9[_0x425c2d(0x134)]<questionsData[_0x425c2d(0x186)]&&(_0x5156a6[_0x425c2d(0x13f)](_0x5156a6[_0x425c2d(0x1a7)],_0x425c2d(0x2e5))?questionStates[_0xf0d0d9[_0x425c2d(0x134)]][_0x425c2d(0x346)]=!![]:_0x1a32d7['ZnTuE'](_0x4d2db9));}});}function toggleBookmark(){const _0x1e56e8=_0x37c9bd,_0x383436={'aibwU':_0x1e56e8(0x234),'elkQQ':function(_0x819411){return _0x819411();}},_0x1fef3e=!questionStates[currentQuestionIndex]['bookmarked'];questionStates[currentQuestionIndex][_0x1e56e8(0x346)]=_0x1fef3e;let _0x55bc45=JSON[_0x1e56e8(0x1d9)](localStorage['getItem'](_0x383436[_0x1e56e8(0x34d)]))||[];if(_0x1fef3e){const _0x569875={'quizName':quizName,'quizFile':window[_0x1e56e8(0x260)][_0x1e56e8(0x2d7)][_0x1e56e8(0x26f)]('/')[_0x1e56e8(0x19e)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x1e56e8(0x1c1)]()};_0x55bc45['push'](_0x569875);}else _0x55bc45=_0x55bc45[_0x1e56e8(0x10d)](_0x48038c=>!(_0x48038c['quizFile'][_0x1e56e8(0x217)](quizName[_0x1e56e8(0x174)]()[_0x1e56e8(0x374)](/ /g,'-'))&&_0x48038c[_0x1e56e8(0x134)]===currentQuestionIndex));localStorage['setItem'](_0x383436[_0x1e56e8(0x34d)],JSON['stringify'](_0x55bc45)),updateBookmarkButton(),_0x383436[_0x1e56e8(0x310)](updateQuestionNav);}function updateBookmarkButton(){const _0x2b3d7d=_0x37c9bd,_0x2184ea={'YPVKU':_0x2b3d7d(0x1a6),'lpcvG':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','PxWug':_0x2b3d7d(0x1ee),'HMPSw':_0x2b3d7d(0x2dd)},_0x26b744=document[_0x2b3d7d(0x1e7)](_0x2b3d7d(0x2ef)),_0x1760d4=document[_0x2b3d7d(0x1e7)](_0x2b3d7d(0x305)),_0x243eb6=questionStates[currentQuestionIndex]['bookmarked'];_0x26b744['className']=_0x243eb6?_0x2184ea[_0x2b3d7d(0x1ae)]:_0x2184ea[_0x2b3d7d(0x35d)],_0x1760d4[_0x2b3d7d(0x171)]=_0x243eb6?_0x2184ea[_0x2b3d7d(0x119)]:_0x2184ea[_0x2b3d7d(0x399)];}function _0x27a8(_0x4c2f11,_0x36d02b){const _0x131b2e=_0x2a52();return _0x27a8=function(_0x19cc29,_0x516120){_0x19cc29=_0x19cc29-0xfc;let _0x4f5485=_0x131b2e[_0x19cc29];return _0x4f5485;},_0x27a8(_0x4c2f11,_0x36d02b);}function toggleMarkForReview(){const _0x368e41=_0x37c9bd,_0x3ed12e={'dcCzH':function(_0xdc0bfd){return _0xdc0bfd();}};questionStates[currentQuestionIndex]['markedForReview']=!questionStates[currentQuestionIndex][_0x368e41(0x2f6)],_0x3ed12e[_0x368e41(0x285)](updateMarkReviewButton),_0x3ed12e['dcCzH'](updateQuestionNav);}function updateMarkReviewButton(){const _0x3c18f3=_0x37c9bd,_0xf3c2d6={'XjshN':'markReviewBtn','dodfz':_0x3c18f3(0x2a4),'UWaFo':_0x3c18f3(0x242)},_0x2620d8=document['getElementById'](_0xf3c2d6[_0x3c18f3(0x149)]),_0x52be2f=document[_0x3c18f3(0x1e7)](_0x3c18f3(0x1fc)),_0xeaf5a8=questionStates[currentQuestionIndex][_0x3c18f3(0x2f6)];_0x2620d8['className']=_0xeaf5a8?_0xf3c2d6['dodfz']:_0x3c18f3(0x254),_0x52be2f[_0x3c18f3(0x171)]=_0xeaf5a8?_0xf3c2d6[_0x3c18f3(0x33f)]:_0x3c18f3(0x2e4);}function previousQuestion(){const _0x214068=_0x37c9bd,_0x483862={'lOGAT':function(_0x155ce4,_0x588937){return _0x155ce4>_0x588937;},'CcBdu':function(_0x5c5e25,_0x12d7fe){return _0x5c5e25-_0x12d7fe;}};_0x483862[_0x214068(0x100)](currentQuestionIndex,0x0)&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x214068(0x32a)]+=_0x483862[_0x214068(0x14e)](Date['now'](),questionStartTime)),currentQuestionIndex--,displayQuestion());}function nextQuestion(){const _0x3a7562=_0x37c9bd,_0x3151ef={'WnKIq':function(_0x52a905,_0x48b051){return _0x52a905>_0x48b051;},'YBFJX':function(_0x46c86a){return _0x46c86a();},'gacMX':function(_0x30c7cf,_0x263097){return _0x30c7cf-_0x263097;},'kKydT':function(_0x5be01d,_0x14c0a3){return _0x5be01d<_0x14c0a3;},'ZdfWd':function(_0x132ffa,_0x25b4dd){return _0x132ffa-_0x25b4dd;},'hGkPf':function(_0x19ae0d,_0x211443){return _0x19ae0d!==_0x211443;},'HaCmi':'oRoqL','sYWCK':function(_0x6624c2,_0x4770e1){return _0x6624c2===_0x4770e1;},'wvwqT':_0x3a7562(0x194),'cWspO':_0x3a7562(0x190),'vbklQ':'You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','GIlYQ':_0x3a7562(0x336),'iMYLF':_0x3a7562(0x135),'mjCxg':function(_0x32b972,_0x517564){return _0x32b972(_0x517564);},'QwOkY':'You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?'};questionStartTime&&(questionStates[currentQuestionIndex][_0x3a7562(0x32a)]+=_0x3151ef[_0x3a7562(0x16e)](Date[_0x3a7562(0x1c1)](),questionStartTime));if(_0x3151ef[_0x3a7562(0x243)](currentQuestionIndex,_0x3151ef[_0x3a7562(0x380)](questionsData[_0x3a7562(0x186)],0x1)))currentQuestionIndex++,displayQuestion();else{if(_0x3151ef['hGkPf'](_0x3151ef['HaCmi'],_0x3a7562(0x255))){if(_0x3151ef[_0x3a7562(0x307)](currentMode,_0x3151ef['wvwqT'])||_0x3151ef[_0x3a7562(0x307)](currentMode,_0x3151ef[_0x3a7562(0x15f)])){if(confirm(_0x3151ef[_0x3a7562(0x1d1)])){if(_0x3151ef['hGkPf'](_0x3151ef[_0x3a7562(0x1ac)],_0x3151ef['iMYLF']))_0x3151ef[_0x3a7562(0x1fd)](submitQuiz);else{const _0x5655e4=_0x1e6a38[_0x3a7562(0x1d3)][_0x3a7562(0x318)][_0x3a7562(0x12e)](_0x2d1b4a),_0x3316be=_0xba4a8d[_0x4dc8c7],_0x43cdc1=_0x1aade9[_0x3316be]||_0x5655e4;_0x5655e4[_0x3a7562(0x316)]=_0x30866c[_0x3a7562(0x12e)](_0x29b4f1),_0x5655e4[_0x3a7562(0x2b2)]=_0x43cdc1[_0x3a7562(0x2b2)]['bind'](_0x43cdc1),_0x41181f[_0x3316be]=_0x5655e4;}}}else _0x3151ef['mjCxg'](confirm,_0x3151ef[_0x3a7562(0x2eb)])&&(currentQuestionIndex=0x0,displayQuestion());}else _0x3151ef[_0x3a7562(0x1fe)](_0x3d6b62,0x0)&&(_0x4e645f&&(_0x21c6f0[_0x2c2867][_0x3a7562(0x32a)]+=_0x38514a['now']()-_0x53097f),_0x26ad83--,_0x3151ef[_0x3a7562(0x1fd)](_0x4052fe));}}function startTimer(){const _0xd9a6ea=_0x37c9bd,_0xa6300={'qKMtL':function(_0x168350,_0x250a51){return _0x168350(_0x250a51);},'ZzvUl':_0xd9a6ea(0x315),'bHDbj':'custom_quiz.html','KRnBO':_0xd9a6ea(0x122),'JhHVW':_0xd9a6ea(0x1b1),'JxFAO':function(_0x32630c,_0x2697a5){return _0x32630c!==_0x2697a5;},'VKyOu':_0xd9a6ea(0x204),'ZClrL':function(_0x1cb8aa,_0x2d46b4){return _0x1cb8aa<=_0x2d46b4;},'RrreT':'timed_exam','kiYQW':_0xd9a6ea(0x2d9),'RhjZC':function(_0x439a01){return _0x439a01();},'rEuwb':function(_0x2d28d7,_0x546517){return _0x2d28d7(_0x546517);},'xcRSM':function(_0x6f84c,_0x37c3e4,_0x1dcef4){return _0x6f84c(_0x37c3e4,_0x1dcef4);}};if(timer)_0xa6300[_0xd9a6ea(0x1f4)](clearInterval,timer);timeRemaining=0x78,_0xa6300[_0xd9a6ea(0x26b)](updateTimerDisplay),timer=_0xa6300[_0xd9a6ea(0x36e)](setInterval,()=>{const _0xbe8c7c=_0xd9a6ea;_0xa6300['JxFAO'](_0xbe8c7c(0x204),_0xa6300[_0xbe8c7c(0x388)])?_0xa6300['qKMtL'](_0x8a871c,_0xa6300[_0xbe8c7c(0x200)])&&(_0x3b69b6['location'][_0xbe8c7c(0x2d7)]['endsWith'](_0xa6300[_0xbe8c7c(0x278)])&&_0x2da1ac['removeItem'](_0xa6300['KRnBO']),_0x35ec20[_0xbe8c7c(0x22e)]()):(timeRemaining--,updateTimerDisplay(),_0xa6300[_0xbe8c7c(0x2af)](timeRemaining,0x0)&&(clearInterval(timer),currentMode===_0xa6300['RrreT']?submitQuiz():_0xa6300[_0xbe8c7c(0x2f5)]===_0xbe8c7c(0x2a3)?_0x37e601['classList']['add'](_0xa6300[_0xbe8c7c(0xfe)]):_0xa6300[_0xbe8c7c(0x26b)](nextQuestion)));},0x3e8);}function updateTimerDisplay(){const _0x2d0a9d=_0x37c9bd,_0x42020e={'FdLyp':function(_0x119a78,_0x4fe33e){return _0x119a78/_0x4fe33e;},'fNnpL':function(_0x2c4aae,_0x58da90){return _0x2c4aae%_0x58da90;},'OfeRr':'timeDisplay','dglIM':function(_0x3c0a26,_0x208d00){return _0x3c0a26+_0x208d00;}},_0x32fd95=Math[_0x2d0a9d(0x29a)](_0x42020e[_0x2d0a9d(0x1d2)](timeRemaining,0x3c)),_0x357b20=_0x42020e[_0x2d0a9d(0x359)](timeRemaining,0x3c);document[_0x2d0a9d(0x1e7)](_0x42020e['OfeRr'])['textContent']=_0x42020e[_0x2d0a9d(0x341)](_0x42020e[_0x2d0a9d(0x341)](_0x32fd95,':'),_0x357b20[_0x2d0a9d(0x2b2)]()['padStart'](0x2,'0'));}function toggleSidebar(){const _0x14a910=_0x37c9bd,_0x487ddc={'OXCib':'quizSidebar','yGZSp':_0x14a910(0x103)};document[_0x14a910(0x1e7)](_0x487ddc['OXCib'])['classList'][_0x14a910(0x24b)](_0x487ddc['yGZSp']);}document[_0x37c9bd(0x1b2)]('DOMContentLoaded',()=>{const _0x5ad6bb=_0x37c9bd;!window[_0x5ad6bb(0x260)][_0x5ad6bb(0x2d7)][_0x5ad6bb(0x1a9)](_0x5ad6bb(0x18c))?document['getElementById']('modeModal')[_0x5ad6bb(0x2b1)][_0x5ad6bb(0x1a0)]='flex':initializeQuiz();}),document[_0x37c9bd(0x1b2)](_0x37c9bd(0x268),function(_0x1d7d8b){const _0x5a08c5=_0x37c9bd,_0x153c4b={'Uorpk':_0x5a08c5(0x18c),'DfBHw':function(_0x4a9629,_0x5e5273){return _0x4a9629(_0x5e5273);},'OzGRr':function(_0x3915be,_0x8b1197){return _0x3915be+_0x8b1197;},'BEpBe':_0x5a08c5(0x1b0),'aJGIu':_0x5a08c5(0x27f),'bvjwz':_0x5a08c5(0x2e0),'aPYOV':_0x5a08c5(0x16c),'AlNCo':function(_0x26fb4d,_0x2148e3){return _0x26fb4d===_0x2148e3;},'BRIiw':_0x5a08c5(0x209),'oVcbe':function(_0x389977,_0x4777d2){return _0x389977>=_0x4777d2;},'olOLo':function(_0x54c554,_0x2d25d0){return _0x54c554-_0x2d25d0;},'RQSjh':function(_0x1b281d,_0x54cdef){return _0x1b281d(_0x54cdef);},'QWZst':_0x5a08c5(0x339),'OrNoe':function(_0x364ca3,_0x2d4805){return _0x364ca3<_0x2d4805;},'vviNe':function(_0x575273,_0x256c8f){return _0x575273(_0x256c8f);},'PPRNh':'ArrowLeft','aJUIz':function(_0xb126fd){return _0xb126fd();},'CHVWx':'ArrowRight','cbgTD':function(_0x3771fe,_0x1fc72f){return _0x3771fe===_0x1fc72f;},'FlGUC':function(_0x1f5aa6,_0xa89453){return _0x1f5aa6!==_0xa89453;},'vPLlf':_0x5a08c5(0x17f),'AGFTq':_0x5a08c5(0x29d),'dvCKE':function(_0x9fb3a4,_0x5a764c){return _0x9fb3a4===_0x5a764c;},'BaFFr':_0x5a08c5(0x194),'nxbAy':_0x5a08c5(0x190),'sXGST':function(_0x5949ab,_0x30fab6){return _0x5949ab===_0x30fab6;},'Prkgl':_0x5a08c5(0x381),'qfFvZ':function(_0x19d483){return _0x19d483();},'iIIzd':function(_0x1abf4f,_0x384ec5){return _0x1abf4f===_0x384ec5;},'iVwgA':function(_0x464154,_0x816feb){return _0x464154===_0x816feb;},'JpyYD':_0x5a08c5(0x39e)};if(document[_0x5a08c5(0x1e7)](_0x153c4b['bvjwz'])['style'][_0x5a08c5(0x1a0)]!==_0x153c4b[_0x5a08c5(0x248)])return;if(_0x153c4b[_0x5a08c5(0x33c)](document[_0x5a08c5(0x1e7)](_0x153c4b[_0x5a08c5(0x17e)])[_0x5a08c5(0x12b)][_0x5a08c5(0x2b9)](_0x5a08c5(0x1b1)),![]))return;if(_0x153c4b['oVcbe'](_0x1d7d8b['key'],'1')&&_0x1d7d8b[_0x5a08c5(0x2ae)]<='4'){const _0x4501ef=_0x153c4b[_0x5a08c5(0x101)](_0x153c4b[_0x5a08c5(0x1e2)](parseInt,_0x1d7d8b[_0x5a08c5(0x2ae)]),0x1),_0x1bfe1c=document[_0x5a08c5(0x196)](_0x153c4b[_0x5a08c5(0x32d)]);if(_0x153c4b[_0x5a08c5(0x123)](_0x4501ef,_0x1bfe1c['length']))_0x153c4b[_0x5a08c5(0x22b)](selectOption,_0x4501ef);}else{if(_0x153c4b[_0x5a08c5(0x33c)](_0x1d7d8b[_0x5a08c5(0x2ae)],_0x153c4b[_0x5a08c5(0x146)]))_0x153c4b[_0x5a08c5(0x289)](previousQuestion);else{if(_0x1d7d8b['key']===_0x153c4b[_0x5a08c5(0x322)]||_0x153c4b[_0x5a08c5(0x2a1)](_0x1d7d8b[_0x5a08c5(0x2ae)],'\x20'))_0x153c4b[_0x5a08c5(0x195)](_0x5a08c5(0x17f),_0x153c4b['vPLlf'])?(_0x2cde43[_0x5a08c5(0x260)]['pathname'][_0x5a08c5(0x1a9)](_0x153c4b[_0x5a08c5(0x1ff)])&&_0x234230['removeItem'](_0x5a08c5(0x122)),_0x2c7daf['reload']()):(_0x1d7d8b['preventDefault'](),_0x153c4b[_0x5a08c5(0x289)](nextQuestion));else{if(_0x153c4b[_0x5a08c5(0x2a1)](_0x1d7d8b[_0x5a08c5(0x2ae)]['toLowerCase'](),'b')&&(currentMode===_0x153c4b['AGFTq']||_0x153c4b[_0x5a08c5(0x33c)](currentMode,_0x5a08c5(0x1d4))))_0x153c4b['aJUIz'](toggleBookmark);else{if(_0x1d7d8b['key'][_0x5a08c5(0x174)]()==='m'&&(_0x153c4b[_0x5a08c5(0x28c)](currentMode,_0x153c4b[_0x5a08c5(0x2b7)])||_0x153c4b[_0x5a08c5(0x2a1)](currentMode,_0x153c4b['nxbAy'])))_0x153c4b['sXGST'](_0x153c4b[_0x5a08c5(0x2bd)],_0x153c4b['Prkgl'])?_0x153c4b[_0x5a08c5(0x219)](toggleMarkForReview):_0x344fb4=_0x56d368[_0x5a08c5(0x10d)](_0x126521=>!(_0x126521[_0x5a08c5(0x24e)][_0x5a08c5(0x217)](_0x228b87[_0x5a08c5(0x174)]()[_0x5a08c5(0x374)](/ /g,'-'))&&_0x126521[_0x5a08c5(0x134)]===_0x1a6408));else{if(_0x1d7d8b[_0x5a08c5(0x2ae)][_0x5a08c5(0x174)]()==='s'&&(currentMode===_0x153c4b[_0x5a08c5(0x2b7)]||_0x153c4b['iIIzd'](currentMode,_0x153c4b[_0x5a08c5(0x2d6)]))){if(_0x153c4b[_0x5a08c5(0x321)](_0x5a08c5(0x183),_0x153c4b[_0x5a08c5(0x2c2)])){const _0x1a72df=zgNGnN[_0x5a08c5(0x12c)](_0x2346e5,zgNGnN['OzGRr'](zgNGnN[_0x5a08c5(0x301)],zgNGnN[_0x5a08c5(0x130)])+');');_0x528917=_0x1a72df();}else _0x153c4b[_0x5a08c5(0x219)](submitQuiz);}}}}}}});</script>

</body></html>